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ABSTRACT
Although laboratory indices, such as drug levels, are in routine use for monitoring 
immunosuppression, these do not always correlate well with an individual’s risk of 
toxicity. In practice individual organs are monitored for toxicity with a combination of 
laboratory and clinical methods. These methods are limited by the fact that one has to 
await compromise before making therapeutic changes and there are often idiosyncrasies 
in the way individuals respond.
Ocular complications can be sight threatening and many have proposed routine ocular 
monitoring in immunosuppressed patients. This study prospectively monitored a cohort 
of patients receiving high levels of immunosuppression for the prevention of rejection 
of heart, lung and heart-lung transplants for the development o f ocular complications 
and to assess ocular morbidity.
Specific surrogate markers that gave more information about the level of 
immunosuppression in a particular patient would improve patient care. Cytokines have 
the advantage of being directly generated by the immune response and offer promise as 
surrogate markers. Various, and not always consistent, cytokine profiles have been 
described for a number of conditions. Flow cytometry with intracellular cytokine 
staining allows quantification of the amount o f cytokine present. These studies used 
this technique to describe the cytokine profile and changes in cytokine profile seen in 
patients during treatment for autoimmune uveitis and in patients with human 
immunodeficiency virus (HIV) receiving combination anti-retroviral therapy (ART).
These studies emphasized the importance of prompt and careful clinical examination in 
the presence of clinical symptoms but did not support routine screening of patients on 
high levels of immunosuppression. Accurate measurements of interleukin-2 (IL-2) and 
interferon-gamma (IFNy) in patients with uveitis did not correlate well with disease 
activity. In contrast patients with different HIV profiles did show measurably different 
Thl cytokine expression providing information on the T cell deficits that persist despite 
treatment with ART.
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HYPOTHESES AND OBJECTIVES
HYPOTHESES
1. Patients on high levels of immunosuppression have unrecognized, asymptomatic 
eye disease which may be sight threatening.
2. Quantification o f immunosuppression by flow cytometric assessment o f 
intracellular cytokines in immunosuppressed patients gives more accurate 
information on the level of immunosuppression and this information can be used 
to improve monitoring of therapy.
OBJECTIVES
1. To prospectively survey eye disease in patients on immunosuppression for the 
prevention o f rejection of heart, lung and heart-lung transplants.
2. To assess the value of screening in asymptomatic recipients of heart, lung and 
heart-lung transplants.
3. To investigate IL-2 and IFNy production by T cells in the peripheral blood of:
■ Normal Subjects
■ Patients with autoimmune uveitis
■ Patients with HIV
4. To investigate the relationship between cytokine profiles and clinical profiles.
5. To assess if cytokine measurements could be a useful adjunct to the
management of immunosuppressed patients.
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CHAPTER 1
C l in ic a l  M o n it o r in g : O c u l a r  C o m p l ic a t io n s  
F o l l o w in g  H e a r t , L u n g  A n d  H e a r t -L u n g  
T r a n s p l a n t a t io n
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1.1 INTRODUCTION
The traditional method of monitoring for toxicity is to monitor end-organ effects. As 
yet there are no laboratory indices that give a direct indication of end-organ toxicity in 
the eye so disease is picked up only when sufficient to cause ocular symptoms or by 
screening. Transplantation continues to be the arena in which immunosuppressive 
drugs are used in the largest quantities and at the highest doses and a myriad of ocular 
complications have been reported.
Heart, lung and heart-lung transplantations have become standard therapy for selected 
end-stage diseases. Advances in surgical and medical management and advances in 
immunosuppressive therapy have led to an improved quality of life and increased 
survival for transplant recipients. Allograft rejection is a constant risk, however, and 
the high levels o f immunosuppression required to maintain the graft continues to place 
the recipient at risk of significant morbidity and mortality, particularly from infection. 
Ocular complications may affect quality of life after recovery and as survival improves 
it becomes increasingly important to identify and appropriately treat these conditions. 
The ocular complications that have been associated with transplantation can be grouped 
as follows:
■ Opportunistic Infections
■ Other Complications Associated with Infection
■ Noninfectious Complications Secondary to Drug Toxicity
■ Noninfectious Complications Associated with Underlying Disease 
Processes
1.1.1 Opportunistic Infections
Infections account for 18-20% of all mortality in transplant recipients(l). The risk of 
opportunistic infection is determined by the interaction between the patient’s net state of 
immunosuppression and the epidemiological exposures the patient encounters (2). The 
patient’s net state of immunosuppression is determined by a variety of pre and post­
transplantation factors. The major post-transplantation factors are the nature o f the 
intensive immunosuppressive therapy that is administered to maintain the graft and 
whether or not infection with one or more immunomodulating viruses such as 
cytomegalovirus and Epstein-Barr virus is present. Nosocomial factors documented to 
increase the risk of infection in the immunocompromised patient include central venous
17
catheterization, bladder catheterization, duration and intensity of systemic antibiotics, 
colonization, total parenteral nutrition, granulocytopenia, diabetic ketoacidosis, hospital 
construction and faulty air filtering mechanisms. Patients who become donors o f solid 
organs are hospitalized before death and if critically ill, requiring intensive support such 
as ventilation, invasive cardiac monitoring and broad spectrum antibiotics, they are 
highly susceptible to the acquisition of nosocomial pathogens (3) (Figure 1.1). Lung 
transplant recipients are at highest risk for pulmonary infections as the transplanted 
organ has continuous contact with the extracorporeal environm ent^). Different 
infections are characteristic at different points along the time course following 
transplantation and have been described as occurring in three phases:
1. early (less than 1 month);
2. intermediate (1-6 months);
3. late (greater than 6 months)(2, 5)
Generally speaking, most infections during the first month after transplantation are 
related to surgical complications and the anatomical region of the transplant dictates to a 
great extent the type o f infection that occurs(6). The period following this is when most 
opportunistic infections tend to occur (Figure 1.2) and from 6 months most transplant 
recipients suffer from the same infections seen in the general community. Patients who 
have had frequent acute or chronic rejection are maintained on higher levels of 
immunosuppression for longer and so remain at risk o f opportunistic infections for 
longer.
Because infection may be allograft and/or life threatening it is managed with a high 
index o f suspicion and an arsenal o f prophylaxis, preemptive and therapeutic 
treatment(2). Solid organ transplantation is a risk factor for endogenous 
endophthalmitis(7) (Figure 1.3) and a number o f the infections characteristic o f 
transplantation have typical ocular manifestations. An advantage of ocular examination 
is that accurate ocular diagnosis may sometimes offer clues to as yet undiagnosed co­
existing systemic infections.
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Figure 1.1: Incidence of Infectious Disease in Solid-Organ Transplant Recipients 
Adapted from Snydman 2001(6)
Incidence of infection (%) in patients receiving
Heart Lung/Heart-lung
Bacterial 21-30 35-66
Cytomegalovirus 9-35 53-75
Herpes Simplex Virus 1 -42 10-18
Varicella Zoster 1-12 8-15
Virus
Candida spp 1-5 10-16
Mycelial Fungi 3-6 3-19
Pneumocystis jerovici 1-8 15
Figure 1.2: Timetable for the Occurrence of Infection After Transplantation 
Adapted from Rubin et al. 1981(5)
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1.1.1.1 Necrotizing Herpetic Retinopath ies
Herpes viruses are the most common cause of viral infections in transplant recipients(l) 
and herpes group viral retinitis are the most common ocular opportunistic infections in 
solid organ transplant recipients (8).
/. /. 1.1.1 Cytomegalovirus (CMV)
Human cytomegalovirus (Herpes virus type 5) is a double-stranded DNA virus that 
belongs to the |3 subgroup of herpes viruses(9). Infection leads to life-long persistence 
in 50-90% of the population and is generally subclinical in healthy subjects due to 
cellular and humoral immunity. In immunocompromised patients infection may lead to 
serious complications and CMV is responsible for a substantial fraction o f the morbidity 
and mortality that follows organ transplantation (10, 11). Before prophylaxis was 
widely used the incidence of symptomatic CMV infection was 25% in heart transplant 
recipients and 39% in heart-lung transplant recipients(12). Active CMV in transplant 
recipients carries a mortality rate of about 5%( 13). Infection may have 3 important 
consequences:
1. CMV disease,
2. immunomodulation leading to superinfection with opportunistic pathogens such 
as Pneumocystis jerovici and Aspergillus fumigatus,
3. injury to the transplanted organ( 14).
The two main risk factors for developing symptomatic CMV disease are:
1. whether the donor, recipient or transfusion products are infected with latent 
virus capable of being reactivated following transplantation.
2. the nature of the immunosuppression administered following transplantation.
The clinical manifestations o f CMV infection are exacerbated by increased 
immunosuppression, particularly by the use of anti lymphocyte antibodies for induction 
therapy( 14).
1.1.1.1.1.1 Clinical Features
The CMV syndrome in transplant patients occurs primarily in the first 3 months post­
transplant when immunosuppression is at its most intense. It usually begins insidiously 
with fever and symptoms of anorexia, malaise, epigastric pain, myalgias and arthralgias. 
Approximately one third o f those with constitutional symptoms develop a dry
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nonproductive cough within the first week of onset and in lung and heart-lung transplant 
recipients CMV pneumonitis may be acute, progressing over a short period of time 
(hours to days) to lung white-out and respiratory failure. Myocarditis occurs rarely in 
heart transplant recipients.
CMV retinitis is an uncommon and late manifestation of CMV disease in transplant 
recipients usually occurring more that 6 months after transplantation. Retinitis typically 
presents as blurred vision. Fundal examination reveals characteristic focal, white areas 
o f retinal necrosis with associated haemorrhage, perivascular infiltrates and minimal 
vitreous inflammation. Granular borders are characteristic. The natural history of 
untreated disease is one o f progression to confluent involvement and healing with 
scarring and retinal detachment(15). Optic disc neovascularization has been described 
in the healing phase of CMV retinitis associated with renal transplantation(16).
There is a single report in the literature of a dendritiform epithelial keratitis in a cardiac 
transplant patient where histopathology and culture o f corneal scrapings where highly 
suggestive of CMV epithelial keratitis(17). CMV disease affecting the cornea has more 
commonly been reported as endothelitis and conjunctivitis in patients with HIV(18, 19).
1.1.1.1.1.2 Prevalence o f  CMV Retinitis
The prevalence of CMV retinitis after solid organ transplantation is not known although 
before the onset o f the AIDS pandemic immunosuppression associated with 
transplantation was responsible for most cases. Fishbume and colleagues (20) reviewed 
the records o f 82 patients who had undergone cardiac transplantation between 
November 1986 and November 1994 (before CMV status matching and prophylaxis 
were routine) to attempt to determine the incidence of CMV retinitis after cardiac 
transplantation. Six out o f 41 o f the patients who had ocular examinations were 
considered to have evidence of CMV retinitis. Of these 6, only 2 had active infection 
and these were asymptomatic. Four of the patients were diagnosed after the infection 
had healed with characteristic scars. Two patients with healed CMV retinitis were 
symptomatic: one due to a retinal break at the border of the scarred retina and one due 
to cystoid macular oedema which resolved without treatment. All patients retained 
good visual function. They estimate the prevalence o f CMV retinitis in cardiac 
transplant recipients to be 7.3% (6/82) and recommend screening of patients 3 to 4 
months after transplantation and thereafter yearly or as symptoms occur. Erakgun (21) 
and colleagues assessed 13 asymptomatic cardiac transplantation patients in the post­
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transplant period. They found that 15% (2 patients) had active CMV retinitis despite 
having no symptoms. These patients had histories of diabetes mellitus, arterial 
hypertension and heavy smoking and one patient had hyperlipidemia. They postulate 
that microvascular disease is an important risk factor for migration o f CMV infected 
monocytes through retinal vessels. This hypothesis is supported by the fact that CMV 
retinitis is common in AIDS where microvasculopathy is characterisitic. They suggest 
screening patients with systemic microvascular risk factors such as diabetes, 
hypertension and smoking for the development o f CMV retinitis after cardiac 
transplantation even if the patients have no visual symptoms.
Because of the important consequences of CMV infection large efforts are put into 
assessing risk factors for CMV disease, rapid detection o f CMV in clinical specimens 
and the use of antiviral chemotherapy and immunoglobulin to prevent and treat CMV 
disease in the post transplant recipient.
1.1.1.1.1.3 Diagnosis
Although the ocular appearance is characteristic the diagnosis of systemic CMV is 
made difficult by the fact that a majority of transplant recipients have asymptomatic 
infection (with virus in saliva, urine and bronchoalveolar fluid) and only a minority will 
have symptomatic disease due to CMV. Ocular disease is often asymptomatic if the 
macula is not involved and therefore only uncovered on ocular examination(15, 21, 22). 
As organ rejection is the major differential diagnosis of CMV disease rapid diagnostic 
tests are used to inform the decision on whether to increase or decrease 
immunosuppression. These include virological tests such as the pp65 antigenemia 
assay and polymerase chain reaction (PCR) for DNAemia and, less commonly, 
serological tests such as complement fixing assay for CMV antibodies and ELISA. 
Diagnosis of ocular disease is often clinical and can usually be confirmed by PCR of 
vitreous samples(23).
1.1.1.1.1.4 Antiviral Strategies
The use of CMV seronegative blood products is effective in preventing CMV infection 
in CMV seronegative solid organ transplant recipients but these are scarce due to the 
high prevalence o f CMV antibodies(12). Instead filtered or leukocyte-poor blood 
products which are associated with a very low risk of CMV transmission can be used 
for seronegative recipients(12). Protective matching o f seronegative donors with
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seronegative recipients is not possible due to the scarcity of donor organs but 
knowledge of CMV status for donor and recipient allows for risk stratification.
The options for prophylaxis against CMV are anti-CMV hyperimmune globulin, high- 
dose oral aciclovir or valaciclovir and IV ganciclovir +/- oral valganciclovir. 
Ganciclovir prophylaxis has been shown to be superior to aciclovir in heart and lung 
transplantation(13). Ganciclovir targets the viral DNA polymerase where it acts as a 
chain terminator: ganciclovir monophosphate is incorporated at the 3’end of the viral 
DNA chain following intracellular phosphorylation. The first phosphorylation step is 
catalyzed by CMV-encoded protein kinase(24). Valganciclovir is an oral prodrug of 
ganciclovir. Vaccination of seronegative renal transplant recipients with live, 
attenuated CMV has been shown to result in a more benign clinical course of disease 
although the incidence of primary infection was not affected(25). A recent meta­
analysis o f randomised controlled trials of prophylaxis with antiviral medications 
demonstrated a significant reduction in cytomegalovirus infection (1786 patients; 
relative risk 0.42 [95% Cl 0.34-0.52]), cytomegalovirus disease (1300 patients; 0.26 
[0.08-0.78]) and all-cause mortality in recipients of solid-organ transplants(26). 
Ganciclovir was seen to be more effective than acyclovir, and valganciclovir and 
intravenous ganciclovir were as effective as oral ganciclovir.
Pre-emptive therapy involves the administration of antiviral agents to a subgroup of 
patients prior to the appearance of disease. When successful it has advantages in terms 
of cost, emergence of resistant viral strains and medication side effects(12, 27). Pre­
emptive therapy has been shown to reduce the incidence o f CMV disease in heart or 
lung transplant recipients(10, 27). Ganciclovir treatment for CMV is given to those 
patients in whom surveillance has shown pre-symptomatic viremia 2 to 7 days before 
the onset o f clinical symptoms consistent with CMV. Patients in whom 
immunosuppression is being augmented by either anti-lymphocyte antibody or pulsed 
steroids also benefit. Side effects include bone marrow toxicity, diarrhoea, renal 
toxicity and seizures. Although CMV antigenemia is generally considered to be a 
reliable and highly sensitive assay in cases of systemic CMV disease, this may not to be 
the case in isolated CMV retinitis occurring in transplant recipients(28). Also in contrast 
to other CMV diseases such as pneumonitis or colitis viral CMV load during retinitis 
does not necessarily correlate with disease progression(9).
Treatment with ganciclovir is indicated for all those who have evidence o f invasive 
CMV disease. Treatment of ocular disease may require local therapy in addition to
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systemic therapy. Either ganciclovir or foscamet can be given by repeated intravitreal 
injection. Foscarnet is not frequently used systemically because of concerns about its 
significant renal toxicity in cyclosporine treated patients. It is a pyrophosphate 
analogue which interferes with the binding of the pyrophosphate to viral DNA 
polymerase during the DNA polymerization process(24). A ganciclovir sustained 
release implant (Vitrasert containing 4.5mg of ganciclovir) is also available for longer 
term control. Complications o f intravitreal injection and vitrasert insertion are 
uncommon but include endophthalmitis, vitreous haemorrhage and retinal detachment. 
Fomivirsen (Vitravene) is the first antisense oligonucleotide analogue to be marketed. 
It is a 21-nucleotide sequence complementary to the immediate early region 2 of CMV 
messenger RNA. Intravitreal injection has been shown to be effective treatment of 
CMV retinitis in AIDS patients(29). Transient ocular complications include anterior 
chamber inflammation and raised intraocular pressure. Treatment with anti-CMV agents 
suppresses viral replication but does not eliminate the virus(30). Relapse is often not a 
problem in transplant patients as improvement in the recipient’s immune function over 
time is likely and may even lead to regression and scarring without ocular treatment(l 5, 
20-22).
CMV resistance to ganciclovir after prolonged treatment for CMV retinitis has been 
recognized amongst patients with AIDS since the late 1980s(31). Ganciclovir resistant 
CMV is only recently becoming a problem in solid organ transplant recipients. Likely 
causes o f this are the widespread use o f oral valganciclovir and the use o f more 
intensive immunosuppressive strategies. Lung transplant recipients are at particular 
risk. Adding foscamet is the intervention o f choice for ganciclovir resistant CMV as 
cidofovir has a theoretical risk for cross resistance(31). CMV hyperimmune globulin 
may also be helpful.
1.1.1.1.2 Varicella Zoster Virus (VZV)
VZV (herpes virus type 3) belongs to the a  subgroup of herpes viruses. Infection is 
almost universal with 95% of adults being VZV seropositive. The small proportion of 
recipients who are seronegative pre-transplantation are at risk o f primary infection.
1.1.1.1.2.1 Clinical Features
Reactivation in those that are seropositive pre-transplantation will result in the 
characteristic localized vesicular eruption of herpes zoster. In one study the herpes 
zoster incidence was 15.1% after lung transplantation and 16.8% after heart
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transplantation(32). The majority o f recipients developed zoster during the first post­
transplant year. Primary VZV in the solid organ transplant recipient can occur at any 
time after transplantation and although rare can cause a life threatening disseminated 
infection characterized by haemorrhagic pneumonia, skin lesions, encephalitis, 
pancreatitis, disseminated intravascular coagulation and hepatitis(l 1). It may also cause 
chicken pox or hepatitis alone.
1.1.1.1.2.2 Ocular Complications
In the general population the ophthalmic division of the trigeminal nerve is involved in 
8-56% of herpes zoster cases and ocular complications develop in 50-71% of these(33). 
In a series of 11 patients who developed herpes zoster after cardiac transplantation one 
patient (9%) had ophthalmic involvement(34). Herpes zoster ophthalmicus has a 
multitude of manifestations including corneal hypoaesthesia, punctate keratopathy, 
pseudodendritic keratitis, stromal keratitis, neurotrophic keratitis, anterior uveitis and 
glaucoma(35). Posterior segment complications are less common.
Acute retinal necrosis syndrome (ARN) was reported first in otherwise healthy 
individuals but has been widely reported in immunosuppressed patients, particularly 
those with AIDS(33). Ng and colleagues reported 5 patients who developed ARN 
following heart, lung or liver transplantation(8). Diagnostic investigations were not 
performed so the herpes virus responsible is not known. ARN may be caused by a 
number of the herpes viruses and may be unilateral or bilateral. Clinically there is 
peripheral retinitis, which may be confluent, severe vitritis, retinal vasculitis and 
papillitis(36). Progression is rapid with early retinal detachment. Laser retinopexy has 
been used to prevent retinal detachment and there is usually a good response to high 
dose intravenous aciclovir.
VZV retinitis (previously known as progressive outer retinal necrosis (PORN) 
syndrome) was seen first in HIV patients. It is characterized by multi-focal deep 
posterior pole or peripheral retinal lesions with minimal, or no, intraocular 
inflammation. VZV retinitis progresses rapidly and bilaterality is common(37). It does 
not respond well to antiviral agents and is more likely to result in a poor visual outcome 
despite treatment with multiple agents(38). Retinal detachment is likely. There are 
scattered reports in the literature o f VZV retinitis in patients with other causes for 
immunosuppression including bone marrow and renal transplantation(39-42) and in
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immunocompetent patients (43). VZV retinitis was not seen in the Ng series of ocular 
complications following heart, lung and liver transplantation(8).
1.1.1.1.2.3 Diagnosis
Diagnosis of VZV is usually made on clinical appearance. Standard criteria exist for 
the diagnosis of ARN(36). Clinical suspicions are best confirmed by PCR for VZV 
DNA and/or the Goldmann Witmer coefficient to determine levels of local antibody 
production. PCR may also be used to exclude CMV. Culture of virus in susceptible 
culture lines, demonstration of multinucleated giant cells on Tzanck smear and/or 
immunofluorescence techniques may also be helpful but these tests are rarely used 
clinically.
1.1.1.1.2.4 Treatment
Primary VZV has a high mortality in this group of patients so seronegative patients are 
advised to promptly report all exposures to VZV so that varicella-zoster immune 
globulin can be administered within 72hrs of exposure. Receiving prolonged CMV 
prophylaxis does not decrease the risk of developing herpes zoster although it does 
reduce the mortality(32). Live attenuated VZV vaccine given several months prior to 
transplantation is increasingly used particularly in the paediatric and seronegative 
transplant populations(44, 45). Aciclovir targets the viral DNA polymerase acting as a 
chain terminator, following intracellular phosphorylation. The first phosphorylation 
step is catalyzed by the virus encoded thymidine kinase making aciclovir specific for 
VZV (and HSV1 and 2)(24). IV aciclovir is administered if a zoster skin rash occurs 
post-transplantation but despite these measures progression to dissemination and death 
can still occur. Famciclovir or valaciclovir may also be used. Oral valganciclovir has 
been used successfully for the treatment of ARN in an immunocompetent patient(46).
1.1.1.1.3 Herpes Simplex Virus (HSV)
HSV (herpes virus type 1 and 2) belong to the a  subgroup of herpes viruses. 
Reactivated HSV is the most common viral infection during the first month after 
transplantation(6). 75% o f adult solid organ transplant recipients have HSV 
antibodies(l 1). Primary infection is usually a childhood illness and is often subclinical. 
Primary infection post-transplantation is very rare and may be transmitted by person-to- 
person contact or via the allograft. Both HSV 1 and 2 may affect the eye.
1.1.1.1.3.1 Clinical Features
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Following primary infection the virus remains latent in the sensory nerve ganglia until 
reactivation leads to oral, corneal or genital lesions usually in the first month post­
transplantation in about one third of adult transplant recipients(l 1). Reactivation or 
primary HSV occasionally causes pneumonitis, tracheobronchitis, oesophagitis, 
hepatitis and rarely disseminated infection.
Typical ophthalmic features are lid and conjunctival vesicles, dendritic epithelial 
corneal ulcers, stromal keratitis and anterior uveitis(47). HSV may affect the retina 
producing ARN syndrome, especially in younger patients(47, 48).
1.1.1.1.3.2 Diagnosis
The diagnosis is usually made clinically and can be confirmed by laboratory techniques. 
A positive IgM titer or a fourfold or greater rise in IgG titer are diagnostic. PCR of 
vitreous samples is useful for the diagnosis of ARN and to exclude CMV.
1.1.1.1.3.3 Treatment
The prophylactic use of oral aciclovir in the immediate post-transplant period has 
significantly reduced the incidence of HSV (6). Treatment o f HSV infection including 
ocular infection is with aciclovir, the dose and route of therapy depending on the site 
and severity of infection. Chorioretinal disease responds to systemic treatment. Side 
effects o f aciclovir infusion include phlebitis after IV infusion, renal toxicity and rash. 
HSV pneumonia is associated with a mortality rate of up to 75% despite treatment with 
aciclovir in solid-organ transplant recipients(l 1). Despite widespread aciclovir use 
HSV resistance has not been a problem in solid organ transplant recipients.
1.1.1.2 Fungal Chorioretinopathies
Fungal infections are reported in all types of solid organ transplantation and are 
associated with higher mortality than other forms of infection (11, 49). They are 
generally rare in the first month after transplantation (see Figure 1.2) (3, 5). 
Nosocomial fungal infections (primarily owing to Candida, Aspergillus and fusarium  
spp) usually occur within the first 2 months after transplantation, at a time that 
correlates with the most intense immunosuppression. Late rejection requiring increased 
immunosuppression contributes to delayed onset o f cryptococosis, Pneumocystis 
jerovici and the endemic mycoses. Fungal endophthalmitis is most likely in the setting 
of fungal bronchopneumonia in a transplanted lung. Drug resistance leads to an 
abysmal outcome and drug resistant bilateral endogenous Scedosporium prolificans
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endophthalmitis with a fatal outcome has been reported following lung 
transplantation(50).
1.1.1.2.1 Aspergillus spp.
Aspergillus fumigatus, A.flavus, A.niger and A.terreus are the most common mycelial 
fungi to cause nosocomial infection in solid-organ transplant recipients(l 1).
1.1.1.2.1.1 Clinical Features
The site of primary infection is usually the lungs (51, 52) and disseminated aspergillosis 
occurs via haematogenous spread. Heart, lung and heart-lung transplantation are 
associated with a higher rate of pulmonary aspergillosis than other solid organ 
transplants(3). In one study, 4.5% of heart transplant recipients seen over a 9 year 
period developed invasive aspergillosis(53) and in another, 15% of all heart-lung 
transplant recipients developed Aspergillus infection (4).
Alveolar macrophages normally kill inhaled aspergillal conidia, while functioning 
neutrophils eliminate residual m ycelia(ll). Neutrophil and macrophage dysfunction 
present in solid organ transplant recipients treated with steroids favour the development 
o f aspergillosis. Once tissue infection develops, invasion of the blood vessels is the rule 
with tissue infarction, haemorrhage and dissemination with metastatic seeding. Most 
Aspergillus spp infections occur within the first 3 months following solid organ 
transplantion(5)(see Figure 1.2). Disseminated aspergillosis is usually fatal despite 
intensive treatment( 11, 51, 54-56).
Endogenous Aspergillus endophthalmitis is a rare manifestation of disseminated 
aspergillosis and often occurs in conjunction with endocarditis(l 1). A literature review 
of 86 patients with endogenous proven Aspergillus endophthalmitis since 1949 revealed 
that 23% of the patients had undergone a solid organ transplant and 17% of the 86 
patients had lung disease (57). The typical appearance is o f grey-white choroidal 
masses with adjacent retinitis, haemorrhage and fluffy collections in the vitreous. A 
“■pseudohypopyon” or preretinal layering of exudate has also been described(57). There 
may also be conjunctival injection, chemosis, anterior chamber activity and hypopyon. 
Aspergillus endophthalmitis is usually rapidly progressive.
1.1.1.2.1.2 Diagnosis
Diagnosis o f systemic disease is made difficult by the fact that the isolation of 
Aspergillus spp. from respiratory and wound specimens does not always imply disease 
as the fungus may be a colonizer or a laboratory contaminant. Helmi et al reported that
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53% of their lung transplant recipients were colonized with Aspergillus spp. prior to 
transplantation(58). Ensuring that solid organ transplant recipients are not cared for 
close to building works and that flowers and potted plants are not allowed in patient’s 
rooms reduces colonization rates. Infection is certain if fungal filaments are present. 
Early recognition of the ocular disease may aid in diagnosis and prompt systemic 
treatment.
Pathological specimens demonstrate numerous branching and septate hyphae in 
thrombosed choroidal vessels (51, 54, 55). Diagnosis is often delayed with 51% of 
patients in the survey by Riddell and colleagues having the diagnosis made after 
enucleation or at autopsy (57). The diagnosis was made by culture or fungal stain in 
90% of vitrectomy specimens taken and 50% of vitreous aspirates. Blood culture and 
anterior chamber samples were rarely revealing.
1.1.1.2.1.3 Treatment
Amphotericin B is a polyene antifungal that was first isolated from Streptomyces spp. in 
1956 (59). It is poorly soluble in water and binds to sterols in fungal cell membranes 
leading to disruption o f the osmotic integrity of the membrane and cellular death. The 
range of activity is very broad and it remains the mainstay o f therapy for most life 
threatening fungal infections in solid organ transplant recipients(3). Side effects of 
treatment include fevers and myalgias which occur commonly and nephrotoxicity and 
bone marrow toxicity which are less frequent. Nephrotoxicity may limit the use of 
amphotericin B particularly in patients on CsA(3). Formulations with lipid carriers 
such as liposomal amphotericin B have improved toxicity profiles. A. terreus is notably 
resistant to amphotericin B but is sensitive to voriconazole (60). Voriconazole is a 
second generation triazole agent based on fluconazole that has been shown to be safe 
and effective in the treatment of invasive mould infections in transplant recipients(61, 
62). It does, however, increase the levels o f immunosuppressive drugs such as 
tacrolimus and CsA on coadministration so care must be taken to avoid renal 
toxicity(62). Azole antifungals inhibit fungal cytochrome P-450 enzymes resulting in 
faulty ergosterol synthesis and production of a defective cell membrane. Voriconazole 
can be administered intravenously if required and treatment can be continued orally. It 
is well tolerated and the main adverse effects appear to be liver disturbance and mild 
and transient visual disturbance such as blurred vision, altered visual perception and 
photophobia. These effects are not sight-threatening and do not necessitate a change in 
therapy.
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Amphotericin B has been the drug of first choice for the treatment o f Aspergillus 
endophthalmitis but due to the extensive vascular occlusion penetration is poor and 
early diagnostic pars plana vitrectomy with empirical intravitreal amphotericin B is 
recommended to deliver adequate drug levels to the eye(51, 57, 63). The half life of 
amphotericin B in the vitrectomized eye is only 2 days (64) so repeated injections are 
required. When intravitreal injections are given systemic treatment must also be given 
to control the systemic disease. Fluconazole and itraconazole cannot be used to treat 
ocular Aspergillus infection because of their poor penetration into the eye but oral 
voriconazole has been shown to achieve broad spectrum fungicidal concentrations in the 
vitreous of uninflamed eyes and may prove to be a useful adjunct to treatment(65). 
Aliyeva and colleagues have reported a case of Aspergillus endophthalmitis following 
cardiac transplantation that was treated with oral voriconazole(66). Although this 
patient proceeded to enucleation the fellow eye remained unaffected despite systemic 
disease and histology showed fungal elements restricted to the preretinal inflammatory 
infiltrate and notably absent from the choroidal and retinal vessels.
Despite intensive therapy progression to severe visual impairment, enucleation and/or 
death remain likely (7, 57). In one study disseminated aspergillosis was the single 
infectious complication responsible for the highest mortality rates in a heart 
transplantation population(67). Voriconazole for systemic disease has been associated 
with a higher survival rate than amphotericin B followed by other antifungal agents(61). 
Of the 86 patients with Aspergillus endophthalmitis in Riddell’s review only 9 (10%) 
regained useful vision and 2 o f these had very early disease restricted to the anterior 
segment(57).
1.1.1.2.2 Candida spp
The yeast Candida albicans is the most common agent in systemic and ocular infection 
although C.kruseii, C. glabrata, C. zeylanoides and C.tropicalis are also reported(l 1). 
Cell-mediated immunity, macrophage and neutrophil function are the defense against 
candidal infections. Cell mediated immunity is compromised by immunosuppressive 
therapy and many other factors in the solid organ transplant recipient such as antibiotic 
use, diabetes mellitus and indwelling bladder and intravenous catheters lead to 
increased candidal colonization( 11). Candidemia leads to disseminated disease in 50% 
of transplant recipients affected and is associated with increased mortality rates(3).
1.1.1.2.2.1 Clinical Features
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Infection can present in a myriad of ways including catheter-related sepsis, pulmonary 
infection, urinary tract infection, arthritis, endocarditis, aortitis, brain abscess, 
mediastinitis and endophthalmitis. Candidal infection in heart and heart-lung transplant 
recipients may be a cause of sudden death either due to rupture of the aortic anastomosis 
secondary to mycotic aneurysms or due to mediastinal abscesses secondary to 
dehiscence of an airway anastomosis(l 1).
Blood borne Candida reaches the choroid, forms collar-stud abcesses into the retina and 
thus enters the vitreous giving a characteristic clinical appearance. Small, multiple 
abscesses are seen with foci of retinal damage and vitreous snowballs(68, 69). The 
endophthalmitis has a relatively indolent course with better treatment results than for 
Aspergillus endophthalmitis(7, 70, 71). Rao and colleagues performed a retrospective 
study of 25 patients who underwent enucleation, 13 with Aspergillus disease and 12 
with Candida disease. They identified 4 cases of endogenous endophthalmitis due to 
Aspergillus spp. in solid organ transplant recipients. None of their patients with 
Candida endophthalmitis had had an organ transplant. They propose that drug induced 
immune suppression and organ transplantation are significant risk factors for 
aspergillosis and less so for Candida endophthalmitis (68, 71).
1.1.1.2.2.2 Diagnosis
Diagnosis of infection is by obtaining yeast fungal stains and cultures o f appropriate 
specimens. In cases of endophthalmitis vitreous samples can be obtained at vitrectomy.
1.1.1.2.2.3 Treatment
A North American prospective observational study assessed ocular candidiasis in 118 
patients with candidemia(72). None o f the patients in this study developed 
endophthalmitis. Only 11 patients (9%) developed chorioretinitis and this was 
effectively treated by prompt systemic treatment initiated for the fungemia. They found 
that the presence of visual symptoms and immunosuppression were significant risk 
factors for ocular involvement and conclude that Candida endophthalmitis is likely to 
represent chorioretinal extension in patients with delayed antifungal therapy(70, 72). 
Donahue and colleagues propose ophthalmology examinations in patients with 
candidemia to allow an objective measure of therapeutic response and so that more 
aggressive local therapy can be initiated in cases of progression to endophthalmitis. 
Amphotericin B is the mainstay of treatment. Because o f the high incidence of 
nephrotoxicity with amphotericin B azole antifungals such as fluconazole or
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itraconazole may be useful for systemic candidemia if sensitivity is demonstrated. 
Voriconazole has shown potent in vitro activity against Candida spp including C. krusei 
and less susceptible isolates(62). Ketoconazole is not used because of low efficacy, 
liver toxicity, interaction with CsA and erratic gastrointestinal absorption.
Treatment of severe ocular disease is with vitrectomy and intravitreal amphotericin B, 
while milder disease can be treated with intravitreal amphotericin B without vitrectomy. 
76-100% of patients are reported to show recovery o f vision(70). Systemic treatment is 
also required and early treatment o f candidemia may reduce the incidence o f 
endophthalmitis.
1.1.1.2.3 Cryptococcus neoformans
Cryptococcus is an encapsulated yeast. The species C.neoformans is the only one to be 
pathogenic in man. It has a large polysaccharide capsule with antiphagocytic properties 
and this together with its ability to grow at 37°C and the enzyme phenol oxidase make it 
a successful pathogen. It is widespread and found in soil, especially soil containing bird 
droppings. Opportunistic infection is most likely to occur later in the time course 
following transplantation (5)(see Figure 1.2).
1.1.1.2.3.1 Clinical Features
Infection is by inhalation and the primary lesion is usually in the lung and may be 
asymptomatic but followed by haematogenous dissemination to other areas o f the body. 
Manifestations include meningitis, pneumonia, pleural infection, cutaneous lesions, 
arthritis, pyelonephritis and pyrexia o f unknown origin. The organism has a 
predilection for the CNS. Ocular involvement is usually a secondary consequence of 
central nervous system involvement. Approximately 40% of individuals with 
cryptococcal meningitis have eye related signs such as papilloedema, optic atrophy or 
extraocular muscle paresis(73).
Endogenous ocular cryptococcosis is rare and is primarily a multifocal choroidal disease 
with secondary invasion of the retina and other intraocular structures. The vitreous 
overlying the chorioretinal lesions usually remains clear (73, 74). Crump and 
colleagues reported 27 patients with cryptococcal endophthalmitis over a period of 23 
years(75). Five (18%) of these patients were on immunosuppressive therapy although 
none of these patients was a transplant recipient. Litmathe and colleagues reported a 
patient with endophthalmitis which progressed to a scleral abscess following heart 
transplantation(73).
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1.1.1.2.3.2 Diagnosis
Diagnosis o f systemic disease is usually by the cryptococcal antigen test performed on 
serum and cerebrospinal fluid. This is also useful for monitoring the response to 
therapy. Culture and fungal stains are also helpful.
1.1.1.2.3.3 Treatment
Recommended treatment of systemic disease is with amphotericin B combined with 
flucytosine followed by an azole. Intravenous amphotericin B will not, however 
penetrate effectively into the eye. Flucytosine does penetrate the eye and is an 
antimetabolite that is activated by deamination within fungal cells to 5-fluorouracil (5- 
FU)(76). It thus inhibits fungal protein synthesis by replacing uracil with 5-FU in 
fungal RNA. Flucytosine also inhibits thymidylate synthetase and thus interferes with 
fungal DNA synthesis. It is used in combination to reduce the emergence of resistant 
strains. Gastrointestinal side-effects, bone marrow depression and hepatotoxicity can 
occur.
1.1.1.2.4 Pneumocystis jerovici (carinii)
Pneumocystis has recently been found to be host specific so the previously named 
P.carinii has been renamed P.jerovici. P.carinii is reserved for species pathogenic in 
rats. Although it has protozoa-like features and debate continues Pneumocystis has 
been reclassified as an Archiascomycetous fungus. Pneumocystis pneumonia occurs in 
approximately 3-10% of heart transplant recipients not given prophylaxis, often within 
the first 4 months after transplantation (11, 77, 78). Pneumocystis infection in the 
absence of effective prophylaxis occurs more commonly in lung and especially heart- 
lung transplant recipients than in other solid-organ groups. One prospective study of 
heart-lung transplant recipients using serial BAL specimens found Pneumocystis in 88% 
o f the patients; infection was symptomatic in 35%, subclinical in 24%, and 
asymptomatic in 41% (79).
1.1.1.2.4.1 Clinical Features
Pneumocystis pneumonia in solid-organ transplant recipients typically has a subacute 
presentation, with fever, dyspnoea, non-productive cough, radiographic findings of 
interstitial infiltrates, and hypoxemia out o f proportion to the physical findings. 
P.jerovici is frequently isolated with CMV(11, 78). Dissemination may occur via 
lymphatics or blood. It most commonly involves thyroid, liver, bone marrow, lymph 
nodes and spleen(80).
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Pneumocystis choroidopathy was first described in AIDS patients(81). Clinically there 
are multifocal, bilateral, plaque-like yellow choroidal lesions which are one-third to two 
disc diameters in size in the posterior pole and mid-periphery. There is no vitritis. 
Histopathologically there are eosinophilic, cellular, vacuolated, frothy choroidal 
infiltrates (81). At the time of writing Pneum ocystis choroidopathy has not been 
reported in solid organ transplant patients.
1.1.1.2.4.2 Diagnosis
The diagnosis is made by histological examination of bronchoalveolar lavage fluid or 
tissue biopsy. Immunocytochemistry and PCR are also helpful. P. jerovici cannot be 
readily cultured. The ocular features are highly characteristic, although not always 
symptomatic, and the initial diagnosis of disseminated Pneumocystis may be made by 
the ophthalmologist(81).
1.1.1.2.4.3 Treatment
Low-dose co-trimoxazole is relatively non-toxic and is very effective prophylaxis 
against Pneumocystis pneumonia (3, 82). It is advised for all solid-organ transplant 
recipients for at least 6 months post transplantation( 11). Prophylaxis beyond 6 months 
post-transplantation is indicated for heart-lung and lung transplant recipients and for 
patients with ongoing risk factors for Pneumocystis pneumonia such as multiple 
episodes of rejection, treatment with OKT3 monoclonal antibodies or persistent 
allograft dysfunction. Low dose co-trimoxazole for a minimum of 6 months also 
provides efficient protection against urinary tract infections, listeria sepsis, nocardiosis 
and toxoplasmosis (82, 83). Alternatives to co-trimoxazole for Pneumocystis 
prophylaxis include aerosolized pentamidine, dapsone, clindamycin and primaquine and 
atovoquone(l 1). Aerosolized pentamidine does not provide adequate prophylaxis 
against Pneumocystis choroidopathy in AIDS patients(81, 84, 85).
Treatment is with high dose co-trimoxazole or, if this is not possible with intravenous 
pentamidine for 14 to 21 days. Systemic treatment is also effective for ocular disease. 
Adverse effects of co-trimoxazole include anorexia, nausea, vomiting, a transient rise in 
creatinine levels and hyponatremia; adverse effects of pentamidine include renal 
dysfunction, bone marrow depression, hypoglycemia, hypocalcemia, liver dysfunction, 
and seizures(l 1).
1.1.1.3 Other Chorioretinopathies
1.1.1.3.1 Toxoplasma gondii
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Toxoplasma gondi is an obligate intracellular protozoan for whom the cat family is the 
definitive host and humans are an intermediate host. Infection with T.gondii is 
widespread and primary infection is usually asymptomatic with latency. T.gondii 
disease in solid organ transplant patients may occur secondary to reactivation or due to 
new infection from the donor organ, transfusion products or food such as uncooked 
meat and vegetables. Intracellular multiplication of tachyzoites leads to foci of 
necrosis. T.gondii is most commonly reported in heart transplantation because of the 
predilection of the parasite to invade muscle tissue. Gallino and colleagues found a 
prevalence of 13% after cardiac transplantation(86). Seronegative recipients receiving 
an organ from a seropositive donor are at the highest risk with 57% of heart 
transplants(87), 20% of liver and <1% of kidney transplant recipients acquiring primary 
T. gondii infection in the absence of prophylaxis(l 1, 88). In one study 25% of D+/R- 
heart transplant patients who were not taking prophylaxis developed lethal 
toxoplasmosis(67).
1.1.1.3.1.1 Clinical Features
Clinical presentations include meningoencephalitis, brain abscess, pneumonia, 
myocarditis, pericarditis, hepatitis, and choroidoretinitis(l 1). The onset o f clinically 
significant infection has been reported to be between 1 day and 7 years after 
transplantation, although most cases occur within 2 months post-transplantation( 11). 
Fulminant toxoplasmosis leading to death has been reported in heart transplant 
recipients(89, 90).
Ocular toxoplasmosis is reported after heart, lung or heart lung transplantation(86, 90- 
92). T.gondii choroidoretinitis was seen in 4 out of 175 patients who underwent cardiac 
transplantation at a single institution between 1989 and 2002(92). Three of the patients 
had acquired disease and one had disease reactivation. Diagnosis o f T. gondii 
choroidoretinitis is generally made clinically in the immunocompetent patient but in 
immunocompromised patients diagnosis may be more difficult as inflammation may be 
minimal and the lesion may be more extensively necrotic or haemorrhagic than 
typical(91, 92). The typical pigmented scar from previous episode of inflammation may 
also be absent.
1.1.1.3.1.2 Diagnosis
Definitive diagnosis is made by the histological demonstration of tachyzoites with 
surrounding inflammation in tissue. This may be very difficult to demonstrate
35
especially in small samples. T. gondii infection is widespread so serological testing is 
often not very useful. The Sabin-Feldman dye test is the most specific test. A positive 
IgM titre or a fourfold rise in the IgG titer supports a diagnosis of toxoplasmosis(86). 
The Goldman-Witmer coefficient between vitreous and serum (11, 92) or between 
aqueous humor and serum(93) can also be used to assess infection. Comparison of 
antibody production with immunoblotting techniques is also helpful(93). T.gondii 
specific DNA can sometimes be demonstrated by PCR in affected tissue. Serological 
investigations and PCR for CMV may be useful to exclude CMV retinitis. Multiple 
infections are more likely in the immunosuppressed patient and concomitant CMV 
infection may occur(90).
1.1.1.3.1.3 Treatment
Prophylaxis is advised when a seronegative patient receives an organ from a 
seropositive donor(3, 87, 92, 94). The standard regime is co-trimoxazole as used for 
Pneumocystis prophylaxis administered for at least 6 months post transplantation(95). 
Daily pyrimethamine may also be used and has been shown to reduce the incidence of 
T.gondii infection from 57% to 14% in mismatched heart and heart-lung transplant 
recipients(94). Alimentary and hygiene precautions are as important in the seronegative 
organ recipient as in pregnancy in seronegative mothers(96), and patients are advised 
not to consume poorly cooked meat or soiled fruits or vegetables and to avoid contact 
with cats.
Standard treatment with pyrimethamine with folinic acid and sulfadiazine for 4-6 weeks 
is usually effective although primethamine may result in bone marrow toxicity and 
sulfadiazine in renal toxicity. Clindamycin is an alternative. Ocular disease responds 
well to systemic treatment.
1.1.1.3.2 Nocardia asteroides
N  asteroides is a gram positive aerobic actinomycete bacterium with both bacillary and 
coccoid elements(97). It is soil-borne and often found in decaying organic matter such 
as wet hay or straw. Other disease causing species exist including N. brasiliensis. It 
has a worldwide distribution and can be recovered from the skin or upper respiratory 
tract of healthy people.
1.1.1.3.2.1 Clinical Features
Infection may be localized or disseminated and the lungs are the most common portal of 
entry although infection may occur through penetration of skin, mouth, intestines or the
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eye. Up to 50% of nocardiosis occurs in otherwise healthy patients but it is common 
and has a worse prognosis in debilitated, immunocompromised or immunosuppressed 
patients(97). Infection is usually chronic and progressive. A series of heart transplant 
patients has shown a 10% incidence o f systemic nocardiosis (98) and nosocomial 
outbreaks have been reported in heart transplant units (99). The disease becomes 
disseminated to the central nervous system in 23% of cases and ocular involvement has 
been reported in 3% of cases of systemic nocardiosis (100).
Intraocular nocardiosis has been reported following heart transplantation (101, 102) and 
following renal and bone marrow transplantation(97, 103, 104). The case reported by 
Chaudhry and colleagues had biopsy proven pulmonary nocardia and complained of 
blurry vision. The visual acuity was 20/20 on both sides but examination revealed 
yellow, nummular, choroidal abscesses with overlying exudative retinal detachment and 
minimal vitritis. The authors reported marked resolution following treatment with 
intravenous imipenem-cilastin. However, the patient immediately developed an area of 
retinitis and polymerase chain reaction in the blood was positive for CMV. This 
responded well to treatment with IV ganciclovir. The case illustrates the possibility of 
co-infections in immunosuppressed patients. Keratitis, conjunctivitis, corneal ulceration 
and episcleral granulomas are other reported manifestations o f intraocular 
nocardiosis(104).
1.1.1.3.2.2 Diagnosis
Definitive diagnosis is by culture o f the organism.
1.1.1.3.2.3 Treatment
Most strains of N. asteroides are sensitive to antimicrobial therapy. Amikacin is often 
the treatment of first choice (105). Sulfonomides in combination with trimethoprim are 
usually effective(l 1). Treatment must usually be prolonged as there is a tendency for 
relapse and prognosis depends upon the extent of the disease and the patients underlying 
immunologic status.
1.1.1.4 Other Bacterial Infections
Bacterial infections occur in 54% of lung transplant recipients and 21-30% of heart 
transplant recipients, usually within 2 months after transplantation (82). They most 
commonly involve the lungs, the urinary tract, surgical wounds or intravascular lines 
and are similar to those that occur in surgical patients who are not immunosuppressed. 
Perioperative antibacterial prophylaxis is standard practice in transplant centres.
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Dissemination of bacterial infection including mycobacteria to the eye following 
transplantation appears to be rare. In a study of 620 consecutive patients undergoing 
orthotopic heart transplantation at Stanford Medical Centre there were 1073 infectious 
episodes(67). None of the bacterial infections involved the retina. A major review of 
endogenous bacterial endophthalmitis did not identify transplantation as a significant 
predisposing factor(106) although it was identified in a series o f culture proven 
endogenous endophthalmitis including both fungal and bacterial causes(7) (Figure 1.3). 
A recent retrospective report of endogenous endophthalmitis in Australia found that 1 
out of 13 patients was post transplant (renal) and this patient died from disseminated A. 
fumigatus infection(107). No patient who developed bacterial endophthalmitis had 
transplantation as a risk factor.
Figure 1.3: Systemic Medical Conditions Associated with Endogenous Endophthalmitis 
Adapted from Schiedler 2004(7)
Medical Condition Number of Patients*
Intravenous line or indwelling catheter 14
Diabetes Mellitus** 11
Immunosuppressive Therapy 9
Organ Transplantation 6
Malignancy 5
Haemodialysis 5
Intravenous Drug Use 3
Human Immunodeficiency Virus 1
*21 patients. 14 patients had more than one associated condition.
**2 patients had steroid-induced hyperglycaemia
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1.1.2 Other Complications Associated with Infection
1.1.2.1 Post Transplantation Lymphoproliferative Disorder (PTLD)
Another complication of organ transplantation related to immunosuppression is post 
transplantation lymphoproliferative disorder (PTLD). This is an abnormal proliferation 
of lymphocytes strongly associated with Epstein Barr Virus (EBV) infection (108). 
EBV is herpes virus type 4. CsA inhibits the virus-specific cytotoxic T cells that 
normally control the expression of EBV infected transformed B cells and this allows the 
development of B cell tumours. These range from benign polyclonal polymorphic B 
lymphocyte hyperplasia to monoclonal B lymphocyte lymphoma. 10% of PTLD is, 
however, of T cell origin suggesting that the condition may sometimes be independent 
of EBV(108).
The overall prevalence of PTLD is less than 5% (109) but rates vary with the type of 
organ transplanted, primary EBV infection, CMV mismatch and the type and intensity 
of the immunosuppression(l 1, 108, 110-113). It has been reported in 5 to 13% o f heart 
transplant recipients and 9% of heart-lung transplant recipients(l 10). The incidence of 
PTLD is highest in the first post-transplant year(114) but for those with ocular 
involvement the latency is often years after transplantation(l 15, 116). Ocular 
involvement has been reported after heart transplantation(l 15, 117) and in a lung 
transplant recipient(l 18). It is most commonly reported in paediatric patients who have 
undergone liver transplantation(l 16, 119-124).
1.1.2.1.1 Clinical Features
EBV infection is usually asymptomatic or mild. Systemic manifestations o f infection 
can take 3 forms: an infectious mononucleosis type illness, disseminated disease with a 
high mortality and focal organ system involvement(108). 50% of paediatric transplant 
recipients are seronegative for EBV and in one transplant centre symptomatic EBV 
infections occurred in 19% of children and 2.7% of adults(l 13).
Ocular manifestations were first described by Brodsky and colleagues as iris nodules, 
iris masses with a uveitic masquerade syndrome, vitritis, subretinal masses and 
chorioretinitis(124). Anterior chamber cells and iris nodules are the most common 
manifestations. Orbital involvement has also been reported(123). Demols and 
colleagues were able to demonstrate more than 1000 times the levels of EBV genomes 
by semiquantitive PCR in the vitreous o f an affected patient compared to the
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blood(125). The clinical course of disease is described as chronic and fluctuating(l 16) 
and corticosteroids are poorly effective. In approximately 50% of patients ocular PTLD 
is part of a systemic disease(108).
1.1.2.1.2 Diagnosis
Definitive diagnosis is by the histological finding of mono or polyclonal B or T cell 
proliferation.
1.1.2.1.3 Treatment
Therapy requires a reduction in immunosuppressants to balance the immune response. 
Antivirals are also given to control the EBV infection although it has been suggested 
that virus replication might not play as important a role in pathogenesis during the later 
stages of PTLD as it does at disease onset(l 16). The response to therapy is often slow 
and local therapy with radiation(l 17, 124) and surgical excision may also be 
required(122).
1.1.2.2 Kaposi’s Sarcoma (KS)
Human herpes virus 8 (HHV8) appears to be central to the aetiology o f Kaposi’s 
Sarcoma (KS) and has been associated with KS in transplant patients. Post 
transplantation KS may be due to HHV8 reactivation as a result o f immunosuppressive 
treatment or to HHV8 primary infection transmitted via organ transplantation(126). KS 
appears at a mean o f 22 months post transplantation and is the malignancy appearing 
earliest following transplantation.
1.1.2.2.1 Clinical Features
Lesions are characterized by multiple red or violaceous plaques or nodules composed of 
a proliferation of vascular channels and spindle-shaped neoplastic cells. The most 
common site of involvement of KS is the skin and periocular skin and conjunctiva may 
be affected. 40% of transplant patients may also have visceral disease(127, 128). The 
immunosuppression associated with organ transplantation is a risk factor for KS and the 
incidence o f KS among transplant recipients in North America is 3-4% compared to
0.02% among the non HIV infected population (127). It is rarely reported in heart(126, 
128, 129) and lung(130) transplant patients. One patient in the series reported by Barete 
and colleagues had conjunctival involvement.
1.1.2.2.2 Diagnosis
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Diagnosis is usually clinical and may be confirmed by the histological finding of 
proliferation of vascular channels and spindle-shaped neoplastic cells.
1.1.2.2.3 Treatment
KS is associated with calcineurin inhibitors, particularly CsA, and reduction of 
immunosuppression or conversion to immunosuppressives with a different mechanism 
of action, such as sirolimus, is usually effective treatment(131-139). Ocular KS may 
not require intervention(38) as the lesions are slow growing, do not invade the eye and 
often do not affect the vision. Eyelid or other organ involvement may require 
intralesional therapy, radiotherapy, reduction in immunosuppression, chemotherapy or 
surgery. When visceral involvement is present mortality may be as high as 60-75% 
despite treatment( 128).
1.1.2.3 Progressive Multifocal Leukoencephalopatlty (PML)
JC virus has been cultivated from human brain of PML patients(140). This virus 
belongs to the polyoma subgroup of the genus Papovaviridae and is ubiquitous (the 
prevalence o f seropositivity ranges from 50% in children to 90% in adults)(141). 
Visual loss due to PML occurs in 50% of cases as there appears to be a predeliction for 
the occipital cortex. Visual loss has been reported as the presenting symptom of PML 
in a heart transplant recipient(142) and after lung transplantation(143).
1.1.2.3.1 Clinical Features
Primary infection usually occurs during childhood and is asymptomatic or causes fever. 
Recovery occurs with latency. Once reactivated the virus may penetrate the brain 
leading neurological sequelae.
1.1.2.3.2 Diagnosis
The diagnosis is made by demonstrating JC virus in the cerebrospinal fluid by PCR or 
by brain biopsy. Histologically there are multifocal sites of demyelination with sparing 
of axons, characteristic gigantic astrocytes with large pleomorphic nuclei and large 
hyperchromatic oligodendrocytes at the periphery of the lesion(142). Diagnosis is made 
difficult by the fact that JC virus may not be demonstrated in CSF until months after the 
initial presentation(143).
1.1.2.3.3 Treatment
Untreated mortality is very high but there has been success with combinations of 
cytarabine and other antivirals including ART in the HIV infected population(143).
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1.1.3 Noninfectious Ocular Complications Secondary to Drug Toxicity
There are difficulties is ascribing particular toxic effects to particular drugs when 
transplant recipients are exposed to a cocktail o f drugs at varying doses for extended 
periods of time. Despite this the drugs used in transplantation characteristically produce 
a number of ocular side effects as described below.
1.1.3.1 Corticosteroids
1.1.3.1.1 Posterior Subcapsular Lens Opacity and Cataract
Posterior subcapsular lens opacities (PSCLO) are a well recognized and studied 
complication of long-term oral corticosteroid use(144-148) and the incidence of cataract 
appears to rise with higher dosage and longer duration of corticosteroid therapy. The 
mechanisms involved in cataract development are not clear but probably include 
increased glucose levels, caused by an increased gluconeogenesis rate; inhibition of 
Na+/K+-ATPase; increased cation permeability; inhibition of glucose-6-phosphate- 
dehydrogenase; inhibition of RNA synthesis; loss of ATP; and covalent binding of 
steroids to lens proteins(149). Glucocorticoids make stable covalent adducts with the 
lysine reidues o f lens proteins in a non-enzymatic way. These adducts are observed in 
steroid-induced cataracts, but not in other human cataracts or normal human 
lenses(150). Although the complication was first documented amongst patients 
receiving steroids for the treatment of rheumatological diseases such as rheumatoid 
arthritis it has also been studied in renal transplant recipients(151-154). Nishimoto and 
colleagues found a 77.8% incidence of posterior subcapsular lens opacities with a mean 
follow-up period of 25 months. Treatment is not indicated unless patients become 
symptomatic with glare and impaired visual acuity. An excellent outcome can be 
expected from cataract surgery.
1. 1.3.1.2 Raised Intraocular Pressure and Glaucoma
The association between oral corticosteroids and ocular hypertension is also well 
recognized and studied (148, 155-158). Steroid-induced ocular side-effects may present 
as ocular hypertension or open-angle glaucoma depending on the duration of treatment 
and the susceptibility of the individual. A retrospective epidemiological study of 
elderly patients on the Quebec health-insurance-plan database demonstrated an 
increased risk of glaucoma in patients receiving oral glucocorticoids(159). This risk 
was shown to be dose dependent and to increase with the duration of treatment. The 
risk of ocular hypertension or glaucoma with oral steroids was found to be lower than
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that for ophthalmic topical steroids. Increased intraocular pressure is thought to result 
from glucocorticoid induced morphological and functional changes in the trabecular 
meshwork( 149). Glucocorticoid effects on trabecular meshwork cells lead to an 
increased accumulation of polymerized glycosaminoglycans(160) possibly due to 
decreased availability of catabolic enzymes(161) as well as an increased production of 
fibronectin and collagen type IV(162).
Raised intraocular pressure is well documented as an ocular complication in renal 
transplant patients(152, 163, 164).
1.1.3.1.3 Central Serous Chorioretinopathy
Friberg and Eller described serous retinal detachment resembling central serous 
chorioretinopathy (CSR) following solid organ transplantation(165). Their two patients 
underwent heart transplantation and subsequently developed bullous, serous detachment 
of the retina associated with retinal pigment epithelium (RPE) mottling and RPE 
detachments and demonstrated leakage on fluorescein angiography typical o f CSR. 
There were no other apparent causes for the exudation. Indocyanine green angiography 
findings in similar patients with CSR are dilated choroidal veins, delayed choroidal 
filling, intrachoroidal hyperfluorescence, and patchy hypofluorescence at or near the 
sites of dye leakage examined by fluorescein angiography(166). The literature contains 
other reports of serous chorioretinopathy following organ transplantation( 167) including 
heart(168, 169) and heart-lung transplantation(170). The heart-lung recipient developed 
leopard-spot geographical areas of RPE clumping which may have been secondary to 
localized choroidal intravascular coagulation or to acute hypertension.
The pathogenesis o f serous chorioretinopathy is uncertain and there are several 
theories( 171). These include focal loss o f RPE barrier function at the leak(172), 
reversal of the RPE pump at the leak(173), diffuse RPE dysfunction in regions beyond 
the defect(174) and choroidal abnormalities including increased choroidal permeability 
and extravascular tissue pressure with dysfunction o f the overlying RPE(175-177). 
Friberg and Eller( 165) and others(178) who have reported serous retinal detachments 
following solid organ transplantation propose that alterations in oncotic pressure 
gradients and extracellular fluid distribution found in their patients, who all had renal 
failure, play an important role in the persistence of subretinal fluid when a serous 
detachment develops. Koyama et al. also describe a case of serous retinal detachment
43
10 months following renal transplantation but information on renal function and the 
extent of the detachment was not presented(179).
Systemic steroids have long been associated with RPE damage(180) and their 
association with serous retinal detachment has been demonstrated in a number of 
studies( 181-185). Reduction of steroid dose appears to lead to recovery(185) with 
relapse being associated with recurrent steroid therapy( 181). The causative mechanisms 
for these effects have not, however, been explained(l 86). Increased plasma cortisol 
concentrations may be responsible for vasospasm or altering permeability in the 
choriocapillaris in one or more focal areas in the posterior fundus so that large proteins 
gain entrance to the RPE and subretinal space causing leakage of fluid into the 
subretinal space (182, 185). Moreover inhibition of collagen synthesis by cortisol may 
produce thinning of capillary walls resulting in increased capillary fragility. It may be 
that systemic steroids predispose towards the development of serous chorioretinopathy 
when there is pre-existing damage to the RPE(187). Idiopathic CSR is self-limited and 
mild in most patients although approximately 5% of patients have severe permanent 
loss o f central vision because of multiple recurrences over a period of time(182). 
Interestingly, recovery from serous chorioretinopathy occurs in post transplant patients 
despite the fact that the steroid dose cannot be promptly reduced because of the risk to 
the transplanted organ(165, 178, 179).
Another association that has been discussed in the literature is psychological stress(182, 
183, 188). Individuals with type-A behaviour have increased levels of plasma cortisol 
and elevated urinary excretion of free cortisol(184). The role o f adrenaline in the 
development of CSR is supported by the fact that serous chorioretinopathy can be 
induced in monkeys by prolonged infusion of intravenous epinephrine(176, 177). 
Stress is certainly a prominent feature in the post transplant period.
The prevalence of these detachments following transplantation is small but Scorolli et al 
suggest that symptomatic disease may underestimate the problem and propose a study 
to screen asymptomatic patients post transplant with fluorescein angiography(178).
Medical treatments have no proven influence on the disease. Laser photocoagulation 
has been used to speed resolution although it does not improve the final visual 
outcome(172). The results of different studies on this subject are controversial and 
inconclusive so laser is recommended only in selected cases(184).
1.1.3.1.4 Idiopathic Intracranial Hypertension.
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This is an uncommon condition that has also been known as pseudotumour cerebri and 
benign intracranial hypertension. The condition is characterized by elevated intracranial 
pressure associated with normal high resolution cranial imaging and normal 
cerebrospinal fluid composition(189-191). The causative mechanism for idiopathic 
intracranial hypertension is not known but there are many associations including 
chronic steroid therapy, increasing steroid dose or recent steroid withdrawal 192-195). 
Symptoms are those of raised intracranial pressure and the major threat to the patient is 
loss of vision. Treatment involves removing any postulated precipitating causes, weight 
loss, acetazolamide, repeated lumbar punctures, shunting and/or optic nerve sheath 
fenestration. Vision and visual fields are used to monitor the course of disease. 
Schowengerdt and colleagues(196) reported a case o f a paediatric heart transplant 
recipient who presented with headache and diplopia 3 months after surgery. 
Examination revealed normal acuity, bilateral sixth nerve palsies and mild optic disc 
oedema; MRI was normal. The visual acuity deteriorated over the following months 
and lumbar puncture demonstrated an elevated opening pressure of 530 mm water with 
normal CSF composition. Despite attempts to both increase and decrease the 
prednisolone dosage, and further aggressive therapy the patient was left with hand 
motion vision on the right and light perception on the left. Severe visual deficits occur 
in 4-12% of patients with idiopathic intracranial hypertension(190). The prevalence of 
idiopathic intracranial hypertension in a population o f paediatric renal transplant 
recipients was 4.4%(197).
1.1.3.2 Cyclosporine A (CsA/Sandimmune/Neoral)
Visual hallucinations and cortical blindness (198) can occur secondary to CsA 
treatment as occipital white matter appears to be uniquely susceptible to its neurotoxic 
effects. CsA has also been associated with disc oedema and idiopathic intracranial 
hypertension in bone marrow(199) and renal(194) transplant patients and with 
ischaemic retinal microvasculopathy. Ischaemic retinal microvasculopathy is most 
often reported after bone marrow transplantation when patients are on CsA having also 
received conditioning therapy such as busulphan or total body irradiation(200) (199). It 
has also been reported in renal transplant patients(201).
In most patients the signs and symptoms resolve on reduction or cessation of CsA(202). 
There is, however, one report in the literature o f sudden, complete and irreversible 
blindness 36 hours after administration of CsA in a kidney-pancreas transplant recipient
45
(203). In this case the onset of blindness coincided with a sudden elevation in serum 
CsA levels following intravenous administration.
1.1.3.3 Tacrolimus (Tac/FK506/Prograj)
The ocular toxicity of Tac is similar to that of CsA(204) described above although in 
one study Tac was shown to be cataractogenic in adult rats (205). This was shown to 
be due to an accumulation of sorbitol in the lens secondary to a pancreas mediated 
diabetogenic effect of Tac. A cataractogenic effect has not been seen in humans 
although post transplant diabetes mellitus does occur.
1.1.3.4 Azathioprine (Imuran)
Ocular toxicity is not a documented feature of azathioprine.
1.1.3.5 Mycophenolate Mofetil (MMF/Cellcept)
Myelosuppression may occur and patients are at an increased risk of opportunistic 
infection, particularly viral infection. Some authors have reported an increased 
incidence and/or severity of cytomegalovirus infections with a higher morbidity in renal 
transplant recipients on MMF(206, 207). This effect appears to be dose related and has 
not been reported in patients on 2g/day MMF or less.
1.1.3.6 Non infectious Complications Associated with Underlying Disease Processes
1.1.3.7 Diabetes Mellitus
Diabetes mellitus is a common finding both before and after heart, lung and heart-lung 
transplantation. Following transplantation it is generally associated with corticosteroid 
therapy. The principle mechanism of steroid-induced diabetes mellitus is increased 
insulin resistance.
1.1.3.7.1 Ocular Manifestations
Diabetic retinopathy is the most significant ocular consequence of diabetes mellitus. 
The pathogenesis is unclear but the earliest histological abnormalities are basement 
membrane thickening, endothelial proliferation, and loss o f pericytes(208). A 
breakdown of the inner blood retinal barrier and increased retinal blood flow is noted 
with early retinopathy. Increased blood flow and vascular dilatation are thought to be 
secondary to altered retinal vascular autoregulation, hyperglycemia and tissue hypoxia. 
Focal intraretinal capillary closure leads to microaneurysms, retinal vascular loops, 
dilated capillaries, and ischemic maculopathy. Increased retinal vascular permeability 
causes dot-blot haemorrhages, macular oedema and hard exudates. Widespread
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capillary closure with retinal ischemia occurs with pre-proliferative retinopathy. These 
changes are noted clinically as venous beading, nerve fibre layer infarcts, and dilated 
pre-existing intraretinal capillaries (intraretinal microvascular abnormalities). 
Proliferative diabetic retinopathy is thought to result from a disturbance of the normal 
complex balance of matrix and growth factors involved in homeostasis of the retinal 
vessels, including vascular endothelial growth factor, fibroblast growth factors, insulin­
like growth factors, platelet-derived growth factor, epidermal growth factor and 
transforming growth factors(208).
Findings are on a spectrum ranging from mild to severe and are classified as shown in 
Figure 1.4. The severity of retinopathy correlates with longer duration o f diabetes 
mellitus, younger age at diagnosis, high glycosylated haemoglobin levels, high systolic 
blood pressure, insulin-dependent diabetes mellitus, proteinuria and small body mass. 
Blinding complications include vitreous haemorrhage, retinal detachment and 
neovascular glaucoma(208). Treatment of ocular disease is by tight control of 
glycaem ia, hypertension and hyperlipidem ia and photocoagulation for 
neovascularisation and leakage.
Figure 1.4: Classification of Diabetic Retinopathy(208)
Classification of Diabetic Retinopathy
Non-proliferative (background) diabetic retinopathy 
-M ild
- Moderate
- Severe (pre-proliferative)
Proliferative diabetic retinopathy
- Low-risk
- High-risk
1.1.3.8 Hypertension
Systemic hypertension is a common finding both before and after heart, lung and heart- 
lung transplantation. Following heart, lung and heart-lung transplantation it is generally 
associated with corticosteroid and CsA immunosuppressive therapy. Mechanisms of 
drug-induced hypertension are not well understood but CsA induced hypertension may
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be due to augmented production o f endothelin, impairment of nitric oxide synthesis, 
neuroendocrine activation, hypervolemia and alterations in vascular reactivity(209).
1.1.3.8.1 Ocular manifestations
The fundus picture in hypertension is related directly to the status of the retinal arteries 
and the rate of rise and degree of systemic blood pressure(210, 211). Pathologically, the 
arterioles narrow and develop thickening o f their walls as a result o f intimal 
hyalinization, medial hypertrophy and endothelial hypertrophy. The age of the patient 
may complicate interpretation of the clinical changes as sclerotic changes also occur in 
the normal aging population. The retinal changes of hypertension may also overlap 
with those seen with other retinal vascular disease such as diabetes. A classification for 
hypertensive retinopathy based on recent population based data is shown in Figure 1.5. 
Secondary ocular complications of chronic systemic arterial hypertension include retinal 
vascular occlusive disease, macroaneurysm formation, and nonarteritic anterior 
ischemic optic neuropathy.
Accelerated (malignant) hypertension is a rare and potentially fatal condition leading to 
changes in the retina, choroid and optic nerve. The acute rise in systemic pressure 
causes fibrinoid necrosis of the arterioles and papilloedema. Clinically there is focal 
retinal arteriolar constriction followed by flame retinal haemorrhages, cotton-wool 
spots, optic nerve oedema and rarely serous detachments. Chronically Elshnig’s spots 
and Siegrisf s streaks are seen.
Figure 1.5: Classification of Hypertensive Retinopathy(211)
Grade of Retinopathy Retinal Signs Systemic Associations
None No detectable signs None
Mild Generalized arteriolar narrowing, 
focal arteriolar narrowing, 
arteriovenous nicking, opacity 
(copper wiring) o f  arteriolar wall or 
a combination o f these signs
Modest association with risk o f 
clinical stroke, subclinical stroke, 
coronary heart disease and death
Moderate Haemorrage (blot, dot or flame 
shaped), microaneurysm, cotton 
wool spot, hard exudate or a 
combination o f these signs
Strong association with risk o f 
clinical stroke, subclinical stroke, 
cognitive decline, and death from 
cardiovascular causes
Malignant Signs o f moderate retinopathy plus 
swelling o f the optic disc
Strong association with death
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1.1.3.8.1.1 Central Retinal Vein Occlusion (CRVO)
CRVO in heart and heart-lung transplant patients has been described in the 
literature(212, 213) (214). Patients characteristically present with sudden loss of vision 
and examination reveals dilated, tortuous veins with retinal haemorrhages in all four 
quadrants. Occlusion is thought to occur secondary to thrombus formation in the 
central retinal vein within or near the lamina cribrosa and is associated with systemic 
abnormalities such as arteriosclerosis, systemic hypertension, diabetes mellitus, 
hyperviscosity, blood dyscrasias, dysproteinemias, hyperlipidemia, chronic lung 
disease(215) and vasculitis as well as chronic open angle glaucoma. Patients 
undergoing cardiopulmonary bypass during heart-lung transplantation may have 
induced systemic hypothermia and may develop systemic hypotension and raised 
intraocular pressure. In addition cardiopulmonary bypass is associated with activation 
of the complement system and alterations in platelet function. These factors have also 
been associated with ischaemic optic neuropathy as a complication o f cardiopulmonary 
bypass surgery(216). Clotting factors are frequently administered during and after 
transplantation. Hypertension, diabetes mellitus, hyperlipidemia, chronic lung disease 
and cardiopulmonary bypass are common in this group of patients and it has been 
postulated that these conditions may all predispose transplant recipients to CRVO (212).
CRVO may be ischaemic with a risk o f rubeosis iridis and glaucoma or non- 
ischaemic(208). Macular oedema is another sight threatening complication. Treatment 
is by intraocular pressure control, induction of chorioretinal venous anastomoses and 
panretinal laser photocoagulation for ischaemic eyes with iris neovascularisation.
1.1.3.9 Horner’s Syndrome
Horner’s Syndrome occurs when the sympathetic innervation to the eye is 
interrupted(217). Lesions at any point along the sympathetic pathway result in Homers 
syndrome. Clinically there is mild-to-moderate ptosis owing to denervation of the 
sympathetically controlled Muller muscle, an abnormally high lower eyelid ‘upside- 
down ptosis’ secondary to involvement of the inferior tarsal smooth muscle, miosis and 
dilation lag. Depending on the level of the lesion, impaired flushing and sweating may 
be found ipsilaterally. Anhydrosis affects the ipsilateral side of the body with central, 
first-order neuron lesions. Lesions affecting second-order neurons may cause 
anhydrosis o f the ipsilateral face. With postganglionic lesions occurring after 
vasomotor and sudomotor fibres have branched off the sympathetic chain, anhidrosis is
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either absent or limited to an area on the forehead. Iris heterochromia is a feature of 
congenital Homer’s or o f long-standing or early onset Homer’s.
1.1.3.9.1 Anatomy
First-order central sympathetic fibres arise from the posterolateral hypothalamus, 
descend uncrossed through the mid brain and pons, and terminate in the 
intermediolateral cell column of the spinal cord at the level of C8-T2 (ciliospinal centre 
of Budge)(217). Second-order pre-ganglionic pupillomotor fibres exit the spinal cord at 
the level of T l, enter the cervical sympathetic chain where they are in close proximity 
to the pulmonary apex and the subclavian artery. The fibres ascend through the 
sympathetic chain and synapse in the superior cervical ganglion at the level of the 
bifurcation of the common carotid artery (C3-C4). Post-ganglionic pupillomotor fibres 
exit the superior cervical ganglion and ascend along the internal carotid artery. Shortly 
after the post-ganglonic fibres leave the superior cervical ganglion vasomotor and the 
sudomotor fibres branch off, they travel along the external carotid artery to innervate 
the blood vessels and sweat glands o f the face. The pupillomotor fibres ascending along 
the internal carotid artery enter the cavernous sinus. The fibres then leave the carotid 
plexus to briefly join the abducens nerve in the cavernous sinus and enter the orbit 
through the superior orbital fissure along with the ophthalmic branch of the trigeminal 
nerve (Vj) via the long ciliary nerves. The long ciliary nerves then innervate the iris 
dilator and Muller muscle.
1.1.3.9.2 Diagnosis
Clinical examination can be supplemented by pharmacologic testing with cocaine 4% 
and hydroxyamphetamine 1% drops. 4% cocaine drops will not dilate a Homer pupil. 
A pre-ganglionic Homer pupil will dilate with 1% hydroxyamphetamine and a post­
ganglionic Homer pupil will not.
Second-order pre-ganglionic neuron damage is common following thoracic surgery and 
chest tube or central venous catheter placement.
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1.2 AIMS
This study aimed to prospectively monitor a cohort of patients for the development of 
ocular complications. These patients were receiving high levels o f immunosuppression 
for the prevention of rejection of heart, lung and heart-lung transplants. As described in 
the introduction many complications can occur in immunosuppressed patients and many 
are sight threatening. This study aimed to ascertain the burden of ocular morbidity and 
the need for screening by monitoring both asymptomatic and symptomatic patients.
1.3 METHODS
1.3.1 Patient Selection
Following local ethics committee approval ocular examination was offered to both 
symptomatic and asymptomatic patients attending a post-transplantation out-patient 
clinic at Harefield Hospital between the beginning of June 1999 and the end of August 
2000. In-patients were also invited for assessment if they were able to tolerate 
examination. Repeat examinations were encouraged if symptoms occurred or during 
follow-up visits.
Most patients were managed on regimes involving steroids, Aza and CsA. A minority 
o f patients were managed on Tac or MMF containing regimes. CMV negative 
recipients were treated prophylactically with high dose oral aciclovir. CMV 
antigenaemia was routinely measured in CMV negative patients and treated with IV 
ganciclovir in the presence of symptoms or other evidence of CMV disease.
1.3.2 Data Collected
The following variables were recorded for each patient: age, gender, date and type of 
transplant, CMV serologic status of donor and recipient prior to transplant, number of 
rejections (in the previous 3 months) and immunosuppressive therapy.
Ocular assessment consisted of history and examination with visual acuity and dilated 
slit lamp examination with direct and indirect ophthalmoscopy using 78D and 28D 
lenses. Visual acuity was measured using a Snellen chart at a 4 metre distance. Patients 
who were too unwell to come to the examination room were examined in their beds and 
a near vision acuity was recorded.
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1.4 RESULTS
115 heart, lung and heart-lung transplant recipients were examined. 78 heart, lung or 
heart-lung transplants were performed at this institution between 1st June 1999 and 1st 
September 2000. Ocular examination was performed 0 to 1300 weeks (25 years) after 
transplantation (median 43 weeks). The median age of patients was 51 (range of 16- 
70). There were 78 men and 37 women. Patients were treated with varying 
immunosuppressive protocols as shown in Figures 1.6-1.8.
1.4.1 Heart Transplant Recipients
70 heart transplant recipients were examined. The patients ranged in age from 16 to 70 
years (54 ± 12.6 years; median ± SD) and consisted of 57 men and 13 women. Reasons 
for transplantation were idiopathic cardiomyopathy in 31 patients(44%), ischaemic 
heart disease in 28 patients(40%), congenital heart disease in 4 patients(6%), valvular 
cardiomyopathy in 2 patients (3%), anthrocycline cardiomyopathy in 1 patient, giant 
cell myocarditis in 1 patient and unknown in 3 patients. 39 patients (57%) were on 
treatment for hypertension at the time of ocular examination, 13 patients (19%) were on 
treatment for diabetes mellitus.
41 of the patients were on oral prednisolone, 57 patients were on CsA based regimes 
and 11 on Tac based regimes, 54 patients were on azathioprine and 2 on MMF. A 
number of patients were on anti-microbials with 10 being on septrin, 13 on aciclovir and 
1 on nystatin.
Ocular assessment was performed within 1 month of transplantation in 14 patients, 
between 1 and 6 months in 12 patients and more than 6 months after transplantation in
42 patients (in 2 patients the information was missing) (median ± SD: 17 ± 54 months; 
range: 1 week to 25 years). Best corrected visual acuities ranged between 6/7.5 and 
hand movements.
7 patients reported visual symptoms before examination. One patient complained of 
gritty eyes and no ocular abnormality was seen on examination. Another complained of 
sticky, bleary eyes and was found to have blepharitis with medial ectropion. Three 
patients complained of blurred vision: in two patients this was due to cataract and in the 
third it was due to posterior capsular opacification following cataract surgery. Two 
patients complained of floaters: one was found to have early lens opacities and a flat 
pigmented choroidal naevus, the other had mild hypertensive change.
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The 14 patients seen within 1 month of transplantation had normal ocular examinations 
although 1 patient had early asymptomatic cortical lens opacities.
The abnormal findings in the group examined between 1 and 6 months post­
transplantation were as follows:
1 patient with a homonymous hemianopia which predated his transplantation,
1 superficial stromal scar in a contact lens wearer,
1 hyperopic patient with narrow angles,
1 patient with prominent optic discs and a history of neuroblastoma,
1 patient with a quiet 1 disc diameter right inferior retinal scar with pre-retinal 
fibrosis and
1 patient with pigment change along a peripheral vessel in the left eye.
The findings in the patients examined more than 6 months after transplantation were:
1 patient with bilateral madarosis,
1 patient with blepharitis and medial ectropion,
1 bilateral pseudophake and 1 unilateral pseudophake,
10 patients with lens opacities of which 2 had posterior subcapsular opacities 
and 1 had congenital cataracts,
1 patient with asymmetrical disc cupping,
1 patient with prominent discs who had a history of neuroblastoma,
1 patient with a solitary cotton wool spot,
6 patients with hypertensive retinopathy,
2 patients with minimal non-proliferative diabetic retinopathy,
2 patients with flat pigmented choroidal naevi,
1 patient with bilateral macular RPE disturbance and
2 patients with inferior retinal scars one o f whom had bilateral, extensive, 
peripheral granular RPE disturbance.
None of the patients had any evidence of active inflammation.
Demographic information and ocular findings are shown in Figure 1.6.
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1.4.1.1 Repeat Examinations
18 patients had repeat ocular examinations with these taking place between 1 week and 
13 months post-transplant (median 3 months). 16 patients were examined twice, one 
patient received 3 ocular examinations within 6 months o f transplantation and another 
received 4 examinations in the first 6 months post transplantation. The only change in 
ocular appearance occurred in patient 29 who developed a single blot haemorrhage 
within 1 month of transplantation. 15 o f the 18 patients who had repeat ocular 
examinations received augmented immunosuppression for rejection episodes and 3 of 
these also required IV ganciclovir for the management of CMV antigenaemia.
Figure 1.6: Demographic Information and Ocular Findings (Heart Recipients)
CMV Time
Pt Age Sex Tx Status HT DM POH Meds Post Ocular VANo Type Donor/
Recipient
Tx
(wks)
Symptoms
Inferior
2 56 M OCTx N/A Y N Nil CyA. Aza 43 Nil 4/5; 4/5 pigmented retinal scar (1.5 
DD)
3 63 M OCTx +/+ N Y Nil P, Tac, aciclovir 40 Nil 4/6; 4/5 Normal
4 55 M OCTx -/- Y Y Nil P, CyA, Aza 43 Nil 4/5; 4/5 Normal
P. CyA.
6 55 M OCTx -/+ Y N Nil Aza,
aciclovir
35 Nil 4/5; 4/5 Normal
7 35 M OCTx -/+ N N Nil
P, CyA,
Aza,
septrin
13 Nil 4/5; 4/5
R inf retinal 
scar (1 DD) 
with pre-retinal 
fibrosis
10 51 M OCTx -/- N N Nil P, CyA. Aza 35 Nil 4/5; 4/5 Normal
P, CyA,
Aza,
13 48 F HCTx -/- N N Nil aciclovir.
septrin,
nystatin
5 Nil 4/5; 4/5 Normal
15 45 F OCTx +/+ Y N Nil 23
16 41 M OCTx +/- N N Nil P. CyA, Aza 35 Nil 4/5; 4/5 Normal
17 48 M OCTx /+ N N Nil P, Aza, Tac 22 Nil 4/6; 4/5 Normal
18 47 M OCTx -/+ Y N Nil P, CyA, aciclovir 17 Nil 4/6; 4/5 Normal
P, CyA,
21 55 M OCTx /- Y Y Nil Aza,
aciclovir
13 Nil 4/5; 4/5 Normal
22 18 M OCTx +/- Y N Astig-matism P, Aza, Tac 13 Nil 4/5; 4/5 Normal
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Pt
No
Age Sex TxType
CMV
Status
Donor/
Recipient
HI DM POH Meds
Time
Post
Tx
(wks)
Ocular
Symptoms VA
24 46 M OCTx +/- N N Nil
P. CyA.
Aza.
aciclovir
13 Nil 4/5; 4/6
Pigment 
change along 
peripheral 
vessel LE
26 16 M OCTx -/- Y M Nil
P. Aza. 
Tac.
aciclovir
9 Nil 4/5; 4/5 ProminentDiscs
27 51 F OCTx +/- Y N Myopia
P. CyA.
Aza.
aciclovir
4 Nil 4/5: 4/5 Normal
29 44 M OCTx /+ Y Y Nil P. CyA. aciclovir 1 Nil 4/5; 4/5 Normal
35 48 M OCTx +/+ N N Nil P. CyA. Aza 1 Nil N5;N5 Normal
36 53 M OCTx -/- N N Nil P. CyA. Aza 43 Nil 4/5; 4/5 Normal
38 21 M OCTx +/- N N Nil P. CyA. Aza 1 Nil N5;N5 Normal
39 30 M OCTx -/- N N
Comeal 
abrasion post- 
op
CyA. Aza 9 Nil N5;N5 Normal
42 49 F OCTx +/- N N Nil P. CyA. Aza 43 Nil 4/5: 4/5
Disc
Asymmetry
44 55 M OCTx +/+ N N Glaucomasuspect
P. CyA.
Aza.
aciclovir
4 Nil 4/5: 4/5 Normal
46 53 F OCTx +/+ N N Nil P. CyA 17 Grittyeyes 4/5; 4/5 Normal
47 59 F OCTx +/+ N N Nil P. CyA. Aza 4 Nil 4/5: 4/5 Normal
48 53 F OCTx /+ N N Glaucomasuspect
P, CyA. 
Aza 4 Nil 4/6: 4/6 Normal
49 61 F OCTx +/+ N Y Nil
P, CyA,
Aza.
aciclovir
5 Nil N5;N5 Normal
50 56 M OCTx -/- Y Y Nil
P, CyA.
Aza.
aciclovir
5 Nil 4/5: 4/5 Normal
52 50 F OCTx -/ N N Nil
P. CyA.
Aza.
aciclovir
2 Nil 4/5: 4/5 Normal
55 23 M OCTx -/+ N N Nil
P. CyA.
Aza
aciclovir
5 Nil N5;N5 Normal
57 49 M HCTx -/- N N Nil P. CyA. Aza 5 Nil 4/5; 4/5 ELO (CLO)
59 55 M OCTx +/+ Y N Nil CyA. Aza 78 Nil 4/5: 4/5 Normal
62 44 M OCTx +/ Y N Nil P, Tac 390 Nil 4/5: 4/5 Normal
63 69 M OCTx N/A Y N Nil CyA, Aza 806 Nil 4/6; 4/5 Normal
64 70 M OCTx N/A Y Y Nil CyA. Aza 702 Nil 4/9; 4/5 ELO (NS)
65 52 M OCTx /+ N N Myopia CyA. Aza 494 Nil 4/5; 4/5 Normal
67 56 M OCTx -/+ Y Y Nil CyA 196 Nil 4/5; 4/5
MildNPDR,
Mild
hypertensive 
change, 
PSCLO
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Pt
No Age
Sex TxType
CMV
Status
Donor/
Recipient
HT DM POH Meds
Time
Post
Tx
(wks)
Ocular
Symptoms VA
68 56 F OCTx /- N N
L
pseudophakia 
R Cataract
P. CyA. 
septrin 36
Blurred 
vision LE 4/5;HM
R PC-IOL; L 
white cataract
69 51 M OCTx /- Y N Nil CyA. Aza 286 Nil 4/5; 4/5 Normal
70 60 F OCTx /+ Y N Nil CyA. Aza 95 Floaters 4/6; 4/5
Flat, pigmented 
naevus R 
fundus, ELO
74 44 M OCTx -/+ N N Nil CyA 156 Nil 4/5; 4/5
Congenital 
cataract (ant 
polar)
75 55 M OCTx /- N N Nil P. CyA 434 Nil 4/5; 4/5
Moderate
hypertensive
change
77 34 M HCTx +/- N N Nil Cy A, Aza 156 Nil 4/5; 4/5
Bilateral 
macular RPE 
disturbance
79 41 M OCTx /+ N Y Nil
P, Tac.
Aza.
Septrin
104 Nil 4/5; 4/5 Normal
80 60 M OCTx N/A Y N Nil Cy A. Aza 78 Nil 4/5; 4/5
Inferior 
granular RPE 
disturbance 
BEs
81 64 M OCTx /+ Y N Nil CyA, Aza 364 Nil 4/5; 4/5
ELO, Moderate
hypertensive
change
85 29 M OCTx -/- Y N Nil
P, Aza
Tac,
septrin
88 Nil 4/5; 4/5 Normal
86 58 M OCTx /- Y N Nil CyA. Aza 364 Nil 4/5; 4/5 Madarosis BEs
87 56 M OCTx -/+ Y N Nil CyA. Aza 118 Nil 4/5; 4/5 Normal
88 59 M OCTx +/+ Y N Amaurosisfugax CyA. Aza 170 Nil 4/5; 4/5
ELO, 1/2 DD 
flat pigmented 
naevus
89 57 M OCTx N/A Y N Nil CyA. Aza 546 N/A N/A Normal
90 64 M OCTx N/A Y N Nil CyA 546 N/A N/A R PSCLO, L ELO
92 65 M OCTx N/A Y Y Squint surgery CyA. Aza 357 N/A N/A Solitary' CWS
93 42 M OCTx -/- Y N Myopia CyA,Aza 130
Nil
4/5
4/5
Normal
94 70 M OCTx N/A N N PC-IOLs
BEs CyA 390
Blurred 
vision L 4/5 4/5
PC-IOLs 
BEs, L PCO
95 59 M OCTx N/A Y N Nil CyA,
Aza 390
Nil 4/5 4/5 Myelinated nerve fibres
97 62 M OCTx +/- N Y Nil CyA,
Aza 128
Nil 4/5 4/5 Normal
98 43 F OCTx -/- Y N Nil CyA,
Aza 286 Floaters 4/6 4/6
Mild
hypertensive
change
100 57 M OCTx N/A Y N Nil CyA,
Aza 380
Nil 4/5 4/5 ELO
103 23 M OCTx +/+ Y N Nil P, Tac, MMF 130 Nil 4/5 4/5 Normal
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Pt
No
Age Sex TxType
CMV
Status
Donor/
Recipient
HT DM POH Meds
Time
Post
Tx
(wks)
Ocular
Symptoms VA
106 47 M OCTx Y N Nil
CyA,
Aza 312 Nil N/A
Mild
hypertensive
change
108 67 F OCTx N/A Y N
T1A with 
diplopia CyA 572
Sticky,
Bleary
eyes
4/54/5
Blepharitis 
with R 
punctual 
eversion
109 64 M OCTx -/+ Y N Cataract
P, CyA,
Aza,
septrin
130 BlurredVision
4/36
4/24
LO BEs 
(PSCLO & 
NS)
110 70 M OCTx N/A N N Nil P, Aza 1300 Nil 4/5;4/5 Normal
111 63 M OCTx /+ Y Y Nil
CyA,
Aza 494 Nil
4/5;
4/5 Mild NPDR
113 49 M OCTx -/- N N
Contact lens
wearer,
astigmatism
P, CyA, 
Aza,
aciclovir,
septrin,
nystatin
6 Nil 4/5;4/5
R superficial 
stromal 
corneal scar
114 56 M OCTx +/+ Y N
L
homonymous
hemianopia
P, CyA, 
Aza,
aciclovir,
septrin
12 Nil 4/5;4/5
Field defect; 
Normal 
ocular exam
115 64 M OCTx N/A Y Y DR CyA,Aza 338 Nil
4/12;
4/5 Mild NPDR
116 60 M OCTx N/A Y N Nil CyA 473 Nil 4/5;4/5
Blepharitis,
Mild
hypertensive
change
117 38 M OCTx -/- N N Nil
P,
CyA,
MMF,
aciclovir,
septrin,
nystatin
N/A Nil 4/5;4/5 Normal
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1.4.2 Heart-Lung Transplant Recipients
16 heart-lung transplant recipients were examined. The patients ranged in age from 20 
to 58 years (33 ± 12.5 years; median ± SD) and consisted of 10 men and 6 women. 
Indications for transplantation were bronchiectasis in 12 patients (75%) of which 11 had 
cystic fibrosis, congenital heart disease in 3 (19%) and primary pulmonary hypertension 
in 1 (6%). 6 patients (38%) were on treatment for hypertension at the time of ocular 
examination, 4 patients (25%) were on treatment for diabetes mellitus.
13 of the patients were on oral prednisolone, 9 patients were on CsA based regimes and
6 on Tac based regimes, 9 patients were on azathioprine and 2 on MMF. A number of 
patients were on anti-microbials with 3 being on septrin and 3 on aciclovir.
Ocular assessment was performed within 1 month o f transplantation in 5 patients, 
between 1 and 6 months in 0 patients and more than 6 months after transplantation in 11 
patients (median ± SD: 12 ± 61 months; range: 1 week to 14 years). Best corrected 
visual acuities ranged between 6/7.5 and 6/18.
7 heart-lung transplant recipients reported ocular symptoms before examination. 4 
complained of blurred vision. Two of these patients had posterior subcapsular lens 
opacities, one had mild non-proliferative diabetic retinopathy with no maculopathy and 
the fourth had asymmetric disc cupping and mild hypertensive change. One patient had 
complained of floaters. He was found to have a left Homer’s syndrome and no retinal 
pathology. One complained of intermittent red eyes and one o f glare at night. Both 
these patients had normal ocular examinations.
All of the patients seen within 1 month o f transplantation had normal ocular 
examinations, 1 patient was amblyopic in one eye.
The findings in the patients examined more than 6 months after transplantation were:
4 patients with lens opacities 2 of which had posterior subcapsular opacities,
2 patients with mild non-proliferative diabetic retinopathy,
1 patient with hypertensive retinopathy (this patient also had asymmetric disc 
cupping),
1 patient with a left Homer’s syndrome,
1 patient with bilateral pigment clumping at the macula.
None of the patients had any evidence of inflammation.
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Demographic information and ocular findings are shown in Figure 1.7.
1. 4.2.1 Repeat Examinations
6 patients had a second ocular examination with this taking place between 1 week and 
15 months after transplantation (median 3 months). No patient had a change in ocular 
findings. One patient had Aspergillus spp in his sputum, 2 patients received IV 
ganciclovir for CMV (one had pneumonitis and the other was treated for antigenaemia) 
and 3 patients received augmented immunosuppression for rejection episodes.
Figure 1.7: Demographic Information and Ocular Findings (Heart-Lung Recipients)
P t
no Age
Sex Tx Type
CMV
Status
Donor/
Recipnt
HT DM POH Meds
Time
Post
Tx
(wks)
Ocular
Symptoms VA
Ocular
findings
5 55 M Heart-lungTx +/+ Y
N Nil P. CyA, 40 Floaters
4/5;
4/5 Homer’s
9 26 M Heart-lungTx -/- N N Myopia
P, Aza, 
Tac, 30 Nil
4/5;
4/5 Normal
12 24 M Heart-lungTx +/- N Y Myopia
CyA.
aciclovir 30 Nil
4/5;
4/5 Mild NPDR
28 42 F Heart-lungTx +/+ N N Nil
P. CyA,
Aza,
aciclovir
4 Nil 4/5;4/5 Normal
30 31 F Heart-lungTx -/- N N Nil
P- CyA, 
Aza, 4 Nil
4/5;
4/5 Normal
34 41 M Heart-lungTx +/+ N N Nil
P- CyA, 
Aza 1 Nil N/A Normal
45 32 M Heart-lungTx +/- N N Nil
P, CyA.
Aza,
aciclovir
3 Nil N5;N5
R amblyopia
54 58 F Heart-lungTx N/A Y N LO P, Aza 728
Blurred
vision
4/5;
4/5
LO (PSCLO 
BEs)
56 20 M Heart-lungTx +/- N Y Nil
P. CyA, 
Aza 5 Nil
N5;
N5 Normal
58 23 M Heart-lungTx +/- N N Nil
P. Tac, 
MMF 65
Blurred
vision
4/5;
4/12
LO (PSCLO 
LE)
60 22 M Heart-lung
Tx /- Y
N Nil Tac,
septrin 65
Glare at 
night
4/5;
4/5
Normal
66 24 F Heart-lungTx N/A N N Nil
P, CyA,
MMF,
septrin
580 Nil 4/5;4/5
LO (CLO 
RE)
72 45 F Heart-lungTx /+ Y Y Nil
P, Tac, 
septrin 565 Red eyes
4/12;
4/12
LO (CLO 
BEs),
Bilateral RPE
change at
macula,
Quiescent
scar R
peripheral
retina
76 34 F Heart-lungTx /+ Y Y Nil
CyA.
Aza 586
Blurred
vision
4/12;
4/12 Mild NPDR
99 54 M Heart-lungTx -/+ Y N Nil P, Tac 442
Blurred
vision
4/5;
4/5
Asymmetric 
cupping, Mild 
hypertensive 
change
102 34 M Heart-lungTx N/A N N Myopia
P, Aza, 
Tac 438 N/A N/A Normal
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1.4.3 Lung Transplant Recipients
29 lung transplant recipients were examined. The patients ranged in age from 28 to 65 
years (52 ± 9.6 years; median ± SD) and consisted o f 13 men and 16 women. 
Indications for transplantation were emphysema in 16 patients (55%) of which 5 had 
alpha-1-antitrypsin deficiency, bronchiectasis in 7 patients (24%) of which 3 had cystic 
fibrosis, fibrosing alveolitis in 3 patients (10%), congenital heart disease in 2 patients 
(7%) and pulmonary fibrosis secondary to busulphan in 1 patient (3%). 15 patients 
(52%) were on treatment for hypertension at the time of ocular examination, 4 patients 
(14%) were on treatment for diabetes mellitus.
26 of the patients were on oral prednisolone, 16 patients were on CsA based regimes 
and 13 on Tac based regimes, 20 patients were on azathioprine and 3 on MMF. A 
number of patients were on anti-microbials with 12 being on septrin, 10 on aciclovir and 
2 on azole antifungals.
Ocular assessment was performed within 1 month of transplantation in 4 patients, 
between 1 and 6 months in 6 patients and more than 6 months after transplantation in 19 
patients (median ± SD: 9 ± 39.2 months; range: 1 week to 11 years). Best corrected 
visual acuities ranged between 6/7.5 and 6/36.
4 lung transplant recipients reported ocular symptoms before examination. One of these 
patients complained o f a red eye and was found to have a sub-conjunctival 
haemorrhage. 3 complained of blurred vision. One of these patients had no ocular 
abnormality. He was advised to see his own optician for refraction. One patient had 
bilateral soft drusen with no evidence of choroidal neovascularization and the third had 
posterior subcapsular lens opacities.
One patient seen within 1 month of transplantation had a quiescent central right comeal 
scar secondary to a corneal ulcer treated 12 years previously and another had a 
pigmented chorioretinal scar in the left superotemporal periphery.
The findings in the group examined between 1 and 6 months post-transplantation were 
as follows:
1 patient with uniocular amblyopia,
1 patient with bilateral quiet pseudophakia,
1 with Homer’s syndrome and
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1 patient with comeal, iris, lens and vitreous changes suggestive of old trauma, 
although there was no corresponding history.
The findings in the patients examined more than 6 months after transplantation were:
5 patients with lens opacities of which 2 had posterior subcapsular opacities,
1 patient with mild hypertensive retinopathy,
1 patient with Homer’s syndrome and a left iris naevus,
1 patient with bilateral quiet pseudophakia and myopic fundal changes,
1 patient with soft drusen,
1 patient with a right peripapillary disciform,
1 patient with large areas of RPE pallor with no pigment clumping and no retinal 
swelling and
1 patient with a right phthisis.
The patient with the pale fundus gave a history of 2 days o f bilateral loss of vision 5 
months after transplantation and 4 months before this examination. This was associated 
with collapse, vomiting, headache and seizures. The patient was on a Tac regime with a 
level of 11.4 ng/ml (therapeutic range). Examination revealed bilateral blindness and 
nystagmus with no other ocular or systemic abnormalities. CT scan, lumbar puncture 
and carotid ultrasound were normal. MRI demonstrated multiple areas o f high signal 
abnormalities in both cerebellar hemispheres and in both parieto-occipital regions. 
These high signal abnormalities were not present 1 week later. The differential 
diagnosis was cerebral vascular occlusion or tacrolimus related leukoencephalopathy. 
Vision returned spontaneously after 48 hours and at examination the visual acuity was 
6/7.5 bilaterally. The patient remained on a Tac regime at the time of this examination.
The patient with a right phthisis developed a right endogenous endophthalmitis 2 weeks 
after transplantation and 8 months before this examination. This was found to be due to 
Aspergillus spp. and although aggressive treatment was systemically successful the eye 
became phthisical. This patient was an insulin treated diabetic on a MMF regime. She 
remained on itraconazole and MMF at the time of this examination.
Demographic information and ocular findings are shown in Figure 1.8.
61
1.4.3.1 Repeat Examinations
5 patients had a second ocular examination with this taking place 1 to 22 months after 
transplantation (median 8.5 months). One patient developed early posterior subcapsular 
lens opacities between visits but the others had no change in their ocular findings. One 
patient had received treatment for intrapulmonary Candida, one remained on 
itraconazole for previous Aspergillus spp infection and 3 received augmented 
immunosuppression for rejection.
Figure 1.8: Demographic Information and Ocular Findings (Lung Recipients)
Pt.
no
Age Sex Tx
Type
CMV
Status
Donor/
Recipnt
in DM POH Meds Time
Post
Tx
(wks)
Ocular
Symp-toms
VA Ocular
findings
1 51 F SLTx +/- Y N Nil P, Tac 48 N 4/5:4/5 LO BEs
8 35 F DLTx +/+ N Y Rendophthalmitis
P. CyA,
MMF,
itraconazole
35 N : 4/5 R phthisis with shell
11 53 F DLTx Y N Nil P, Tac. aciclovir 30 N
4/5;
4/5 LO BEs
14 54 M SLTx -/- Y N Nil
P, CyA, 
Aza,
aciclovir,
septrin
5 N 4/5;4/9
Pigmented CR 
scar LE, 
superotemporal 
periphery 
1.5DD
20 45 F DLTx -/+ Y Y Ametropicamblyopia
P, CyA,
Aza,
aciclovir
17 N 4/24;4/18 Amblyopia
23 38 F DLTx +/+ Y N Nil
P, CyA,
Aza,
aciclovir
13 N 4/5;4/5 Normal
25 50 F SLTx +/- N N Nil P, Tac, aciclovir 13 N
4/5;
4/5 Homer’s
31 42 F SLTx +/+ Y N Nil P, CyA, aciclovir 35 N
4/5;
4/5 Normal
32 57 M SLTx +/+ N N
Left herpes
simplex
keratitis
P, Aza. Tac 48 N 4/9;4/5 Normal
33 56 M SLTx -/- N N R corneal ulcer P. CyA. Aza 1 N R corneal scar
37 52 M SLTx +/- N Y Floaters post op P, CyA, Aza 13 Blurred vision
4/5;
4/5 Normal
40 47 M DLTx +/+ N N Nil P, CyA, Aza 40 N
4/5;
4/5 Normal
41 35 F SLTx -/- N N Nil P, Aza, Tac, septin 4 N
4/5;
4/5 Normal
43 55 F SLTx -/+ N N Squint Sx
P, CyA, 
Aza, 4 N
4/5;
4/5
Normal
aciclovir
51 59 F SLTx +/+ N N
Cortical
blindness
P, Aza. Tac 39 Red eye
4/5;
4/5
S/conj haem
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Pt. Age Sex Tx CMV HT DM POH Meds Time Ocular VA Ocular
no Type Status
Donor/
Recipnt
Post
Tx
(wks)
Symp-toms findings
53 53 F SLTx +/+ Y N Nil
P. CyA. 
Aza
69 N
4/12;
4/5
LO BEs; L 
Homer's; L iris 
naevus
71 58 M SLTx /- Y N
Pseudophakia
BEs
P. Aza.
Tac. septin.
292 N
4/9:
4/9
PC-IOL BEs: 
Myopic fundi
73 53 F SLTx /+ N N Nil
P. Aza.
Tac. septrin
494 N
4/9;
4/9
Normal
78 36 M SLTx /- Y N Nil
P. CyA. 
Aza
552 Blurred vision
4/6;
4/5
LO
CyA. Aza.
4/6:
82 57 M SLTx /- N N FB RE septrin. 156 N Normal
4/6
aciclovir
P. CyA.
MMF. 4/6:
83 28 F DLTx /- N Y  Myopia 41 N Normal
septrin. 4/6
aciclovir
P. Aza.
84 34 M DLTx +/- Y N Nil
Tac.
312
septrin.
itraconazole
N
4/6;
4/6
LO
Tac. L cornea, iris.
91 43 M DLTx +/- N N Nil
septrin.
21
aciclovir.
itraconazole
N
4/9;
4/6
lens & vitreous 
changes ? old 
trauma
96 52 M DLTx -/- Y N Nil
CyA. Aza.
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septrin
N
4/5;
4/5
Normal
101 65 M SLTx +/ Y N Nil
P. Aza.
386
Tac. septrin
Blurred vision
4/9;
4/5
Soft drusen 
BEs
DLTx
104 57 F
+
N/A
ASD
Y N Nil
P. Tac.
452
septrin
N
4/6;
4/6
Normal
repair
105 39 F DLTx /+ Nil
P. Tac.
434
MMF
N
Mild
hypertensive
change
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Pt Age Sex Tx CMV HT DM POH Meds Time Ocular VA Ocular
no Type Status
Donor/
Recipnt
Post
Tx
(wks)
Symp-toms findings
107 63 M SLTx -/+ Y Nil
P. CyA. 
Aza. septrin
78 N
4/5;
4/5
Right
peripapillary
disciform
112 46 F SLTx +/- Y
Pseudophakia
BEs
P. CyA, 
Aza
9 N PC-IOL BEs
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1.5 SUMMARY
18 patients (16%) were symptomatic at examination with the most common symptom 
being blurred vision (Figure 1.9). Of the 115 transplant recipients examined 62 (54%) 
had findings at ocular examination. The most common findings were cataracts (17% of 
those examined) followed by hypertensive change (8%), chorioretinal scarring (5%) and 
diabetic retinopathy (3%). The 6 patients with chorioretinal changes all had quiescent 
scars. 5 had focal scars, one of which was a peripapillary disciform. One of the 
patients had bilateral, peripheral, granular scarring inferiorly that would be consistent 
with previous retinitis but no evidence of active inflammation at the time of 
involvement in this study. Only one patient was seen to have ocular infective 
complications following surgery and this was Aspergillus spp. endophthalmitis. This 
patient was treated with amphotericin B but ultimately the eye became phthisical. 33% 
of asymptomatic patients had ocular findings that may be associated with their 
immunosuppression (Figure 1.9) compared to 43% of symptomatic patients (Figure 
1.10). The most common finding in symptomatic patients was cataract with almost a 
quarter of patients having posterior subcapsular lens opacity that could be attributed to 
steroid therapy.
Figure 1.9: O cular Symptoms in Transplant Recipients
3 %
r 2 ° / o
■  Asymptomatic
■  Blurred Vision
□  Floaters
□  Red Eyes
■  Glare
■  Sticky Eyes
□  Gritty Eyes
r 1%
1%83% 16%
1%9%
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Figure 1.10: Asymptomatic Patients - O cular Findings tha t may be Associated with 
Immunosuppression
■  No O c u l a r  A b n o r m a l i t y
■  Other
□  Cataract
□  Hypertensive Change
■  Chorioretinal Scars
H Non-Proliferative Diabetic 
Retinopathy
■  Phthisis
Figure 1.11: Symptomatic Patients - Ocular Findings that may be Associated with 
Immunosuppression
B No Ocular Abnormality
BOther
37% □  Cataract29%
43%
□  Non-Proliferative Diabetic 
Retinopathy 
B Hypertensive Change19%
B  Subconjunctival 
Haemorrhage
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1.6 DISCUSSION
It has been advocated that solid-organ transplant recipients require regular ophthalmic 
screening because the overall visual prognosis is poor in the face of opportunistic 
infection leading to a reduction in quality of life(20, 151,218). Ocular symptoms may 
be ignored and remain unreported as they may be overshadowed by concerns about life- 
threatening complications particularly in the early post operative period and particularly 
if transitory(178). Delay in presentation and delay in referral contribute to delay in 
diagnosis and a poor outcome.
Ocular disease can be recognized early by screening examinations allowing for specific 
therapy and early treatment to improve prognosis. The situation is complicated, 
however, by the very large array of rare conditions that can rarely cause severe ocular 
disease. Because of the rarity of the conditions the incidence in the transplant 
population is often not precisely known making power calculations difficult. A multi­
centre study with large numbers of participants would be required to ascertain the risk 
of ocular disease following transplantation.
A number of small studies have attempted to assess the incidence and morbidity of 
ocular complications following heart, lung, or heart-lung transplantation with varying 
results. For example, three out of 19 (16%) patients with symptomatic ocular 
complications following solid-organ transplantation in Ng et al’s retrospective series 
had CMV retinitis(8) whereas only 3 out of 62 (5%) patients with ocular symptoms in 
Wapner et al’s retrospective cardiac transplantation series had CMV retinitis(219). In 
other series of 62(152) and 61(153) patients following renal transplantation none of the 
patients suffered from acute CMV retinitis. Egbert and colleagues at Stanford 
University reported 11 patients who developed CMV retinitis following heart or kidney 
transplantation over a 5 year period from 1974(22). Their patients had been routinely 
screened for ocular complications and half were asymptomatic. In a small Turkish 
study prospective assessment of 13 patients that underwent cardiac transplantation 
revealed asymptomatic CMV retinitis in 2 patients (15%)(21).
Solid organ transplantation is now common practice and general screening would result 
in large numbers of normal patients being screened. Targeted screening has been 
suggested as a way to minimize the resources required for maximum return. Porter and 
colleagues suggested screening the subset of patients in whom vigorous and prolonged 
rejection phenomenon necessitates the persistent use of immunosuppressive drugs in
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high doses (151). Cho and colleagues suggest screening the subset of patients with 
post-transplant lymphoproliferative disorder as 2 o f their 3 cases with ocular 
involvement were asymptomatic (116). Erakgun et al propose CMV screening in the 
subset of patients with systemic microvascular risk factors such as diabetes, 
hypertension and smoking(21).
In this study 115 recipients of heart, lung or heart-lung transplants received ocular 
examinations by a single observer whilst attending a post-transplant clinic or on the 
ward. Patients were not asked to make extra appointments for ocular examination and 
the frequency of screening therefore correlated with the frequency of attendance 
required to manage complications such as rejection or opportunistic infection. Heart, 
lung and heart-lung recipients were chosen as the study population because they are 
subject to high doses of immunosuppression for extended periods of time. Ideally 
patients would have been examined pre-transplant in order to obtain a baseline and then 
periodically after transplantation for a period of a year. Unfortunately due to the large 
number of patients awaiting transplant, the scarcity o f donors and the speed of 
transplantation once a donor becomes available this was not done. All patients 
attending the post-transplant clinic or on the ward were invited for screening 
examinations. 59 (51%) patients screened were seen for the first time within 12 
months of transplantation. 78 transplants were performed at this institution over the 15 
months of the study. A number of the patients were being seen regularly in the clinic 
years after transplant and these patients were included as they were still receiving 
systemic immunosuppression. 30 (26%) of the patients examined were examined 
repeatedly over the period of the study providing longitudinal data. Examination would 
be improved by using LogMar visual acuity assessments and photographic 
documentation would have made the examination more objective.
18 patients (16%) were symptomatic at examination with the most common symptom 
being blurred vision. The most common finding in symptomatic patients was cataract 
with almost a quarter of symptomatic patients having posterior subcapsular lens opacity 
that could be attributed to steroid therapy. 3 patients in this study had sight-threatening 
disease that could be attributed to systemic immunosuppression. One patient had fungal 
endophthalmitis, one had a white cataract and one had bilateral loss of vision which 
recovered and may have been secondary to drug toxicity. In all three cases the 
pathology preceded the first examination. This study suggests that the incidence o f 
CMV retinitis after modem immunosuppression is quite low. This is supported by the
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fact that a 14 year follow-up of 5721 patients on immunosuppression following 
haematopoietic stem cell transplantation identified only 10 CMV retinitis cases, one of 
whom was asymptomatic although asymptomatic individuals were not routinely 
examined(220). The asymptomatic patient in this case series was being examined for 
manifestations of graft-versus-host disease. The variations in incidences o f CMV 
retinitis reported post-transplantation are most likely due to centre effects. Because the 
ocular complications of transplantation are often associated with organ and life 
threatening events transplant patients are extremely well monitored for many events. 
Although CMV antigenaemia, does not correlate well with ocular disease(28) improved 
surgical technique, immunosuppressive regimes and anti-microbial treatment and 
prophylaxis have changed the natural history o f opportunistic infection following 
transplantation. Prophylaxis is likely to be the reason for the low incidence of herpetic 
eye disease seen in this study.
The low incidence of common complications such as cataract, diabetic retinopathy and 
hypertensive retinopathy is surprising. Cataract was the most common ocular 
complication (17%) and was the most common finding in symptomatic transplant 
recipients. 4 patients were pseudophakic at examination reflecting access to diagnosis 
and management o f cataract. The low incidence of diabetic and hypertensive 
retinopathy and the mild signs seen probably reflect the good control and high patient 
motivation that is required before embarking on transplant surgery.
This study aimed to ascertain the burden of ocular disease following heart, lung and 
heart-lung transplantation in asymptomatic as well as symptomatic individuals. Sight 
threatening asymptomatic disease was not seen over the period of study. Thus the study 
does not support screening of asymptomatic individuals following heart, lung or heart- 
lung transplantation. Rather, a high index of suspicion is required with prompt and 
aggressive action when a problem is identified. Patient education must therefore form 
an important part of any plan to reduce sight-threatening complications. Transplant 
patients should be encouraged to report promptly if they have ocular symptoms rather 
like they report exposure to VZV.
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C H A P T E R  2
Q u a n t if ic a t io n  O f  Im m u n o s u p p r e s s io n  B y
F l o w  C y t o m e t r ic  A s s e s s m e n t  O f  In t r a c e l l u l a r
C y t o k in e s  -
A  G e n e r a l  In t r o d u c t io n
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2.1 OVERVIEW OF THE INDUCTION OF THE IMMUNE RESPONSE
Protection against foreign agents involves many different mechanisms some of which 
are non-specific and some of which are exquisitely specific. Nonspecific defenses are 
innate and include: mechanical barriers such as the integrity of the epidermis and 
mucosal membranes, physicochemical barriers such as the acidity o f the stomach fluid, 
antibacterial substances such as lysozyme and defensins present in external secretions, 
ingestion and elimination of bacteria and particulate matter by granulocytes(221). 
Specific defenses are induced by the immune response. The immune system is able to 
discriminate between self and non-self, tolerating self whilst rapidly processing and 
destroying non-self (foreign) antigens in a primary immune response. In addition, a 
functioning immune system remembers previous encounters with specific foreign 
antigens, resulting in a more vigorous and rapid secondary response (immunologic 
memory).
2.1.1 Cells of the Immune System
2.1.1.1 Lymphocytes
Lymphocytes play a key role in the control and regulation of immune responses, as well 
as in the recognition of infected or foreign cells which the lymphocytes can recognize as 
undesirable and thus eliminate. They differentiate from stem cells in the fetal liver, 
bone marrow and thymus into two main functional classes the B lymphocytes and the T 
lymphocytes. Lymphocytes are present in bone marrow, lymphoid organs (i.e. thymus, 
lymph nodes, tonsils, spleen, etc) and peripheral blood. They are categorized by the 
presence of specific cell surface markers called clusters of differentiation (CD). Each 
CD marker has a number and the function of a cell can often be predicted by the 
specific CD markers present.
2.1.1.1.1 B Lymphocytes
The site of B lymphocyte differentiation is unclear and may be the bone marrow or the 
peri-intestinal lymphoid tissues(222). Human B cells are CD 19+ and CD3-. B cells 
also carry immunoglobulins on their cell membrane which function as antigen 
receptors. After proper stimulation B cells differentiate into morphologically different 
antibody producing cells (plasma cells). B cells can also play the role of antigen 
presenting cells although this function is much more commonly performed by cells o f 
monocytic/macrophage lineage.
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2.1.1.1.2 T Lymphocytes
T lymphocytes differentiate in the thymus. They are central to cell mediated immunity 
and to the regulation of the immune response. Mature human T cells have CD3 on their 
cell surface (CD3+) and carry T cell receptors on their membranes that are the 
mechanism for specific antigen recognition. The two main populations are the CD4+ T 
cells and the CD8+ T cells. CD4+ and CD8+ cells recognize antigens associated with 
major histocompatibility complex class II and class I molecules, respectively. Other cell 
markers and cytokine production can be used to further differentiate cells with different 
effector functions.
CD4+ T cells predominantly have a helper function; proliferating in response to 
antigen. Upon recognizing an antigen and receiving additional signals from auxiliary 
cells a small resting T cell rapidly undergoes blastogenic transformation into a large 
lymphocyte or lymphoblast. This subdivides to produce an expanded population of 
medium and small lymphocytes with the same antigenic specificity. Activated and 
differentiated T cells are morphologically indistinguishable from a small resting 
lymphocyte. A small but important subset, the CD4+ T regulatory cells, has suppressor 
functions.
CD8+ T cells are capable o f killing target cells (cytotoxic T cells) and o f 
downregulating immune responses. T cell mediated cytotoxicity is a complex process 
involving several possible pathways. Some pathways involve the release of proteins 
known as perforins which insert themselves in the target cell membranes, forming 
channels(222). The formation of such channels results in cell death by allowing 
diffusion of water into the hypertonic intracellular environment causing cellular 
swelling and eventually loss of integrity. The perforin channels also allow the diffusion 
of enzymes (serine esterases called granzymes) into the cytoplasm. Once in the 
cytoplasm, granzymes induce apoptosis, the pathway of which is calcium dependent. 
They are also involved in a second pro-apoptotic pathway requiring cell-cell contact by 
way of Fas-Fas ligand receptor contact.
T cells have a longer lifespan than B cells and are important in the development o f 
immunological memory(223).
2.1.1.2 Plasma Cells
These are differentiated B lymphocytes. They are characterized by eccentric nuclei 
with clumped chromatin and a large cytoplasm with abundant rough endoplasmic
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reticulum(222). Plasma cells produce and secrete large amounts of immunoglobulin but 
do not express membrane immunoglobulins. They divide very poorly if at all and are 
usually found in the bone marrow and in the perimucosal lymphoid tissues.
2.1.1.3 Natural Killer Cells (NK)
These are large granular lymphocytes(222). They do not carry antigen receptors of any 
kind but can recognize antibody molecules bound to target cells and destroy those cells 
using the same general mechanisms involved in T lymphocyte cytotoxicity. They also 
have a recognition mechanism that allows them to destroy tumour cells and virus- 
infected cells.
2.1.1.4 Monocytes, Macrophages and Related Cells
Monocytes are leucocytes in transit through the blood and macrophages are monocytes 
fixed in tissue(222). Blood monocytes may also give rise to dendritic cells in 
appropriate conditions(224). These monocytes derived cells have phagocytic functions 
and antigen presenting functions. They process complex antigen and present it on their 
cell membrane in forms that can be recognized by the appropriate helper T cell thus 
inducing the immune response. All antigen presenting cells express MHC class II and 
these histocompatibility antigens are essential for the interaction with helper T cells. 
Antigen presenting cells also release cytokines such as interleukin 1, -6 and -12 which 
promote the proliferation of antigen stimulated lymphocytes.
2.1.1.5 Granulocytes (polymorphonuclear leucocytes)
Granulocytes are white blood cells with segmented or lobulated nuclei and granules in 
their cytoplasm(222). Different subpopulations o f granulocytes (neutrophils, 
eosinophils and basophils) can be distinguished by differential staining o f the 
cytoplasmic granules. Neutophils are the largest subpopulation of white blood cells and 
have two types of cytoplasmic granules containing bactericidal agents. They are 
phagocytic and this function is most efficient in the presence o f antibody and 
complement. They are attracted to areas of inflammation by chemotaxis. Chemotactic 
factors may be released by microbes or may be generated during complement activation 
as a consequence o f an antigen antibody reaction. Eosinophils are found in high 
concentrations in allergic reactions and during parasitic infections. Basophils are 
involved in antiparasitic immune mechanisms and play key pathogenic roles in allergic 
reactions.
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Figure 2.1: Overview of the Immune Response(221)
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2.1.2 Induction of an Immune response
B cells recognize epitopes expressed by unmodified, native molecules whilst T cells 
recognize short peptides generated by antigen processing or derived from newly 
synthesized proteins cleaved in the cytoplasm(225). The immune response is initiated 
when an antigen or a peptide associated with a MHC molecule is recognized as non-self
by immunocompetent cells. The immune system of a normal individual may recognize
6  8 •as many as 10 -10 different antigenic specificities.
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2.1.2.1 Antigen Receptors
In B cells the antigen receptors are membrane inserted immunoglobulins(225). In T 
lymphocytes the antigen receptors are specific T cell receptors (TcR). Each T cell 
carries a particular TcR that can recognize peptide complexed with MHC. A number of 
TcRs can recognise each MHC-peptide complex and any given TcR may be capable of 
cross-recognising several MHC-peptide complexes. There are two types of TcR. In 
differentiated T cells the TcR most frequently found is made up of two polypeptide 
chains designated as alpha and beta with similar molecular weights. A second type of 
TcR is made up of two different polypeptide chains known as gamma and delta and is 
predominantly found in submucosal lymphoid tissues. The two chains of the a p  TcR 
have extracellular segments with variable and constant domains, short cytoplasmic 
domains and a transmembrane segment. A disulfide bridge joins them just outside the 
transmembrane segment. The p chains are highly polymorphic and are encoded by a 
multigene family that includes genes for regions homologous to the V, C, D and J 
regions of human immunoglobulins. The a  chains are encoded by a more limited 
multigene family with genes for regions homologous to the V, C, and J regions of 
human immunoglobulins. Similar polymorphisms have been defined for the yb chains. 
Together the variable regions of a p  and yb chains define the highly specific binding 
sites for peptide epitopes presented in association with MHC II molecules.
2.1.2.2 Antigen Processing and Presentation
Antigen presenting cells (APCs) express MHC II molecules on their membrane where 
antigen fragments can be bound and presented to lymphocytes(225). Additionally they 
often express ligands for co-stimulatory molecules and release cytokines that assist the 
proliferation and/or differentiation of T and B lymphocytes. Antigen processing and 
presentation is a complex sequence of events that involves endocytosis o f antigens on 
membrane patches and transport to an acidic compartment (lysosome) within the cell 
that allows antigen degradation into small peptides. As antigens are broken down 
vesicles coated with newly synthesized MHC-II molecules fuse with the lysosome. 
Some of the peptides generated during processing have affinity for the binding site 
located with the MHC-II heterodimer. The resulting MHC-peptide complexes are then 
transported to the cell surface where they are able to form an immunological synapse 
with the T cell receptors on T cells.
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2.1.2.3 Activation o f  Helper T cells
The selectivity of the TcR results from selection in the thymus(225). Activation of 
helper T cells is made specific by the interaction of the TcR and the peptide MHC 
complex. TcR activation involves a number of signals delivered by accessory cells as 
well as by the release of soluble factors or cytokines:
1. Signals mediated by CD4-MHC II interactions. The TcR-peptide-MHC II 
interaction is the only signal in the immune response that is antigen specific. It 
is of low affinity and other receptor-ligand interactions are required to maintain 
T cell adhesion to APC and for the delivery of required secondary signals. 
These receptor-ligand interactions include interactions with nonpolymorphic 
regions of the MHC molecules: the CD4 molecule on helper T cells interacts 
with MHC II Molecules while the CD8 molecule on CD8+ cells interacts with 
MHC-I molecules.
2. Signals mediated by other cell-cell interactions. Several other cell adhesion 
molecules can mediate lymphocyte-APC interactions for example: CD2 (T cell): 
CD58 (APC); lymphocyte function antigen (LFA)-l(T cell): intercellular 
adhesion molecules (ICAM)-l, -2, and -3(APC); CD40L (T cell): CD40 (APC); 
CD28 (T cell): CD80, CD86 (APC). These interactions are not antigen specific 
and serve to bring the membranes of the two cells into close proximity. This 
allows additional activating signals to the T cell and allows for high local 
concentrations and maximal effects o f interleukins and cytokines released by 
antigen presenting cells and T lymphocytes.
3. Signals mediated by cytokines such as interleukin 1 and interleukin 12.
The TcR heterodimer itself has no recognizable kinase activity. Occupancy and cross- 
linking of the TcR signals the cell through a closely associated complex of molecules 
known as CD3 that has signal transducing properties. Co-stimulatory signals are 
delivered by CD4 as a consequence of the interaction with MHC-II and by CD45, a 
tyrosine phosphatase activated as a consequence of TcR occupancy. Activation of 
CD45 initiates the sequential activation of several protein kinases closely associated 
with CD3 and CD4. The activation of the kinase cascade leads to phopholipase C and 
other protein kinase activation and results in the mobilization of calcium dependent 
second messenger systems such as inositol triphosphate. These promote an increase in 
intracellular free calcium released from intracellular organelles and taken up through the
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cell membrane and thus activate a serine threonine phosphatase known as calcineurin. 
Diacylglycerol (DAG), another product released by phopholipase C, activates another 
serine/threonine kinase known as protein kinase C (PKC). Multiple other enzymes and 
adapter molecules are activated in the ensuing cascade.
The activation of second messenger systems results in the activation and translocation 
of transcription factors such as the nuclear factor-kappa B (NF-kB) and the nuclear 
factor of activated T cells (NF-AT). Once translocated to the nucleus these factors 
induce genes controlling cytokine production and T cell proliferation such as those 
encoding interleukin-2 (IL-2) and the IL-2 receptor.
Activation of the protein kinase cascade also leads to upregulation and modification of 
several membrane proteins on the T cell membrane such as CD28 and CD40 ligand 
(CD40L). These molecules interact, respectively with CD80/86 and CD40 on the APC 
membrane. The interactions involving this second set of molecules deliver additional 
signals that determine the continuing proliferation and differentiation o f antigen- 
stimulated T cells.
2.1.2.4 Antigen presentation and Activation o f  CD 8+ T Cells
When an APC is infected by an intracellular organism (virus, bacteria, or parasite) the 
infecting agent will multiply in the cytosol producing its own proteins(225). Some of 
the microbial proteins diffuse into the cytoplasm where they become associated with 
degradative enzymes forming a peptide-enzyme complex known as a proteasome. 
Within these complexes the protein is partially digested and the resulting peptides bind 
to specialized transporter proteins which deliver them to the endoplasmic reticulum, the 
site of MHC-1 synthesis and assembly. In the endoplasmic reticulum the foreign/non­
self peptides bind to newly synthesized MHC class I molecules and the resulting MHC- 
peptide complex is transported to the membrane of the infected cell. There the MHC-I 
peptide complex is presented to a special population of effector T cells capable of 
killing target cells bearing specific antigen. These T cells are largely CD8+. Resting, 
circulating CD8+ T cells carry antigen receptors able to recognize associations of 
MHC-I and non-self peptides; occupancy of the binding site on the TCR by MHC-I 
associated peptide provides the antigen-specific signal that drives CD8+ T cells. As 
with T helper cells the stimulation of CD8+ T cells also requires additional signals 
including cell-cell contact and cytokines. Examples of other important cell-cell
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interactions include: CD2(T cell): CD58; LFA-1 (T cell): ICAM family members; 
CD28 (T cell): CD80/CD86.
The expansion of antigen-activated CD8+ T cells requires the secretion of IL-2. Rarely, 
activated CD8+ T cells can secrete sufficient quantities of IL-2 to support their 
proliferation and differentiation and thus proceed without help from other T cell 
subpopulations. More frequently activated helper T cells provide the IL-2 necessary for 
CD8+ T cell differentiation.
CD8+ T cells also differentiate and proliferate when exposed to cells from an individual 
of the same species but from a different genetic background as a consequence of tissue 
or organ transplantation. In vitro the degree of allostimulation between lymphocytes of 
two different individuals can be assessed by the mixed lymphocyte reaction. Two types 
of recognition have been analyzed:
1. Donor peptides presented by nonpolymorphic MHC molecules of donor cells 
appear to trigger the initial stages of the mixed lymphocyte reaction.
2. As a consequence of the release of cytokines during the initial activation of the 
rejection reaction the expression of non-self MHC molecules is upregulated on 
donor tissues. Donor MHC molecules are shed into the circulation taken up by 
professional APCs of the recipient and processed and presented as non-self 
peptides associated with self MHC molecules to the immune system of the 
recipient.
MHC-II expressing cells must be present for the mixed lymphocyte reaction to take 
place. This requirement suggests that activation of helper T cells by recognition of 
MHC-II peptide complexes is essential for the differentiation of CD8+ cells. Graft 
rejection is usually more intense with increasing MHC disparity between donor and 
host. This is probably due to the greater structural differences between the non-shared 
MHC molecules. Thus MHC differences are likely to perpetuate the rejection reaction 
in that self (host-derived) MHC molecules will present non-self peptides derived from 
the donors MHC molecules.
2.1.2.5 Stimulation o f a B cell Response by a T dependent Antigen
In contrast to T cells, B cells recognize external epitopes of unprocessed antigens which 
do not have to be associated to MHC molecules(225). Some special types of APC such 
as the Langerhans cells of the epidermis and the follicular dendritic cells o f the germinal 
centers appear to adsorb complex antigens onto their membranes where they are
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expressed and presented for long periods of time. Accessory cells and helper T cells 
provide additional signals necessary for B cell activation, proliferation and 
differentiation. A complex of proteins is associated non-covalently with the membrane 
immunoglobulin including CD 19 and CD21. These proteins appear to potentiate the 
signal delivered through occupancy of the binding site on membrane immunoglobulin. 
Activation and translocation of transcription factors (eg NF-AT, NF-kB) activates the 
expression of genes coding for immunoglobulin polypeptide chains. For a B cell to 
complete its proliferation and differentiation into an antibody producing plasma cell or 
memory B cell a variety of additional signals are required. In the case of the stimulation 
of a B cell response with a T dependent antigen the additional signals are delivered by 
helper T cells in the form of both cytokines and interactions between complementary 
ligands (co-stimulatory molecules) expressed by T cells and B cells. A naive B cell is 
initially stimulated by recognition of an epitope of the allergen through the membrane 
immunoglobulin. Two other sets of membrane molecules are involved in this initial 
activation: the CD45 molecule and the CD19/CD21/CD81 complex. CD21 is a receptor 
for C3d a fragment of complement component 3. It is possible that B cells interacting 
with bacteria coated with C3 and C3 fragments may receive a co-stimulatory signal 
through the CD19/CD21/CD81 complex.
In the same microenvironment where B cells are being activated, helper T cells are also 
activated. This occurs because the macrophage can present membrane-absorbed, 
unprocessed molecules with appropriate immunogenic epitopes to B lymphocytes as 
well as present antigen in association with MHC-II to helper T cells. Also the B cell 
may internalize the immunoglobulin-antigen complex, process the antigen and present 
MHC-II associated peptides to the helper T cells.
The progression of the immune response requires complex interactions between 
accessory cells (macrophages or B cells), helper T cells, and B cells. The helper T cell 
receives a variety of co-stimulatory signals from APCs and the activated helper T cell in 
turn delivers activating signals to APC and B cells. Some of the signals are mediated 
by interleukins and cytokines such as IL-2 and IL-4 that stimulate B cell proliferation 
and differentiation, and interferon gamma (IFNy), which increases the efficiency of 
APC, particularly macrophages. Other signals are mediated by cell-cell interactions 
involving CD40L (on T cells) and CD40 (on B cells). As a consequence of signalling 
through the CD40 molecule, B cells express CD80 and CD86 which deliver
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differentiation signals to T cells through the CD28 family of molecules. Additional 
activation signals are then delivered.
Cell-cell contact also plays a significant role in promoting B cell activation by 
delivering co-stimulatory signals to the B cell and/or by allowing direct traffic of 
unknown factors from helper T cells to B cells. Transient conjugation between T and B 
cells seems to occur constantly due to the expression of complementary CAMs on their 
membranes. For example, T cells express CD2 and CD4 and B cells express the 
respective ligands, CD58 (LFA-3) and MHC II; both T and B cells express ICAM-1 and 
LFA-1, which reciprocally interact.
Once an immune response has been triggered the total number of antigen-specific T and 
B cell clones will remain the same but the number of cells in those clones will have 
increased several-fold. It is estimated that the initial helper T cell population is capable 
o f expanding to more than 1000-fold its starting number by day 10. Following such 
rapid T cell expansion many of the activated effector cells will undergo apoptosis. 
When the immune response subsides, however, an expanded population of memory T 
cells will remain and will be able to assist the onset of subsequent responses to the same 
antigen with greater efficiency and speed which is characteristic of the memory 
response. As lymphocytes develop into memory cells following antigenic stimulation 
they cease to express CD45RA and begin to express CD45RO on their surface(226).
2.1.2.6 Regulatory T cells
Regulatory T cells (T reg cells) are a subset of T lymphocytes important for down­
grading and thus achieving balance in the immune response. T reg cells express CD4 
and CD25(227). Activated non-regulatory cells also upregulate CD25 and T reg cells 
are characterized further by their expression of the transcription factor Foxp3  in 
mice(228) (FOXP3 in humans). It is thought that these cells are likely to represent a 
separate T cell lineage(229, 230) although in some situations Foxp3 expression may be 
induced from naive T cells after antigen exposure in the periphery. It is likely that 
several subpopulations of suppressor T cells exist.
The hallmark o f the adaptive immune system is the random generation of antigen 
receptors in developing lymphocyte clones through a process of somatic cell gene 
rearrangement mediated by the recombination-activating gene recombinase(228). 
However the diversity of antigen recognition afforded by the system also poses the 
threat of autoimmunity because of the generation of self-reactive receptors. The
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emergence of MHC restricted T cell recognition exacerbates this threat because to 
develop T cells must express antigen receptors that interact with self peptide MHC 
complexes. Autoreactive lymphocyte clones are eliminated during development and 
this clonal deletion together with anergy of self-reactive lymphocytes is known as 
recessive tolerance. T reg cells further prevent the development of autoimmunity by 
actively suppressing immune activation, thereby acting as critical mediators of self­
tolerance and immune regulation(231).
T reg suppression is mediated by a number of effector mechanisms(232):
1. Cytokine production: IL-10 and TGF-beta have been linked to suppression 
mediated by T reg cells in in vivo experimental models(233-235)
2. Cell-cell contact: reverse signaling occurs through crosslinking of B7 (CD80 
and CD86) on the cell surface of antigen-presenting cells or activated T 
cells, mediated by CTLA-4 expressed by T reg cells(236).
3. After activation human T reg cells may directly kill activated CD4 and CD8 
T cells in a granzyme A and perforin dependent way(23 7).
4. T reg cells may suppress immune activation by competitive consumption of 
T cell growth factors such as IL-2(238-240)
Balance is critical and although T reg activity may be usefully responsible for 
dampening excessive inflammation they may also hamper the effective control o f 
viruses and bacteria. Likewise T reg depletion may usefully lead to more effective 
immunosurveillance of tumours but may also lead to autoimmunity. The central role of 
FoxpS is demonstrated by the syndrome of immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked (IPEX). This is a fatal human autoimmune disorder in which 
there are mutations in the gene encoding FOXP3(241). Affected males present with 
massive lymphoproliferation, early-onset insulin dependent diabetes mellitus, 
thyroiditis, eczema, severe enteropathy, food allergies, autoimmune haemolytic anaemia 
and thrombocytopaenia and severe infections. They die between 3 and 4 weeks o f 
age(242). A similar syndrome scurfy occurs in Foxp3 defective mice(243).
2.2 CYTOKINES
Cytokines are a diverse group of soluble proteins and peptides that act as humoral 
regulators at nano- and picomolar concentrations(225). They are secreted by a wide 
range of cells including those of the immune system. Some secreted cytokines also
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have membrane-bound forms. Many cytokines are produced by multiple cell types such 
as lymphocytes, monocytes/macrophages, mast cells and eosinophils and each 
individual cytokine can have multiple functions depending upon the cell that produces 
it, the target cell upon which it acts and the other cytokines present in the 
microenvironment. There is also redundancy in the system with several different 
cytokines having the same biological function. They can exert their effect through the 
bloodstream on distant target cells (endocrine), on target cells adjacent to those that 
produce them (paracrine) or on the same cell that produces the cytokine (autocrine). 
Physiologically most cytokines probably exert their most important effects in a 
paracrine and/or autocrine fashion. They exert their effects on target cells by binding to 
specific high-affinity receptors which in turn initiate intracellular signal cascades, 
ultimately determining the overall cellular response. The array of biological responses 
that can be elicited includes activation, differentiation, proliferation, inhibition and 
apoptosis of immunocompetent cells.
Classification of cytokines is difficult because of their overlapping origins and 
biological activities. They can be classified according to major origin e.g. lymphokines 
and monokines or according to major function e.g. interferons, chemokines, colony 
stimulating factors, tumour necrosis factors and interleukins. No classification is ideal. 
Most interferons also interfere with virus replication. IFNy is produced by activated T 
cells and is an important immunoregulatory molecule. Chemokines are cytokines 
involved in chemotaxis. The CSFs are so named because they support the growth and 
differentiation of various elements of the bone marrow. The TNFs are so called because 
they cause haemorrhagic necrosis of tumours when injected into animals. Interleukins 
are the largest group and these communicate between various populations o f white 
blood cells. Interleukins are differentiated with numbers. They are produced by a 
variety of cell types such as monocytes/macrophages, T cells, B cells and even non­
leucocytes.
2.2.1 T Helper Subsets
Stimulation of CD4+ T cells in appropriate ways can lead to differentiation into 
subtypes with polarized cytokine production profiles and effector functions(225, 244- 
248). T helper 0 (ThO), Thl and Th2 cells have been defined but these subsets do not 
have specific membrane markers. Thl cells produce cytokines such as TNF|3, IFNy and 
IL-2 that assist in the proliferation and differentiation of CD8+ T cells and natural killer
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cells (cell-mediated immunity); Th2 cells produce IL-4 and/or IL-5 and assist in B cell 
proliferation and differentiation. Th2 cytokines also promote mast cell and eosinophil 
proliferation and function. ThO cells produce both Thl and Th2 type cytokines. They 
are postulated to be a transitory precursor cell type but may also be an autonomous cell 
type resulting from differentiation in the absence of clearly polarizing signals(249). The 
Thl/Th2 dichotomy was seen first in mice and rats (244, 245, 250) but has also been 
widely demonstrated in human cells(246, 248, 251).
The type of subtype produced is dependent on(249):
1. The type of antigen presenting cell with macrophages and dendritic cells 
favouring a Thl response and B cells a Th2 response.
2. The strength of the interaction between the TCR and peptide. This is dependent 
on the affinity of the interaction of the TcR with the MHC II associated peptide, 
the concentration of MHC-peptide complexes on the cell membrane and signals 
dependent on cell-cell interactions. Strong interactions favour the development 
of Thl cells and weak ones the development of Th2 cells.
3. The cytokines present at the time. The early stages of proliferation of the 
common precursor ThO cells are IL-2 dependent. IL-2 is the main cytokine 
released by activated ThO cells and has both autocrine and paracrine effects thus 
promoting ThO proliferation. As the cells continue to proliferate IL-12 promotes 
Thl differentiation while IL-4 seems to be crucial for Th2 differentiation. The 
cellular source of IL-12 is the APCs and experimental work suggests that 
specific antigens or bacterial products with adjuvant properties may induce the 
release of IL-12 by those cells thus tilting the immune response towards Thl 
differentiation. Cross-regulation of Thl and Th2 cells through their specific 
cytokines is also important in determining the nature of the immune 
response(252). Thl cytokines including IFNy are potent inducers o f the 
differentiation of Thl cells and antagonists of Th2 development and function. 
On the other hand Th2 cytokines such as IL-10 promote Th2 differentiation 
whilst inhibiting the production o f Thl cytokines and subsequently down- 
regulating Thl driven responses. The Thl/Th2 dichotomy has been shown to be 
a simplification of the situation and there are very complex networks of cytokine 
regulatory patterns which are produced in response to, and specifically tailored 
to, different offending agents.
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2.2.2 Interleukin-2 (IL-2) and the Interleukin-2 Receptor (IL-2R)
Two critical early events in T cell activation are the appearance of mRNAs for IL-2 and 
for the IL-2 receptor in the cytoplasm(225). The upregulation o f the IL-2 gene, an 
essential step for T cell proliferation at the onset of the immune response, requires 
occupancy of the promoter region by NF-AT/AP-1/NF-kB complexes. The expression 
of the IL-2 receptor is primarily controlled by NF-kB. The release of IL-2 into the 
cellular environment of activated T cells expressing IL-2 receptors has significant 
biological consequences.
IL-2 stimulates lymphocyte proliferation in both autocrine and paracrine loops. 
Autocrine stimulation involves release of IL-2 from an activated T cell and binding and 
activation of IL-2 receptors expressed by the same T cell. Paracrine stimulation is 
likely a consequence of IL-2 overproduction after persistent stimulation of CD4+ T 
cells. The released IL-2 exceeds the binding capacity of the IL-2 receptors expressed by 
the producing cell and can stimulate other nearby cells expressing those receptors. The 
targets of the paracrine effects of IL-2 are CD4+ T cells, CD8+ T cells, B cells and NK 
cells all of which express IL-2 receptors of varying affinities.
The IL-2R expressed by T and B cells is composed of three different polypeptide 
chains. The binding of IL-2 to the trimeric high affinity IL-2R induces the association 
of the IL-2R to specific tyrosine kinases. The end result is the phosphorylation of 
transcription factors of the ST AT family which dimerize after phosphorylation and then 
translocate to the nucleus. In the nucleus, activated STAT factors upregulate the 
expression of genes coding for cytokine receptors and induce the appearance of cyclins. 
As a consequence the cell enters into S phase of the cell cycle. Co-stimulatory signals 
such as CD86-CD28 interactions are required to sustain this response. IL-2 synthesis 
and IL-2R expression by CD4+ cells are sustained for about 48 hours to allow clonal 
expansion of antigen specific CD4+ cells and subsequently downregulated. If the 
CD86-CD28 interaction is inhibited the T cells become anergic. NK cells constitutively 
express IL-2 receptors and will secrete tumour necrosis factor alpha (TNFa), IFNy and 
GM-CSF in response to IL-2 which in turn activate monocytes.
2.2.3 Pro-inflammatory Cytokines
IL-1, TNFa, IFNy, IL-6, IL-8 and migration inhibition factor (MIF) are the main 
soluble factors that influence inflammatory reactions(225). IL-1 and TNFa have
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membrane-associated and secreted forms and are involved in the systemic metabolic 
abnormalities and circulatory collapse characteristic of shock associated with severe 
infections. They induce acute phase proteins such as alpha 1-antitrypsin, fibrinogen, and 
C reactive protein. They cause the upregulation of cell adhesion molecules, particularly 
P-selectin and E-selectin in vascular endothelial cells. This upregulation promotes the 
adherence of inflammatory cells which eventually migrate to the extravascular space 
where they form tissue inflammatory infiltrates. IL-1 interacts with nuclei in the 
anterior hypothalamus causing fever (secondarily to stimulation o f prostaglandin 
synthesis) and sleep and increases the production of ACTH. IL-1 exists in two 
molecular forms, IL-1 a  and IL-1 (3 encoded by two separate genes and displaying only 
20% homology to one another. In spite of this structural difference both forms of IL-1 
bind to the same receptor and share identical biological properties. IL-1 a  tends to 
remain associated to cell membranes whilst IL-ip synthesized as an inactive precursor 
is released from the cell after being processed post-translationally by interleukin- 
converting enzyme. Macrophage derived IL-1 is an important stimulus for the synthesis 
and secretion of IL-2 by activated T cells.
IL-4 induces IgE synthesis and is enhanced by IL-5. IL-5 drives eosinophilic 
differentiation and is dependent on IL-4. IL-6, synthesized primarily by monocytes, 
macrophages, and other APCs has pro-inflammatory and haematopoietic activities. It 
also induces the synthesis of acute phase response proteins by the liver.
2.2.4 Cytokines with Predominant Immunoregulatory Functions
IFNy produced by activated CD4+ cells and NK cells has a wide range of effects as 
nearly all cells express receptors for IFNy(225). It induces class I MHC antigen 
expression on all somatic cells and induces class II MHC on APCs thus initiating and 
perpetuating the immune response. In concert with IL-1|3 it induces an increase in the 
expression of ICAM-1 on the cytoplasmic membrane of endothelial cells, enhancing T 
cell adherence to the vascular endothelium, an essential first step for T lymphocyte 
migration from the vascular bed. Large numbers of T cells will therefore exit the 
vascular bed in areas near the tissues where activated T cells are releasing interleukins 
and will form perivenular infiltrates characteristic of delayed hypersensitivity reactions.
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IFNy stimulates CD8+ and NK cells as well as activating monocytes. After exposure to 
IFNy, monocytes undergo a series of changes typical of their differentiation into 
phagocytic effector cells:
1. The cell membrane becomes ruffled and the number of cytoplasmic microvilli 
increases by a factor of 10. This change reflects a considerable increase in 
phagocytic capacities.
2. The expression of MHC class II antigens and Fey receptors increases. The 
increase in the expression of MHC-II enhances the efficiency of monocytes as 
APCs and the increased expression of Fc receptors further enhances their 
efficiency as phagocytic cells.
3. The production of cytokines such as TNFa and IL-12 and of several 
antimicrobial proteins and compounds (including defensins, cathepsins, 
collagenases, superoxide radicals and inducible nitric oxide synthase) is 
upregulated. Engulfed organisms are therefore rapidly killed and ingested 
proteins are efficiently digested in the phagolysosmes. Excessive and protracted 
production of IFNy will have adverse effects. Hyperstimulated monocytes may 
become exceedingly cytotoxic and may mediate tissue damage in inflammatory 
reactions and autoimmune diseases.
IL-12 is produced by antigen presenting cells after endocytosis of particulate 
materials or microbes and plays as crucial role in linking innate and adaptive 
immunity. It induces the production of IFNy by CD4+ T cells and NK cells at the 
early stages of the immune response before the differentiation of effector T cells.
IL-18 acts as an IFNy inducing factor. It is produced and released by APCs and its 
main targets are ThO/Thl CD4+ T cells and NK cells.
2.2.5 Clinical Correlations
Thl type profiles have been found to be typically induced by infection with intracellular 
bacteria, protozoa and viruses, whereas Th2 type profiles predominate during 
helminthic infestations and in response to common environmental allergens(247). 
Strong and persistent Thl responses have been shown to be involved in organ-specific 
autoimmunity such as uveitis(253, 254), contact dermatitis and some chronic 
inflammatory disorders of unknown aetiology. In contrast polarized Th2 responses 
favour are responsible for triggering allergic atopic disorders(255) such as vernal
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conjunctivitis(256) and asthma(257) in genetically predisposed hosts(258). As well as 
being characteristic of different immunopathological reactions polarized Thl and Th2 
responses are also characteristic of different protective roles. It is hypothesized that a 
predominance of Th2 cytokines will be protective against Thl mediated disorders such 
as allograft rejection(259) and uveitis(260) and conversely, induction of Thl activity 
will dampen Th2 mediated actions including hypersensitivity reactions and 
eosinophilia(252).
Cytokine measurement techniques have been used to provide information on cytokine 
profiles in clinical disease states(255, 261-264) and to correlate with clinical and 
laboratory indices. For example Beilin et al found that reduced post-operative pain was 
associated with an attenuated production of proinflammatory cytokines(265), Jambrik Z 
et al found a correlation between IL-6 and haemodynamic abnormalities in rabbits with 
acute pancreatitis(266); Reinisch et al describe a correlation between IL-6 and clinical 
activity in Crohns Disease(267) and Schuerwegh and co-workers(268) found a 
correlation between the number of IFNy producing T helper cells and rheumatoid 
arthritis disease activity.
2.2.6 Measurement of Cytokines
There are a large number o f techniques for the measurement o f cytokines(269-271). 
These include ELISA, ELI SPOT, in situ hybridization, immunohistochemistry, limiting 
dilution analysis, single cell PCR and flow cytometry. Each technique has advantages 
as well as limitations such as cost, technical difficulty, labour intensive collection 
and/or analysis and the technique used will depend on the question being asked. Flow 
cytometry is an ideal technique for the assessment of cytokines in patient samples 
because it allows the rapid, simultaneous investigation o f a number o f cellular 
characteristics including the expression of intracellular markers. In contrast to other 
techniques individual cells within diverse populations can be assessed, large numbers of 
events can be collected from each sample and large numbers o f samples can be 
processed. The results can also be quantified.
2.2.6.1 Flow Cytometry
Flow cytometry provides high sensitivity and levels of accuracy. It measures certain 
characteristics of cells or particles as they travel singly in suspension past a sensing 
point. The flow cytometer consists of a light source, collection optics, electronics and a 
computer to translate signals to data. The light source is a laser that emits coherent light
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at a specified wavelength. Scattered and emitted fluorescent light is collected by two 
lenses (one set in front of the light source and one set at right angles) and by a series of 
optics, beam splitters and filters, specific bands of fluorescence can be measured. This 
can be used to measure physical characteristics such as cell size and any cell component 
or function that can be detected by a fluorescent compound can be examined. 
Multicolour analysis allows the investigation of antigens that co-exist on the same cell 
and the ability to simultaneously measure multiple parameters on a cell by cell basis 
makes flow cytometry a powerful tool. In addition, sorting can be used to physically 
separate a cell or particle of interest from a heterogeneous population. Testing can be 
rapidly performed on thousands of cells allowing even cells that have only low 
frequencies to be assessed.
These features make flow cytometry ideal for the quantification of cytokine producing 
cells and simultaneous immunophenotyping and intracellular cytokine staining 
identifies the subpopulation responsible for cytokine production(248, 271-275).
2.2.6.1.1 Principles o f  Flow Cytometry
2.2.6.1.1.1 Optics
The typical optical system consists of a laser that emits a single wavelength of blue light 
(488 nm) that excites a number of different fluorochromes(276). When conjugated to 
antibodies, fluorochromes become markers o f reactions between the antigen on the cell 
o f interest and the antibody. Cells labelled with the fluorochrome are excited by the 
laser and the emitted light is detected by using photomultiplier tubes (PMTs) designed 
to capture only the wavelength of interest. The level of fluorescence can then be 
determined and displayed. Fluorescence signals above that o f autofluorescence and 
non-specific binding represent cells that are positive for the antigen of interest and those 
that express only autofluorescence are negative. Thus the percentage of a population of 
cells that possesses a particular antigen can be determined.
2.2.6.1.1.2 Fluidics
Cells in suspension are measured individually by introducing them into pressurized 
sheath fluid that travels through a clear cuvette. The cells are focused into a stream in 
the centre of the cuvette(276) (laminar flow) and this ‘hydrodynamic focussing’ results 
in the cells actually passing single-file through the cuvette where the laser light 
intersects the stream.
2.2.6.1.1.3 Signal Processing
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The electronic system measures signals from the PMTs or detectors on a number of 
parameters on each cell as it passes through the laser light(276). These parameters 
include fluorescence and light scattering. Forward light scatter is correlated with the 
size of the cell; side scatter is correlated with the granularity of the cell. The number of 
fluorochromes detected is limited to the number of fluorochrome-laser light-PMT 
combinations available. Typically flow cytometers contain three PMTs to detect three 
fluorochromes simultaneously with one argon laser (488 nm wavelength). Examples of 
fluorochromes include fluorescein isothiocyanate (FITC), which emits light at 525 nm; 
phycoerythrin (PE) which emits light at 575 nm; and peridinin chlorophyll protein 
(PerCP) which emits light at 625nm.
Figure 2.2: Flow Cytometry
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Instrument setup and compensation are critical for consistent results and must be 
checked periodically. Thresholds and gates are set to identify the data of interest and to 
exclude nonviable lymphocytes and cellular debris.
2.2.6.1.2 A ctivation and Staining
2.2.6.1.2.1 Harvesting Cells
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Whole blood or peripheral blood mononuclear cells (PBMCs) may be used for analysis. 
PBMC are isolated from whole blood using density gradient separation. A whole blood 
technique may better reflect physiological responses occurring in vivo(277). It has the 
advantage of maintaining any drug effect during the incubation period as buffering by 
erythrocytes is maintained and drugs are not washed out.
2.2.6.1.2.2 Activation
The cells are set up in primary culture to induce cytokine production(276). In vitro 
stimulation of cells is required for detection of cytokines by flow cytometry since 
cytokine levels are typically too low in freshly prepared cells. This can be done for 
example with the combination of phorbol esters and a calcium ionophore which induces 
intracellular signal cascades. The optimal stimulation period for induction of a given 
cytokine is variable and is determined individually. The short stimulation times 
required minimise apoptosis and cell proliferation allowing the cellular population that 
was sampled to be investigated. The addition of costimulatory antibodies such as CD28 
enhances the frequency of T cell subsets expressing cytokine.
2.2.6.1.2.3 Accumulation o f  Intracellular Cytokines
One big advantage of flow cytometry over ELISA is that it detects intracellular 
cytokines. This requires that the secretion of cytokines is blocked. The addition of 
protein transport inhibitors leads to the cytoplasmic accumulation of proteins and 
generates an increased signal intensity(274). The two commonly used inhibitors are 
monensin, an ionophore that disrupts ion gradients across cellular membranes and 
brefeldin A, a fungal metabolite that interferes with vesicular transport from the rough 
endoplasmic reticulum to the Golgi complex.
2.2.6.1.2.4 Imm unophenotyping
Surface markers are selected depending upon the type of cell to be studied. T helper 
cells are identified as CD3+ CD8- cells because of the downregulation o f CD4 after 
phorbol ester stimulation(278).
2.2.6.1.2.5 Intracellular Staining Procedure
The intracellular staining procedure requires the fixation, permeabilization and 
subsequent staining of the activated cell population with fluorochrome conjugated 
antibodies. Fixation with paraformaldehyde allows preservation of cell morphology and 
intracellular antigenicity while also enabling the cells to withstand permeabilization by 
detergent(279). Membrane permeabilization by saponin allows the fluorchrome-
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conjugated cytokine specific monoclonal antibody to penetrate the cell membrane and 
membranes of the endoplasmic reticulum and Golgi apparatus(280). High affinity 
anticytokine antibody conjugates with very low levels of background staining are used.
2.2.6.1.3 Controls
The specificity of the anti-cytokine antibody is checked using unlabelled anti-cytokine 
antibody or isotype control. Unstimulated samples also serve as controls.
2.2.6.1.4 Acquisition and Analysis
The cell population of interest is identified by gating using light scatter and by cellular 
antigen expression(276). Gated cells are analysed using dual histograms. Quadrants 
are placed so that the negative populations are on one side of the histogram and the 
positive ones are on the other. The software can then calculate the proportion of gated 
cells that are positive for a given antigen.
2.3 LABORATORY TECHNIQUES USED IN THESE STUDIES
2.3.1.1 Cell Stimulation
Peripheral blood was collected in sodium heparin vacutainer tubes and analyzed within 
2 hours without refrigeration. A whole blood stimulation method(281, 282) was used 
on freshly collected cells. lOOpl of whole blood was diluted 1:1 with RPMI 1640 (Life 
Technologies, Paisley, UK) in Trucount tubes(Becton Dickinson, San Jose, CA). Cells 
were stimulated with phorbol-12-myristate-13-acetate (25ng/ml; PMA; Calbiochem, 
UK) and ionomycin (1 pg/ml; Sigma; Poole, UK) in the presence of brefeldin A 
(lOpg/ml; BFA; Sigma, UK) which allows cytokines to accumulate within the 
cell(283). The strength of the TCR-ligand interaction as well as the degree of 
costimulation will determine the nature of the T cell response. In these studies a strong 
mitogen stimulation of PMA+ionomycin was used in order to obtain the maximal level 
of T cell activation for each sample. This was particularly important for reducing 
variability when comparing repeated measurements over time. In addition CD28 is 
known to be down-regulated with progression of HIV disease so this was not used in 
order to avoid variable costimulation in the HIV samples(284). Samples were cultured 
at 37 C, 5% CO2 for 16 hours. Unstimulated whole blood samples with BFA added 
were used as controls.
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2.3.1.2 Phenotypic and Cytokine Staining
After stimulation blood cells were stained with directly conjugated mabs, anti-CD3 
conjugated to FITC or PE and anti-CD8 conjugated to PerCP; (Becton Dickinson, 
Oxford, UK) 25pl/ml) and incubated for 15 minutes in the dark at room temperature. 
Red blood cells were then lysed using FACSLyse (Becton Dickinson). The leucocytes 
were resuspended and fixed and permeabilised using lOOpl Cytofix/cytoperm 
(Pharmingen) for 20 minutes at 4 C. The cells were washed in lxPermwash buffer 
(Pharmingen), pelleted by centrifugation, resuspended and stained with previously 
optimised anti-IL-2-PE (Becton D ickinson), anti-IFNy-FITC, anti-IL-10-PE 
(Pharmingen) and anti-IL-4-FITC. In the uveitis study anti-CD69-FITC (Becton 
Dickinson) was also used. Cells were incubated for a further 30 minutes at 4 C before 
washing in Perm wash, pelleting by centrifugation and final resuspension in FACS Flow 
(Becton Dickinson). Both Thl and Th2 cytokine production were assessed. The 
induction of IL-2, IFNy, IL-4 and IL-10 were measured in time course experiments to 
determine the optimal time of PMA stimulation for their detection for use in the study. 
No one time point was optimal for all the cytokines so the study was focused on IL-2 
and IFNy production which was maximal at 16 hours. At this time point we were 
unable to demonstrate significant production o f either IL-4 or IL-10 in patients or 
controls and therefore did not look further at these cytokines.
2.3.1.3 Flow Cytometry
The FACSCalibur flow cytometer (Becton Dickinson) was used for acquisition and data 
was analysed with CellQuest software (Becton Dickinson). Forward and side scatter 
profiles were used to identify the lymphocyte region. 10 000 events were collected 
within this gate for the uveitis patients and a secondary gate set using fluorescent anti- 
CD3 mab. The number of events collected for the HIV patients was limited by the cell 
count. As CD4 is known to be down regulated in the presence of phorbol esters, CD8- 
CD3+ was used to identify CD4 subset(285). Cytokine production by the CD4+ (CD8 
negative) and CD8+ T cells at the single cell level was assessed. Results are expressed 
as the percentage of cells of a particular T cell subset that stained positive for a given 
cytokine, e.g.: %CD4IL2= CD4+IL2+/[(CD4+IL2+) + (CD4+IL2-)] x 100.
92
Figure 2.3: Flow Cytometry; Acquisition
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c. Unstimulated T lymphocytes showing no production of IL-2
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3.1 INTRODUCTION
3.1.1 Definition of Uveitis
Uveitis is a generic term describing inflammation of the vascular, pigmented uvea (iris, 
ciliary body and choroid) and its adjacent tissues: the retina, retinal vessels, vitreous and 
sclera. The term gives no clue as to pathogenesis. It has an incidence of only 17/100 
000 of the population(286) but is responsible for 10% of those registered legally blind 
or partially sighted under the age of 65(287). This is likely to be an underestimate as 
complications of uveitis such as glaucoma, cystoid macular oedema, arterial occlusions 
and optic atrophy are often recorded on the blind registration form rather than the 
original diagnosis.
The clinical spectrum is wide and uveitis may occur as an isolated disease or as part o f a 
systemic process. The characteristics of a particular uveitic entity allow it to be put into 
categories that can provide information on natural history and prognosis for vision. A 
number of classification systems exist and these are usually used together to 
characterise a particular condition. The International Uveitis Study Group(288) 
recommends that patients be classified according to the location of pathology within the 
eye. Anterior uveitis describes inflammation that is mainly limited to the anterior 
segment i.e. iritis, anterior cyclitis and iridocyclitis. Intermediate uveitis describes 
inflammation of the vitreous, pars plana and peripheral retina. Posterior uveitis may be 
focal, multifocal or diffuse. It is named choroiditis, chorioretinitis, retinochoroiditis, 
retinitis or neuroretinitis depending on the predominant site o f inflammation. 
Panuveitis describes inflammation throughout the eye. Because the uvea may not 
always be the initial target of the inflammation an alternative classification system has 
also been proposed which dispenses with the term uveitis and uses the term intraocular 
inflammation instead(289). Intraocular inflammation can then be described as being 
confined to the anterior segment, confined to the posterior segment or present in both 
parts of the eye.
Clinically the uveitides are subdivided into those with infectious and those with non- 
infectious causes. Pathologically this is analogous to exogenous or endogenous 
initiating stimuli. In most, the aetiology is said to be endogenous or autoimmune 
although it is likely that in some cases where a trigger is thought to be endogenous the 
particular genetic and environmental background allows micro-organisms to exert an 
adjuvant like effect. Both infectious and autoimmune uveitides lead to tissue
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destruction and scarring and thus to loss of function. Some uveitides are associated 
with a systemic disease whilst others manifest as idiopathic ocular autoimmune disease.
Posterior uveitis may manifest as a wide range of clinical syndromes. Many of these 
conditions are discrete clinical entities with well-defined characteristics. Other 
conditions are less readily diagnosed and pathogenically may represent different aspects 
of a spectrum of chorioretinal responses that are essentially the same.
3.1.2 Pathology of Posterior Uveitis and Effect on Cytokine Profile
The term posterior uveitis applies to a heterogeneous group of disorders ending in a 
common final pathway of inflammation, scarring and visual morbidity. Despite much 
investigation the pathogenesis of posterior uveitis is not well characterised(290) and 
even within single disease entities it is often difficult to assess the nature of the immune 
response.
3.1.2.1 Histopathology
Human studies are limited by the paucity of material(290). Sympathetic ophthalmia and 
Beh^ets disease are the two examples of panuveitic conditions for which histopathology 
has been most studied and these will be discussed here as examples of posterior uveitis.
3.1.2.1.1 Sympathetic Ophthalmia
Sympathetic ophthalmia is a classic example of an autoimmune disorder. It is a 
bilateral inflammatory disease that follows trauma or surgery to one eye(291). 
Panuveitis occurs and the degree of inflammation and visual prognosis is very variable. 
The main histopathological features are diffuse granulomatous, non-necrotizing 
inflammation of the uvea with lymphocytic infiltration of the choroid(292) and Dalen- 
Fuchs nodules. Dalen-Fuchs nodules are focal collections o f epithelioid cells with 
occasional giant cells and rare plasma cells located between Bruch’s membrane and the 
retinal pigment epithelium(293, 294). Immunocytochemical analysis shows CD4+ T 
cells dominating early in disease with CD8+ cells becoming more common later(295). 
B cells have been shown to make up only a small minority of the cellular infiltrate(292, 
296, 297) and may correlate with prolonged disease(290).
The traditional hypothesis is that ocular antigens such as on the choroidal melanocyte, 
which are usually sequestered because of the blood brain barrier, become exposed to the 
blood stream and to the immune system thereby inciting a uveal autoimmune reaction in 
the other eye(298). The precise nature of the ocular antigen has still to be determined.
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The role of infection in sympathetic ophthalmia continues to be debated. 
Epidemiological studies have previously shown a higher incidence of sympathetic 
ophthalmia following accidental (0.19%) rather than surgical (0.07%) trauma and it has 
been argued that this may be because accidental trauma is more frequently associated 
with microbial contamination(290). It is postulated that such microbes could be directly 
infectious, could act indirectly as an adjuvant to upregulate the local immune response 
or may have structural homology to an endogenous ocular antigen, thus causing disease 
through molecular mimicry. More recent studies have, however, demonstrated a change 
in the epidemiology with an increase in the incidence following ocular surgery, in the 
elderly and in women(299). Sympathetic ophthalmia has been shown to be associated 
with HLA-DRB1*04 and DQA1*03 in white and Japanese patients (300) and this 
further suggests that the immune system contributes to disease expression.
3.1.2.1.2 Beh get’s Disease
B elie fs  Disease (BD) is a chronic, relapsing, multisystem disorder that is characterized 
by an occlusive vasculitis of unknown aetiology. Typical ocular findings are vitritis, 
retinitis, optic disc oedema, retinal vasculitis, haemorrhage, oedema and cellular 
infiltration and these can be associated with blindness in over 70% of the eyes of 
B e lie f  s patients(301).
Genetic factors are known to be important with the incidence o f BD being markedly 
different in different ethnic groups. It is relatively common in Japan, for example, 
where it is responsible for up to 20% of all blindness acquired before middle age. A 
close association has been found between the HLA-B5101 allele and BD in Japanese 
and Greek pedigrees(302, 303). However, epidemiological associations have also been 
found with dental caries, tonsillitis, periodontitis and streptococcal infection and it may 
be that superantigens can sometimes stimulate the immune response independently of 
the HLA molecule utilizing the gamma-delta T cell subset(304). Moleular biology 
techniques have confirmed an association with herpes simplex virus and HSV has been 
isolated from ocular fluids of patients with BD(305). An animal model exists with HSV 
inoculated ICR mice showing an induced BD-like syndrome. Histopathological 
analysis demonstrates a panuveitis with perivasculitis and tissue destruction involving 
both the anterior and posterior segments although the choroid does not appear to be 
primarily involved. Inflammatory cells are found in the anterior chamber, corneal 
endothelium, iris and ciliary body; the retina shows oedema with focal areas of 
infarction and necrosis and the retinal vessels have thickened, hyalinized walls
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infiltrated by lymphocytes(306, 307). The CD4+ T lymphocyte has again been shown 
to be the major infiltrating cell in blood vessel walls and in the immediate perivascular 
area(308, 309). A proportion o f the retinovascular lymphocytes are activated, 
expressing IL-2R whereas those found in the anterior segment are IL-2R negative. 
Studies have reported the presence of B cells, plasma cells(306, 310), eosinophils(311), 
macrophages(307, 309) and polymorphonuclear cells. IgG, IgA, complement and 
immune complexes have all been detected(312).
Histopathology has provided important information on pathogenesis but histological 
and immunohistochemical studies are limited by the fact that they represent single time 
points in the inflammatory process and these time points are usually at a burnt out, end 
stage. This may be responsible for apparently conflicting results(290). For example 
although chorioretinal biopsies o f multifocal choroiditis lesions have shown large 
numbers of B cells in the choroid(313), vitrectomy specimens demonstrated T cell 
predominance with macrophages making up about one third of the cell population and B 
cells a rarity(314). A post-mortem case similarly identified 70-80% T cells with around 
20% B cells(315) whereas in other reports of multifocal choroiditis the infiltrates were 
predominantly B cells and plasma cells with some T cells(316). Furthermore in situ 
immunocytochemical studies of enucleated eyes with a history of chronic inflammation 
has shown the presence of the cytokines IL-2 and IFNy which were not present in 
control eyes with no inflammation(317).
3.1.2.2 Analysis o f Peripheral Blood
Increased peripheral T cell activation has been demonstrated in patients with 
uveitis(318, 319). This is true both for patients with systemic syndromes associated 
with intraocular inflammation and for patients with intraocular inflammation. In some 
studies analysis of peripheral blood in patients with BD supports a strong polarization 
of CD3+ cells to a Thl type in patients with active disease(254, 319). Frassanito and 
colleagues also made a correlation between serum IL-12 levels and peripheral Thl cells 
and disease progression. Oprempak et al. showed that patients with uveitis had 
significant frequencies of in vivo activated helper T cells in their peripheral blood as 
determined by IL-2 analysis(320). Memory and naive T cells in patients with an 
underlying systemic disease have been shown to be abnormal although those in patients 
with idiopathic uveitis did not differ from controls(321).
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Abnormal production of various cytokines in the blood appears to be an intrinsic part of 
many autoimmune disease processes such as rheumatoid arthritis and systemic lupus 
erythematosis(322). Numerous studies have been done to analyze the cytokine profile 
of the peripheral blood in uveitis(254, 319, 323-326).
In a study o f mRNA from PBMCs, 9 patients with Vogt-Koyanagi-Harada disease 
(VKH) and 9 controls the PBMCs from VKH patients produced predominantly Thl 
cytokines(324). These are postulated to be responsible for the pathological changes. 
The levels o f IFNy and IL-2 were significantly higher in the stimulated cell culture 
supernatant o f the patients than those of controls and the proportions of IFNy or IL-2- 
producing CD4+ cells by flow cytometry were significantly higher in the patients than 
in controls in both stimulated and unstimulated conditions. However, no significant 
difference was found in IL-4 producing CD4+ cells.
Likewise, early studies by Ohno et al found that serum levels of IFNy were significantly 
higher in BD patients than in normal controls. They also found that the levels of IFNy 
varied significantly with stage of disease: higher serum IFNy levels being seen in 
patients in the inactive stage o f Beh9 ets compared to those in the acute stage(325). 
More recently, studies using intracellular cytokine staining and flow cytometry have 
demonstrated increased frequencies of Thl-type CD4+ and CD8+ cells in patients with 
active BD(254). The frequency of IL-4 producing cells was not increased compared to 
normals. Sugi-Ikai and colleagues were also able to show that successful treatment with 
CsA and Tac diminished the frequencies o f Thl type cells whereas unsuccessful 
treatment did not affect the frequencies o f Thl type cells. They proposed that the levels 
of Thl and Th2 type cells in BD could be used as efficient markers for assessment of 
disease activity and treatment.
In contrast other studies have suggested Th2 type cytokine profiles. For example, one 
study using ELISA showed that PBMC from patients with BD produced higher levels 
of IL-4, IL-10, and IL-13 (Th2 cell response), almost normal levels o f  IL-2, but highly 
deficient IFNy and IL-12(327). Another found above normal levels o f  IL-10 in patients 
with BD compared to controls associated with low levels o f IL -12 using ELISA on 
previously frozen venous blood samples(328). These results are supported by those that 
have suggested a marked decrease in CD4+ cells and an increase in CD8+ cells in BD 
patients with active uveitis(323, 329).
100
3.1.2.3 Analysis o f  Aqueous and Vitreous Samples
Analysis of ocular samples aims to give a clearer picture o f the in situ disease processes 
involved in ocular inflammation. Immunocytochemistry o f enucleated eyes has clearly 
demonstrated a central role for the T cell(317) and in particular for the CD4 cell(330, 
331) in chorioretinal inflammation. Investigation of aqueous and vitreous samples from 
patients with uveitis have confirmed that the majority o f infiltrating leucocytes are T 
cells(290. 297, 318, 332-334). T cells in the intraocular fluids of uveitis patients can be 
shown to be activated and a positive correlation has been made between lymphocyte 
activation and clinical uveitis activity(318, 332). The proportion of CD4+ T cells and 
o f activated CD4+ T cells in the aqueous humour o f patients with anterior uveitis is 
increased compared with peripheral blood(332, 333, 335, 336). Several studies have 
demonstrated the presence o f cytokines such as IFNy, IL-2, IL-10, IL-6, IL-12 and 
TN F-a in the aqueous humour of patients with uveitis although the cellular source of 
these cytokines was not determined(317, 332, 335-342). Muhaya et al(343) showed that 
T cell lines derived from vitreous humour cells o f patients with uveitis produced 
significantly higher levels of IL-2, IFNy and IL-10, but not IL-4, compared with those 
derived from peripheral blood T cell lines. They also found significantly higher IL-2 
production by cells derived from the vitreous o f patients with more aggressive 
intermediate uveitis compared to those patients with the more benign Fuchs 
heterochromic cyclitis (FHC) (P = 0.009). In contrast IL-10 production was 
significantly higher by the vitreous derived T cells from FHC compared with 
intermediate uveitis patients. Similar results were found when comparing aqueous 
humour cytokines in patients with FHC and those with idiopathic anterior uveitis(336). 
They suggest that high IL-10 production by T cells infiltrating the vitreous of FHC 
patients could be anti-inflammatory: down-regulating the inflammatory responses and 
thereby contributing to the more benign clinical course seen in these patients. Lacomba 
et al(341) also found high levels o f IFNy and IL-2 and low levels of IL-4 in patients 
with uveitis compared to controls. However, they demonstrate no differences between 
uveitis and control groups for aqueous IL-10 levels. Hill et al used flow cytometry 
techniques to demonstrate the cytokines produced by T cells in the aqueous(344). They 
found increased percentages of interleukin IL-10, but not IFNy producing T cells in the 
aqueous humour compared with peripheral blood in patients with acute anterior uveitis, 
FHC or chronic panuveitis.
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These, often conflicting, results make analysis of the disease processes involved 
difficult. Differences may be related to differences in the activity of the disease or in 
the populations studied. Although differences in technique and processing are also 
likely to be responsible for the variations seen it is probable that the cytokine profiles 
change over the course o f the disease process. The diversity and degree of polarization 
o f T cell subsets may reflect the nature of the antigenic and environmental stimuli to 
which the cells have been exposed, previous antigen exposure, the duration o f the 
inflammation as well as the immunogenetic status o f the host(290). It appears that 
although cytokines direct the course o f disease by specifying an initial pathway, the 
commitment is not rigid and over time there may be a shift from Thl towards Th2. 
Despite these problems many investigators have suggested correlations between 
cytokine production by T cells in uveitis and disease activity or response to treatment. 
Other cell activation markers such as CD69(345) and ICAM-1(346) have been similarly 
studied.
3.1.3 Treatment of Posterior Uveitis
Therapy for uveitis is limited by the fact that the immunological mechanisms 
responsible for ocular inflammation are not clearly defined. Patients are usually 
managed empirically with non-specific immunosuppressive therapies. An accurate 
index o f diseases activity and a more precise knowledge o f the predominant 
pathophysiological processes would allow more effective evaluation, treatment and 
follow-up o f these diseases(320). Immunosuppression is the mainstay o f treatment and 
aims to dampen the common effector mechanisms of the inflammatory response before 
irreversible damage occurs. At present treatments are generally non-specific and may 
therefore have significant systemic side effects associated with them. Medical 
treatments may be topical, periocular, intraocular or systemic depending on the 
condition. This discussion focuses on systemic treatment of the posterior uveitides.
3.1.3.1 Systemic Steroid Therapy
Systemic steroids are used in the treatment o f bilateral and sight threatening 
disease(347). The starting dose must be sufficiently high to suppress inflammation and 
doses o f 1 mg/kg/day of prednisolone are often used. After the initial high dosage the 
steroid is tapered slowly titrating clinical response against dose. Reactivation requires a 
return to high dose. The risk/benefit balance o f therapy needs to be discussed with 
patients before starting treatment and must be monitored throughout treatment. In view
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of the possible side effects systemic steroid is not used for inflammation that is not sight 
threatening. If an infectious agent such as toxoplasma or mycobacterium spp. has been 
identified the relevant anti-microbial cover is required to avoid fulminating infection. 
Patients are made aware that treatment might be long-term and recurrent. High dose IV 
methylprednisolone is effective for severe sight threatening uveitis(348) but although 
the response is rapid, it is short-lived and associated with an increased risk of 
anaphylaxis, circulatory collapse and death.
3.1.3.2 Second Line Therapy
When doses of more than approximately lOmg/day of oral prednisolone are required to 
control disease relapse, or if toxicity is limiting adequate dosage for long-term 
management, then second line steroid sparing agents are needed. Combination therapy 
allows more effective control of a severe uveitic process as well as allowing the gradual 
reduction o f steroids whilst maintaining a therapeutic remission(349). Drugs used as 
second line agents in the treatment of uveitis include CsA, azathioprine, methotrexate, 
mycophenolate m ofetil, tacrolim us and more rarely cyclophosphamide and 
chlorambucil. Unlike steroids these drugs do not have an immediate onset of action and 
high dose steroids must be maintained until they are effective. Immunosuppressants 
vary in their mechanisms o f action and side effect profiles so treatment must always be 
tailored to an individual patient and situation.
3.1.3.3 Limitations o f  Therapy
Often the response to immunosuppressive drugs at high dose is clearly dose dependent 
but the relationship becomes less clear at lower doses when the disease is coming under 
control. Maintaining an initially good response whilst reducing the dose may be 
difficult to achieve. The methods available for the monitoring of immunosuppression 
help to make therapy safer but are limited by the fact that due to variable 
pharm acokinetics and pharm acogenetics different patients may have highly 
idiosyncratic sensitivities to treatment. The relapsing/remitting or chronic nature of 
many o f the posterior uveitis entities necessitates long term or recurrent treatment and 
the doses required for efficacy may therefore result in cumulative toxicity. Adjustment 
o f dose also depends on clinical response, the most important indicators o f which are 
visual acuity and uveitis activity. Visual acuity may be limited by the complications of 
uveitis such as cataract, macular scarring or ischaemia in the absence of active 
inflammation and uveitis activity may be difficult to accurately grade in the chronic 
phase(345).
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3.1.4 Medical Suppression of the Inflammatory Response
Immunosuppressive therapy aims to affect the events of T cell activation pathways and 
downstream cytokine production and thus modulate the immune response.
3.1.4.1 Glucocorticoids
3.1.4.1.1 Mechanism o f  A ction and Effect on Cytokine Profile
The actions of corticosteroids are divided into mineralocorticoid actions and 
glucocorticoid actions. It is the glucocorticoid actions that are the mainstay of 
immunosuppressive and anti-inflammatory therapy and that are used in controlling 
heightened immunity accompanying transplant rejection, autoimmune diseases and 
inflammatory disorders(252). The mechanisms of action of glucocorticoids are multi­
faceted and incompletely understood. Corticosteroids penetrate the cell membrane and 
bind with glucocorticoid receptor a  forming an intracytoplasmic steroid-receptor 
complex(350, 351). This complex then rapidly enters the nucleus where it binds to 
DNA at specific sequences in the promoter region of steroid-responsive genes known 
as glucocorticoid response elements. The transcription o f target genes can then be 
directly or indirectly regulated. A myriad of metabolic functions are affected involving 
inflammation, cytokine synthesis and apoptosis(221). The mechanisms used are both 
direct and indirect and it is likely that more than one mechanism is brought into play 
depending on the target cell and the specific activation conditions.
Glucocorticoids inhibit leucocyte adhesion to target tissue by down modulating 
the expression of leucocyte adhesion molecules and leucocyte transmigration to 
affected tissues(352).
They may have a limited inhibitory effect on early events of TcR/CD3 signal 
transduction thereby attenuating more distal downstream activation events(252).
They block monocyte-macrophage and T cell derived cytokine production at the 
transcriptional and post-transcriptional levels(353-355). This involves direct 
binding to promoter regions of cytokine genes and/or antagonism o f nuclear 
factors such as NF-kB(252, 350). Glucocorticoids probably exert their 
immunosuppressive effects directly by inhibiting pro-inflammatory Thl 
cytokine production and indirectly by sparing or perhaps enhancing the 
production of Th2 cytokines(252, 356). For example there is an inhibition of 
IL -12 secretion by monocytes/macrophages and dendritic cells and a
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glucocorticoid induced decrease in the ability of T cells to respond to IL-12. IL- 
12 is a potent differentiation factor for Thl cells but not for Th2 cells. They also 
suppress Thl stimulated IL-1 synthesis by monocyte/macrophages whilst 
upregulating Th2 supported production of the IL-1R antagonist(252). The 
promotion of a Th2 cytokine secreting profile by glucocorticoids induces a state 
of immune tolerance that may persist long after glucocorticoids have been 
withdrawn.
They have been reported to stimulate the production of transforming growth 
factor beta (TGF|31), an immunosuppressive cytokine which inhibits further 
cytokine production and T cell proliferation^ 5 7).
The nitric oxide synthase gene is downregulated leading to reduced release of 
nitric oxide and less vasodilator effect.
They have been shown to act more distally inhibiting T cell activation through 
inhibition of signalling events through high affinity cytokine receptors such as 
the IL2-R(358).
They inhibit T cell activation indirectly by inducing the production of 
phospholipase A j inhibitory proteins, collectively called lipocortins. These 
proteins control the biosynthesis of potent mediators of inflammation such as 
prostaglandins and leukotrienes by inhibiting the release of their common 
precursor arachidonic acid from membrane bound stores.
3.1.4.1.2 Side Effect Profile
Little is known about the molecular mechanisms of corticosteroid side effects such as 
osteoporosis, growth retardation, skin fragility and metabolic effects. These actions of 
steroids are related to their endocrine effects(350). In general, serious unwanted effects 
are unlikely if the daily dose is <50 mg hydrocortisone or lOmg of prednisolone or 
equivalent. A retrospective review of 2111 patients pooled from 71 clinical trials found 
a relative risk of infections of 1.6 (95% confidence interval, 1.3-1.9) in patients on 
systemic glucocorticoid treatment(359). The risk was related to the dose with no 
increased risk of infection being seen in patients given a daily dose of less that lOmg 
prednisolone a day. Monitoring for the side effects of immunosuppression for patients 
on oral steroids involves monitoring for end-organ toxicity. In particular, blood 
glucose, hypertension and bone density are measured. Prophylaxis with
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bisphosphonates and/or calcium and vitamin D reduces the risk of osteoporosis in 
patients on long-term steroids(360).
3.1.4.2 Azathioprine (Imuran)
3.1.4.2.1 Mechanism o f  Action and Effect on Cytokine Profile
Azathioprine was first synthesized in 1957 as a cytotoxic agent(361). It is an imidazole 
derivative o f 6-mercaptopurine (6-MP) into which it is converted non-enzymatically 
after oral administration. 6-MP is then enzymatically converted by xanthine oxidase to 
6-thiouric acid, by thiopurine S-methyltransferase (TPMT) to 6-methyl-MP, and by 
hypoxanthine phosphoribosyl transferase (HPRT) to 6-thioguanine (6-TG). It is 
thought that the 6-TG generated by the HPRT pathway is most likely to mediate the 
immunosuppressive properties of 6-MP whereas the TPMT pathway is important for 
azathioprine-mediated side effects(362). Lymphocytes have been shown to 
enzymatically convert 6-MP to 6-TG. The pharmacologically active 6-mercaptopurine 
metabolites are known to interfere with DNA and RNA synthesis leading to inhibition 
o f T and B cell proliferation as well as neutrophil production and macrophage 
activation. Changes in cytokine profile occur secondary to this. The mode of action of 
azathioprine has been further elucidated more recently(362). Tiede and colleagues have 
demonstrated that, in addition, the azathioprine metabolite 6-thio-GTP induces T cell 
apoptosis by specifically inhibiting the activation of Racl, a GTPase normally activated 
upon CD28 co-stimulation of T cells. Inhibition of Racl target genes including NF-kB 
and STAT-3 leads to T cell apoptosis. They propose that unchecked proliferation of 
lymphocytes promotes the development of chronic inflammatory and autoimmune 
diseases.
3.1.4.2.2 Side Effect Profile
Adverse drug reactions with azathioprine occur in 15-28% of patients(363). The 
primary toxicity is reversible myelosuppression and epithelial injury, which results in 
oesophagitis and mild gastrointestinal complaints(351). Hepatotoxicity can occur due to 
the high rate of RNA synthesis by hepatocytes and acute pancreatitis is reported rarely. 
Ocular toxicity is not a recognized feature of azathioprine. Monitoring for the side 
effects of therapy aims to identify end-organ toxicity before it becomes clinically 
important. Genetic polymorphisms in the TPMT pathway exist which have been 
shown to result in marked inter-patient variability in the risk of myelosuppression(364). 
Those with undetectable TPMT activity (lin  300 individuals) have been shown to be at
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risk o f rapid-onset, prolonged, life-threatening pancytopaenia when treated with 
conventional doses of azathioprine(363). The use of pretreatment erythrocyte TPMT 
measurements is therefore advocated, with azathioprine being contraindicated in those 
with very low or absent TPMT activity. Routine monitoring for azathioprine toxicity 
involves weekly monitoring of full blood count (FBC) and liver function tests (LFTs) 
until the maintenance dose is achieved reducing to a minimum of once every 3 months 
for the duration o f therapy.
3.1.4.3 Cyclosporine A (CsA/Sandimmune/Neoral)
3.1.4.3.1 Mechanism o f  Action and Effect on Cytokine Profile
Cyclosporine A was discovered in 1969 and is an 11 amino acid cyclic polypeptide 
product of a number o f fungi including Tolypocladium inflatum Gams{365). It 
revolutionised solid organ transplantation when it was introduced by providing specific 
and potent T cell immunosuppression(209, 366, 367). CsA forms CsA-cyclophilin 
complexes which bind to calcineurin in the cytoplasm(367). Calcineurin normally acts 
as a serine-threonine phosphatase that dephosphorylates nuclear regulatory proteins 
such as the NF-AT, facilitating their passage through the nuclear membrane, where they 
act as transcription factors for the activation o f the promoter regions o f various 
cytokines. The CsA-cyclophilin complexes inactivate the enzymatic activity of 
calcineurin and thus ultimately inhibit the transcription of cytokines namely IL-2, -3, -4 
and -5, IFNy, TNF-a and granulocyte/macrophage colony-stimulating factor. The 
production of IL-2 and the expression of IL-2R have been demonstrated to be reduced 
in the peripheral blood of patients undergoing treatment with CsA for disease 
states(368). In addition CsA enhances the expression of transforming growth factor-p 
(TGF-p) which inhibits IL-2 stimulated T cell proliferation and the generation of CD8+ 
T cells. CsA is therefore a potent selective immunoregulator of the cellular arm of the 
immune response. Evidence also suggests that CsA can inhibit the function of already 
activated lymphocytes, and is therefore useful in helping to overcome a rejection crisis. 
The drug appears to be more effective when used with other agents, usually 
corticosteroids and/or azathioprine and it is often used as a steroid sparing agent, 
allowing the dose of oral corticosteroids to be reduced.
3.1.4.3.2 Side Effect Profile
Counter balancing the efficacy of CsA is its considerable toxicity. Initially CsA was an 
oil-based product with significant intra- and inter-individual variation in absorption,
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distribution and elimination that complicated its use. Neoral is the modern formulation 
with CsA incorporated into a micro-emulsion that is readily soluble in fluids, has more 
predictable pharmacokinetics and can be taken orally. The main problems associated 
with its use are nephrotoxicity and hypertension. CsA nephrotoxicity may be acute or 
chronic and appears to be mediated via vasoconstriction o f afferent preglomerular 
arterioles, leading ultimately to necrosis and refractory hypoperfusion. Tremor, 
hyperlipidemia, gingival hyperplasia and hypertrichosis(365) -including CsA induced 
trichomegaly(369) can occur. Opportunistic infection, central nervous system toxicity 
and increased incidence of neoplasm are also significant side effects as discussed below. 
Ocular toxicity is discussed in Section 1.1.3.2. The therapeutic window is very narrow 
and therapeutic drug monitoring, for example by radioimmunoassay, is an aid to patient 
management. Drug levels may be used to monitor the intravenous formulation for 
toxicity or where drug interactions or altered bioavailability are suspected. They do not 
have good predictive value. They are used routinely in transplantation medicine to 
ensure therapeutic levels are reached to prevent rejection. In the treatment o f 
autoimmune disease treatment is usually guided by clinical response. Measurements of 
blood pressure, creatinine, serum potassium, serum uric acid and LFTs are also 
required. These can be checked, for example, every 2 weeks for the first 3 months then 
monthly thereafter. Blood lipids should be measured before treatment and then as 
appropriate^ 70).
3.1.4.3.2.1 Opportunistic Infection
Over immunosuppression increases the risk of opportunistic infections. As CsA mainly 
affects T cell responses with no significant effect on antibody production, the response 
to bacterial and fungal infection is relatively preserved. CsA has intrinsic antibiotic 
activity and theoretically should inhibit certain viruses, fungi, protozoa and helminthes 
but in practical terms these effects are insignificant (209).
3.1.4.3.2.2 Neurotoxicity
Between 10-28% of patients on CsA experience neurotoxic symptoms such as tremor, 
neuralgia or peripheral neuropathy(371). Severe symptoms affect up to 5% of patients 
and include psychoses, seizures, leukoencephalopathy, visual hallucinations and 
cortical blindness (198). Calcineurin inhibition by CsA alters sympathetic outflow 
which may play a role in the mediation of neurotoxicity. Injury to both the major and 
minor vasculature may cause hypoperfusion or ischemia and local secondary toxicity in 
the white matter. Neurotoxicity is associated with severe, diffuse abnormalities of the
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white matter on MRI. In most patients the signs and symptoms resolve on reduction or 
cessation of CsA(202).
3.1.4.3.2.3 Malignancy
CsA immunosuppression increases the risk of malignancies, especially those implicated 
with a viral aetiology such as lymphoma and Kaposi's sarcoma(209). This mechanism 
is supported by the observation that in many patients regression is seen after 
discontinuation or reduction in the dose of CsA.
3.1.4.4 Tacrolimus (Tac/FK506/Prograf)
3.1.4.4.1 Mechanism o f  Action and Effect on Cytokine Profile
Tac is a hydrophobic macrocyclic lactone derived from Streptomyces tsukubaensis(367, 
372). After binding to intracellular binding proteins (FKBP-12, -13, -25 or -52) the 
resulting dimer engages the calcineurin/calmodulin/calcium complex, thereby inhibiting 
calcineurin phosphatase activity(373). This affects cytokine expression and Tac 
therefore blocks IL-2 production and IL-2R expression by activated T cells in a similar 
way to CsA although it is not related to it structurally. In vivo and in vitro models of 
immunosuppression have shown Tac to be up to 100 times more potent than CsA(372).
3.1.4.4.2 Side Effect Profile
Nephrotoxicity (thrombotic microangiopathy), neurotoxicity or gastrointestinal toxicity 
are the most common adverse effects o f Tac and alopecia has also been 
documented(374). Ocular toxicity is discussed in Section 1.1.3.3. Tac has been shown 
to be diabetogenic although this may not be clinically significant in the majority o f 
patients(375). Like CsA, Tac can be used as a steroid-sparing agent. Inter-patient 
variability in Tac pharmacokinetics makes therapeutic drug monitoring an important 
adjunct to treatment. Although there is poor correlation between Tac levels and drug 
efficacy, the relative risk of toxicity is increased with higher trough concentrations. 
Serum creatinine and serum potassium must be measured regularly. Cardiomyopathy 
has been reported in children on Tac so monitoring o f cardiac status with 
electrocardiograms and ECHO is important(370).
3.1.4.5 Mycophenolate Mofetil (MMF/Cellcept)
3.1.4.5.1 Mechanism o f  A ction and Effect on Cytokine Profile
M ycophenolate mofetil is a prodrug that is hydrolyzed by liver esterases to 
mycophenolic acid (MPA). MPA is an anti-proliferative agent that is a potent, non-
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competitive reversible inhibitor of inosine 5*-monophosphate dehydrogenase(367, 376, 
377). This is the rate-limiting enzyme in the de novo pathway for purine synthesis. 
Resting lymphocytes rely on a salvage pathway involving the enzyme hypoxanthine- 
guanine-phophoribosyl-transferase for purine biosynthesis whereas activated 
lymphocytes are dependent on the de novo pathway. MPA suppresses T and B cell 
proliferation more potently than that o f other rapidly dividing cells such as neutrophils 
and ery throcytes that can use the salvage purine synthesis pathway instead. Changes in 
the cytokine profile will occur secondarily to the inhibition o f proliferation. Because 
MMF is relatively selective for lymphocytes it has fewer side effects than other 
immunosuppressive drugs. Its effects are rapidly reversible upon discontinuation(376). 
An additional immunosuppressive effect o f MMF on impairing APC function in 
dendritic cells has also been demonstrated(378).
3.1.4.5.2 Side Effect Profile
The most common side effects o f MMF therapy are gastrointestinal such as nausea, 
vomiting and diarrhoea. Myelosuppression with neutropaenia may also occur and 
patients are at an increased risk of opportunistic infection, particularly viral infection. 
Some authors have reported an increased incidence and/or severity of cytomegalovirus 
infections with a higher morbidity in renal transplant recipients on MMF(206, 207). 
Ocular toxicity is discussed in Section 1.1.3.5. Monitoring for toxicity involves FBC 
weekly during the first month, twice monthly in months 2 and 3 and then monthly 
throughout the first year(370).
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3.2 AIMS
The management of autoimmune disease is often hampered by problems with assessing 
the level o f inflammation. This is particularly true in chronic ocular disease where 
media opacities, scarring and oedema may limit visual acuity and make clinical 
assessment difficult. This study aimed to evaluate cytokine measurements as an 
indicator o f the efficacy of immunosuppression and thus as a means of titrating drug 
dose. If shown to be quantitative and to correlate with dosage, cytometric assessment of 
intracellular cytokines could improve the accuracy of clinical monitoring.
3.3 METHODS
3.3.1 Patient Selection
The study was open to all patients on or requiring systemic treatment in the uveitis 
clinic at Moorfields Eye Hospital. 62 patients requiring systemic immunosuppression 
were recruited and informed consent was obtained following local ethics committee 
approval. Blood samples were taken for analysis by flow cytometry at standard 
outpatient clinic visits.
3.3.2 Data Collected
Patient characteristics recorded at each visit included age, sex, uveitis diagnosis and 
drug history. Ophthalmology examination including visual acuity testing, tonometry, 
slit-lamp examination and indirect ophthalmoscopy was performed. Clinical activity at 
each visit was assessed using Snellen visual acuity, the presence or absence o f cells and 
flare in the anterior chamber, keratic precipitates, the presence or absence of cells and 
haze in the vitreous, the presence or absence cataract and the presence or absence of 
cystoid macular oedema. Anterior chamber cells, flare, and vitreous haze were each 
graded 0-4. These findings, together with comparisons with previous examinations 
were used to classify patients as having active or inactive disease. The International 
Uveitis Study Group Classification was used for disease classification(288).
Patients were divided into sub-groups for analysis according to their 
immunosuppressive drug regime, whether or not their disease was considered to be 
active and associated systemic disease (see Figure 3.1). Comparisons were made 
between cytokine expression in the patient groups and that in samples from healthy
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laboratory workers (“Normals”). Samples were requested from patients on multiple 
occasions.
Cell stimulation, phenotypic and cytokine staining and flow cytometry were performed 
as described in Section 2.2.7.
3.3.3 Statistical Analysis
Statistical calculations were performed using SPSS for Windows (version 9.0-12.0 
SPSS Inc, IL, USA). Non-parametric Kruskal-Wallis testing was used with Mann- 
Whitney testing to locate differences. In order to limit the number o f  comparisons 
Mann-Whitney testing was only used if a difference was seen with the Kruskal-Wallis 
test. Results are presented in Figures 3.5-3.21. “N/A” denotes not applied and “Sig.” 
denotes significance. P<0.05 was taken to be significant. A Bonferroni correction was 
used for multiple pairwise comparisons. Boxplots show the median, interquartile range, 
outliers and extreme cases. When analyzing for the effect of drug regime general linear 
model multivariate analysis was used with Tukey’s honestly significant difference as a 
correction for the larger number o f multiple comparisons. Correlations were assessed 
by calculating Spearman’s rank correlation coefficient.
In those patients providing repeat samples cytokine production at the first and second 
visit was compared using the Wilcoxon test for 2 related samples.
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Figure 3.1: Groups for Analysis
ANALYSIS GROUP
I 1. Normals
(1st Visit) 2. Uveitis Patients
II
(1st Visit)
1. Normals
2. No Immunosuppression (active)
3. Active on Systemic Rx
4. Controlled on Systemic Rx
III 1. Normals
(1st Visit) 2. Ocular Syndrome
3. Systemic Disease
1. Normals
2. No Immunosuppression (active)
IV 3. Steroids only
(1st Visit) 4. Steroids + CyA
5. Steroids + Aza
6. Steroids + Cellcept
7. Others
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3.4 RESULTS
61 patients (35 female, 26 male) were analyzed. 1 patient was not analyzed because all 
his clinical and laboratory data was missing. Missing values for other individuals were 
included in the analysis. The median age was 49 years (range 16-78 years) (see Figure 
3.2.) Six patients had anterior uveitis with 3 of these having chronic anterior uveitis. 8 
had idiopathic intermediate uveitis. 15 had posterior uveitis with 4 o f these patients 
having idiopathic retinal vasculitis, 4 birdshot chorioretinitis, 2 toxoplasmosis, 1 
bilateral acute retinal necrosis, 1 unspecified retinitis and 2 patients developed CMV 
retinitis whilst on systemic immunosuppression for treatment o f systemic conditions 
(systemic lupus erythematosus and renal transplantation). 28 patients had panuveitis 
with 10 of these having a diagnosis of systemic Behcet’s, 4 sarcoidosis and 2 Vogt- 
Koyanagi-Harada’s syndrome. HIV status was not checked but none of the patients in 
this study had suggestive clinical features. Figures 3.3 and 3.4 are graphic 
representations of patient diagnoses. The visual acuity in each eye ranged from 6/5 to 
NPL with a median of 6/12. Results were compared to those obtained from 15 healthy 
laboratory workers (“Normals”; ages 22-47, median 31, 7 males, 8 females) and 
between patient sub-groups. In each analysis Group 1 is the Normal group unless 
otherwise stated. Results are limited to the type 1 cytokines IL-2 and IFNy as neither 
IL-4 or IL-10 expression were detected in patients and Normals.
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Figure 3.2: Age Distribution of Patients
39% a  <20 
■ 20-40
□ 41-60
□ >60
Figure 3.3: Distribution of Patients by Uveitis Classification
7% 10%
13%
45%
■  Anterior
■  Intermediate
□  Posterior
□  Panuveitis
■  Scleritis
Figure 3.4: Systemic Associations
■ None
■  Ankylosing Spondylitis
□  Behcets Syndrome
□ Glomerular nephritis
■  Juvenile Idiopathic Arthritis 
B Reiters
a  Renal transplant 11/10/98
□  Sarcoidosis 
b S L E  
b VKH
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3.4.1 ANALYSIS I: Effect of Uveitis Diagnosis
Patients with a diagnosis o f uveitis (both on and off treatment) had significantly 
different IFNy but not IL-2 production compared to healthy controls (‘Normals’). IFNy 
production was significantly increased in both the CD4+ and CD8+ subsets (p=0.008 
and p=0.003 respectively). Figures 3.5-3.7.
Figure 3.5: Statistical Analysis; Normals vs Uveitis Patients
CD4IL2 CD8IL2 CD4IFN CD8IFN
Mann-Whitney Testing
Normals vs 
Uveitis patients
Sig. 0.564 0.398 0.008 0.003
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Figure 3.6: CD4 Cells Producing IFNy; Uveitis Patients vs Normals
Uveitis Pts 1st Visit -
CL
3O
0
Normals - oo
111
0.00 20.00 40.00 60.00 80.00 100.00
% CD4+ lym phocytes producing IFNy
Figure 3.7: CD8 Cells Producing IFNy; Uveitis Patients vs Normals
Uveitis Pts 1st Visit
a3
2
0
Normals
0.00 20.00 40.00 60.00 80.00 100.00
% CD8+ lym phocytes producing IFNy
3.4.2 ANALYSIS II: Effect of Uveitis Activity
When patients were grouped according to uveitis activity no significant differences 
could be seen between Normals, those active on no immunosuppression, those active on 
immunosuppression and those with controlled disease on immunosuppression. This 
applied to both IL-2 and IFNy expression in both CD4+ and CD8+ subsets. See Figures 
3.8 and 3.9.
Figure 3.8: Patient Characteristics: Effect of Uveitis Activity
Group n Age (range)
2.
No Immunosuppression 
(active)
8 33 (21-68)
3.
Immunosuppression
(active)
22 41 (16-66)
4.
Immunosuppression 31 50 (22-78)
(controlled)
Figure 3.9: Statistical Analysis; Effect of Uveitis Activity
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
C om paring all x2 6.487 7.263 0.983 1.779
groups df 3 3 3 3
(1-4) Sig. 0.116 0.066 0.776 0.486
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3.4.3 ANALYSIS III: Effect of Associated Systemic Disease
When patients were grouped according to whether they had purely ocular disease or an 
associated systemic disease no differences were detected in IL-2 or IFNy expression in 
both CD4+ and CD8+ subsets.
Figure 3.10: Patient Characteristics; Effect of Associated Systemic Disease
Group n Age (range)
2.
Ocular Syndrome 37 50(16-78)
3.
Systemic Disease 24 47 (22-75)
Figure 3.11: Statistical Analysis; Effect of Associated Systemic Disease
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing all
->
X“ 1.841 2.781 7.170 8.567
groups df 2 2 2 2
d-3) Sig. 0.398 0.249 0.028 0.014
Mann-Whitney Testing
1 vs 2
Sig.
(Corrected)
N/A N/A 0.007
(0.021)
0.006
(0.018)
1 vs 3
Sig.
(Corrected)
N/A N/A 0.032
(0.096)
0.008
(0.024)
2 vs 3
Sig.
(Corrected)
N/A N/A 0.724
(1)
0.901
(1)
119
3.4.4 ANALYSIS IV: Effect of Drug Regime
Kruskall Wallis testing identified changes in IL-2 production by CD4+ cells (p=0.007) 
and CD8+ cells (p=0.009) when comparing all the subgroups for analysis o f drug 
regime as shown in Figure 3.11. No differences in IFNy production were seen in this 
sub-group analysis. Further testing was able to demonstrate a significant fall in IL-2 
production by CD4+ cells o f patients on a Steroid + CsA regime compared to Normals 
(p=0.012). A similar fall was seen in IL-2 production by CD8+ cells of patients on a 
Steroid + CsA regime compared to Normals but this did not achieve significance after 
correcting for multiple comparisons (p=0.066). None o f the other drug regimes were 
demonstrated to show significant differences in IL-2 production compared to normal 
controls. See Figures 3.10-3.13.
Further analysis using Kruskal Wallis testing suggested between sub-group differences 
in IL-2 production by CD4+ and CD8+ cells. See Figure 3.14. Multivariate analysis 
was not able to identity a significant difference in IL-2 production by CD4+ cells in the 
different patient groups. In the CD8+ subset a significant difference was seen between 
CD8+ production of IL-2 by patients on a Steroid + CsA regime and CD8+ production 
o f IL-2 by patients on a Steroid + Aza regime (p=0.02).
Figure 3.12: Patient Characteristics; Effect of Drug Regime
Group n Age (range)
2. No Immunosuppression 8 33 (21-68)
3. Steroids Alone 15 41 (22-66)
4. Steroids + CsA 16 40(16-62)
5. Steroids + Aza 6 57 (49-75)
6. Steroids + MMF 9 54 (31-76)
7. Others 7 61 (49-78)
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Figure 3.13: Statistical Analysis 1; Effect o f Drug Regime
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing all x2
17.695 16.953 7.560 9.760
groups df 6 6 6 6
(1-7)
Sig. 0.007 0.009 0.272 0.135
Mann-Whitney Testing
Sig. 0.796 0.796 N/A N/A
1 vs 2
(Corrected) (1) (1)
Sig. 0.123 0.504 N/A N/A
1 vs 3
(Corrected) (0.738) (1)
Sig. 0.002 0.011 N/A N/A
1 vs 4
(Corrected) (0.012) (0.066)
Sig. 0.815 0.024 N/A N/A
1 vs 5
(Corrected) (1) (0.144)
Sig. 0.949 0.606 N/A N/A
1 vs 6
(Corrected) (1) (1)
Sig. 0.087 0.029 N/A N/A
1 vs 7
(Corrected) (0.522) (0.174)
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Figure 3.14: CD4 Cells Producing IL-2; Effect of Drug Regime
Others
Steroids + MMF
Steroids + Aza
Q.
3O
( i)  Steroids + CyA
Steroids Alone
No Rx
Normals
Figure 3.15: CD8 Cells Producing IL-2; Effect of Drug Regime
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Figure 3.16: Statistical Analysis 2; Effect o f Drug Regime
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing patient
groups
(2-6)
X"
df
Sig.
10.602
4
0.031
11.117
4
0.025
N/A N/A
GLM Multivariate Analysis (Tukey)
2 vs 3 Sig.Corrected 0.885 0.996 N/A N/A
2 vs 4 Sig.
Corrected
0.115 0.543 N/A N/A
2 vs 5
Sig.
Corrected 0.988 0.148 N/A N/A
2 vs 6 Sig.
Corrected
1 1 N/A N/A
3 vs 4 Sig.
Corrected 0.401 0.207 N/A N/A
3 vs 5 Sig.Corrected 0.644 0.183 N/A N/A
3 vs 6 Sig.Corrected 0.942 0.997 N/A N/A
4 vs 5 Sig.
Corrected 0.057 0.002 N/A N/A
4 vs 6 Sig.Corrected 0.164 0.526 N/A N/A
5 vs 6 Sig.Corrected 0,969 0.154 N/A N/A
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3.4.5 ANALYSIS V: Effect of CsA Dose
Patients on a Steroid + CsA regime were ordered according to CsA dose to assess if the 
dose of CsA could be correlated with IL-2 production. Figures 3.15 and 3.16 are scatter 
plots o f cytokine expression against CsA dose. Spearman’s testing did not reveal any 
significant correlations.
Figure 3.17: CD4 Cells Producing IL-2; Effect o f CsA Dose
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Figure 3.18: CD8 Cells Producing IL-2; Effect o f CsA Dose
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3.4.6 ANALYSIS VI: CD69 Expression
To assess whether low IL-2 or IFNy levels were due to problems with activation a 
number of samples were also tested for CD69. CD69 data was available for 81 out of a 
total of 120 samples processed.
84% of PM A + ionomycin stimulated samples showed 80% or more CD69 expression 
(See Figure 3.17). Median CD69 expression of CD3+ cells was 95% (range 2-100). 
Interestingly the patient with 2% CD69 expression on stimulation had good IL-2 and 
particularly IFNy expression despite poor markers of activation. She was being treated 
with systemic immunosuppression for glomerular nephritis before presentation. 
Clinically she had an endophthalmitis type picture with a visual acuity o f hand 
movements, an actively inflamed left eye with, flocculant material in the anterior 
chamber and no fundal view. No microbiological diagnosis was comfirmed.
Kruskall Wallis testing (1 sample per patient; n=38) showed no significant difference in 
CD69 expression between drug groups (p=0.360).
67 o f these samples (83%) had less than 1% of CD3+ cells showing CD69+ expression 
under non-stimulated conditions. The median o f the unstimulated samples showing 
more than 1% CD69+ expression was 2 (range 1-15). Figure 3.18 describes the patients 
showing unstimulated CD69+ expression.
Figure 3.19: Stimulated CD3 Cells Expressing CD69
***** * *100.00  -
80.00
O) 60.00 —
toao
40.00 -
20.00 -
0 .00 -
0.00 20.00 60.0040.00 80.00 100.00
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Figure 3.20: Unstimulated CD3 Cells Expressing CD69; Pt Characteristics
Pt. no Diagnosis Visit Visual
Acuity
Activity Drug Regime CD69
unsti
m
CD69+
stim
5 VKH 1 6/18:6/24 Active nil 6 100
7 Idiopathic
Intermediate 3 6/12:6/24 1 Omg Pred
4 100
10 Idiopathic
Panuveitis 6/18:6/36
30 mg Pred + 
300mg CyA 7 94
11 Idiopathic Retinal 
Vasculitis 2 6/6:6/6
15mg Pred + 
300mg CyA
2 94
12 B ehcet's
Panuveitis 1 6/18:6/36
25mg Pred + 2g 
MMF
1 100
12 B ehcet's
Panuveitis
2 6/18:6/36 Active 25mg Pred + 2g MMF
12 71
12 Behcet’s
Panuveitis 3 6/18:CF
3 Omg Pred + 2g 
MMF 3 36
15 JCA 2 6/36:6/36 Active lOmg Pred + 350mg CyA
2 95
23 Behcet's
Panuveitis 2 6/9:6/9
5mg Pred + 50mg 
Aza
15 97
26 Idiopathic
Panuveitis 6/60:6/18
25mg Pred + 
200mg CyA 
+ 150mg Aza
2 58
30 Birdshot C-R 4 6/9:HM 5 mg Pred 2 99
47 BARN 2 NPL:HM 20m g Pred + 150mg Aza
1 90
47 BARN 3 NPL:HM 15mg Pred + 
150mg Aza
2 96
59 Scleritis 1 616:616 Active 50mg Pred + 150mg Aza
2 93
3.4.7 ANALYSIS VII: Repeat Samples
A total o f 120 serum samples were taken from the uveitis patients at different clinic 
visits and at different levels o f immunosuppression. Figure 3.19 shows the 
immunosuppression regimes at the time o f sampling. 32 patients provided repeat 
samples at multiple visits (see Figure 20). The median time between first and second 
visits was 49 days (range 0-151). The majority o f patients showed a reduction in IL-2 
and IFNy expression at the second visit compared to the first. This was seen to be most 
significant for IFNy expression by CD8+ cells (p=0.023 See Figure 3.21).
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Figure 3.21: Drug Regime at Sample Points
Number of Patients
■ Others
□ Steroids + Aza + Cellcept
■ Steroids + Cellcept
□ Steroids + Aza
□ Steroids + CsA
■ Steroids only
□ No immunosuppression
Figure 3.22: Frequency of Uveitis Visits
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Figure 3.23: Multiple Visits; Comparing 1st and 2nd Visits
CD4IL2 CD8IL2 CD4IFNy CD8IFNy
Median 1st Visit 46.7 23.0 24.4 41.1
(range) 2nd Visit 31.7 26.3 19.5 29.0
Minimum 1st Visit 0 0 2.8 6.9
2nd Visit 1.6 1.7 0 1.6
Maximum 1st Visit 84.2 58.8 71.43 81.1
2nd Visit 85.6 77.8 50.0 68.0
Wilcoxon Signed Ranks Test
2nd-lst Z -1.7 -0.2 -1.7 -2.3
Sig. 0.082 0.809 0.086 0.023
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3.4.7.1 Case Studies
3.4.7.1.1 Patient 19
Patient 19 was a 32 year old woman with Behcet’s disease. Figure 3.22 charts her 
clinical progress, immunosuppression regime and IL-2 and IFNy production over a 
period of 8 months. Her initial activation in the left eye appears to be associated with an 
increase in both IL-2 and IFNy production. Although cytokine production is then 
effectively reduced by an increase in immunosuppression the patient reactivates in the 
other eye. Clinical control of the inflammation occurs despite a small increase in IL-2 
and IFNy production by CD4+ cells.
Figure 3.24: Case Study; Patient 19
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3.4.7.1.2 Patient 15
Patient 15 was a 32 year old man with juvenile idiopathic arthritis. Figure 3.23 follows 
his clinical progress, drug regime and IL-2 and IFNy production over a period of 5 
months. Samples taken at 10 months were analyzed as 'missing' because of insufficient 
information. At his first visit he was on no systemic immunosuppression and was noted 
to have recent onset cystoid macular oedema. This was associated with both high IL-2 
and IFNy production. Treatment with steroids and CsA can be seen to have effectively 
reduced cytokine expression although, similar to patient 19, control of type 1 cytokine 
expression was not associated with clinical control of the inflammation. In fact 
cytokine expression had risen slightly at the third visit despite control of inflammation.
Figure 3.25: Case Study; Patient 15
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3.4.7.1.3 Patient 11
Patient 11 was a 26 year old Caucasian woman with idiopathic retinal vasculitis. Figure 
3.24 follows her over a period of 8 months. At time point 0 she was clinically active 
with vasculitis and cystoid macular oedema. Testing showed elevated levels of IL-2 
and IFNy production with the IFNy production being particularly high in the CD8+ 
subset. This is despite treatment with 35mg of prednisolone and 500mg of CsA. 
Clinically there was a good response to treatment and the immunosuppression was 
tapered. Flow cytometry showed a reduction in cytokine production compared to the 
initial high response although there was a small increase noted at the 4th visit when 
immunosuppression had been reduced to 5 mg prednisolone and 150mg CsA. At this 
time ocular appearances were clinically normal.
Figure 3.26: Case Study; Patient 11
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3.4.7. 1.4 Patient 18
Patient 18 was a 76 year old woman with panuveitis and a diagnosis of sarcoidosis. 
Figure 3.25 follows her over a period of 8 months. At none of the visits where cytokine 
activity was measured was this woman active although she did have recurrences 
requiring an increase in immunosuppression over this time period. Her steroid dose was 
increased to 40mg prednisolone at the second visit and this can be seen to be associated 
with dramatically reduced IL-2 and IFNy production.
Figure 3.27: Case Study; Patient 18
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3.4.7.1.5 Patient 30
Patient 30 was a 50 year old man with Birdshot chorioretinitis. Figure 3.26 follows him 
over a period of 3 months. He was active at his first visit and prescribed oral 
prednisolone. Unfortunately he did not comply with treatment and was active when 
seen taking no prednisolone 1 month later. Treatment with high dose steroids was 
reinitiated and IL-2 and IFNy production remained remarkably constant despite control 
of the intraocular inflammation.
Figure 3.28: Case Study; Patient 30
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3.5 SUMMARY
Autoimmune uveitis patients had significantly different IFNy but not IL-2 production 
compared to normal controls. IFNy production was significantly increased in both the 
CD4+ and the CD8+ subsets (p=0.008 and p=0.003 respectively).
No significant differences in type 1 cytokine production by both CD4+ and CD8+ cells 
could be seen when patients where analyzed according to uveitis activity or according to 
systemic versus purely ocular disease.
Analysis of results according to drug regime demonstrated a significant fall in IL-2 
production by CD4+ cells of patients on a steroid + CsA regime compared to normal 
controls (p=0.012). A similar fall was seen in IL-2 production by CD8+ cells of 
patients on a steroid + CsA regime compared to Normals but this did not achieve 
significance after correcting for multiple comparisons. None of the other drug regimes 
were demonstrated to result in significant differences in IL-2 production compared to 
Normals. No correlation between the dose of CsA and IL-2 production could be 
demonstrated.
83% o f samples from uveitis patients had less than 1% of T cells showing CD69+ 
expression under non-stimulated conditions. Stimulation with PMA and ionomycin 
resulted in a median CD69+ expression by T cells from uveitis patients of 95% (range 
2- 100).
Examination of repeat samples in individual patients did not reveal parallels between 
percentage expression of cytokine and the clinical course o f disease.
3.6 DISCUSSION
Analysis to investigate whether uveitis patients have different Thl cytokine expression 
compared to that of Normals found that IFNy production was significantly increased in 
both CD4+ and CD8+ T cells of patients. This is consistent with reports of Thl cytokine 
profiles in active autoimmune disease(254). The finding supports that o f Lacomba and 
colleagues who used ELISA techniques to demonstrate elevated IFNy production in 
both the serum and aqueous of 23 patients with various uveitides(341). Imai and 
colleagues demonstrated a similar finding using mRNA techniques and flow cytometry 
in 9 patients with Vogt-Koyanagi-Harada syndrome although they report elevated IFNy 
and IL-2 production in both stimulated and unstimulated conditions(324). Ooi et al
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have demonstrated significantly elevated IFNy in pooled aqueous from 36 patients with 
active uveitis compared to cataract controls(379). Skurkovich and Skurkovich have 
used intramuscular anti-IFNy antibodies in the treatment o f various autoimmune 
diseases and reported good results and tolerability in prelim inary clinical 
investigations(380, 381). Interestingly they also reported that topical anti-IFNy 
antibodies were helpful in reducing inflammation in 13 eyes undergoing rejection 
following penetrating keratoplasty(382). A difference between IL-2 expression in 
patients and Normals was not seen although the effect may have been masked in the IL- 
2 subsets by the effect of drugs.
No significant difference in IL-2 and IFNy production of patients with systemic disease 
compared to those with purely ocular disease was demonstrated suggesting the 
importance o f peripheral activation even for organ specific disease. Further analysis to 
find the effect of clinical uveitis activity was unable to detect a significant difference 
between Norm als, those active on no imm unosuppression, those active on 
immunosuppression and those with controlled disease on immunosuppression. This 
was a surprising result and was true for both for IL-2 and IFNy expression. The effect of 
the drugs would be expected to result in a difference and in contrast Ohno and 
colleagues reported elevated IFNy production in BD patients that varied with the stage 
of disease(325).
Our failure to demonstrate a difference may have been due to difficulties in the 
classification of patients into these groups. Clinical activity in uveitis is notoriously 
difficult to assess particularly in the setting o f chronic disease(288, 383-386). In this 
study patients were assessed by the clinic doctor at their usual clinic appointment 
resulting in inter-observer variation. This was minimised by having a study proforma 
that was filled out for each patient but could have been overcome by having each study 
patient examined by the same observer. LogMar visual acuity testing would provide 
better quantitative information on visual acuity(387). Laser flare readings(388-390) 
provide objective measurements which can be useful as an adjunct to clinical 
examination when deciding on activity, particularly in the setting o f chronic disease. 
Similarly Optical Coherence Tomography is now widely used in uveitis clinics to aid 
the diagnosis of macular oedema even in the context of hazy media. Both these tests 
were not widely used at the time o f this study. Photographic documentation would have 
improved reliability by reducing subjectivity.
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Samples taken at fixed times along the time course of disease progression would be 
easier to interpret and if each patient was sampled before starting therapy this would 
have provided the ideal control group for assessment of the effect of therapy on 
cytokine production. This, however, was difficult to achieve in the setting o f this 
tertiary referral clinic as patients presented at varying points in the progression o f their 
disease and on varying medications. Even after presentation the chronic or relapsing, 
remitting nature o f the disease entities resulted in very different follow up profiles. 
Where possible samples were taken from patients before starting treatment to provide a 
control group for comparisons (No immunosuppression, active) but this group was 
small (n=8).
A major limitation o f these studies is that they have been performed in a heterogenous 
group of uveitis patients. Each uveitis diagnostic category will have a typical natural 
history and response to immunosuppression but this varies markedly between and 
sometimes within categories. Treatment must always be adjusted to an individual’s 
response so drug regimes are in a constant and often unpredictable state o f flux. 
Because most o f the uveitis conditions requiring systemic immunosuppression are 
uncommon or rare identifying a more homogenous study group would lead to much 
reduced numbers and an even further reduction in power to assess the effect o f drug 
dose on cytokine production.
In 1998 Van den Berg and colleagues published work in which they were able to use 
flow cytometry to quantify the level of immunosuppression in transplant patients(282). 
They were able to show a negative correlation between the percentage of CD4+ T cells 
producing IL-2 and CsA levels and suggested that prospective studies should be 
performed to determine whether this method is useful for clinical monitoring.
Sub-group analysis to investigate the effect o f drug regime on Thl expression showed 
no differences in IFNy expression as would be expected considering that none of the 
drugs target IFNy expression specifically. Testing for sub-group differences in IL-2 
production revealed inhibition of IL-2 production in patients on Steroid + CsA regimes 
compared to Normals. This inhibition reached statistical significance in the CD4+ but 
not the CD8+ subset. The lack o f significance in the CD8+ subset is likely to be due to 
the conservative adjustment for multiple comparisons and would require further 
investigation to confirm or refute. In view o f what is known about the mechanisms of 
actions o f steroids some changes in IL-2 and perhaps IFNy production for patients
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compared to Normals may have been expected. This was not demonstrated statistically 
and comparisons o f medians does not suggest a measurable change in IL-2 production 
compared to Normals (See Charts III(i&ii)). Likewise no changes in IL-2 or IFNy 
production o f patients on Aza or MMF regimes were seen compared to Normals but this 
is in keeping with what is known about the mechanism of action of these drugs(361, 
362, 391). Kilmartin et al also found no significant changes between control groups and 
uveitis patients on MMF for IL-2 and IFNy intracellular cytokine expression(345).
The effect o f CsA dose was analyzed to assess whether intracellular cytokine analysis of 
IL-2 could be used as a marker o f the degree of immunosuppression. Charts V(i&ii) 
demonstrate that most patients on Steroid + CsA had effective suppression of IL-2 even 
at lower doses. A direct relationship between CsA dose and IL-2 expression was not 
seen.
CD69 expression by stimulated T cells was found to be high in the vast majority of 
samples. This is in contrast to published reports that CD69 expression is completely 
blocked by brefeldin A in mice(392). Kilmartin and colleagues were also able to 
measure CD69 expression in the presence of brefeldin A(345). They reported CD69 
expression in unstimulated CD4+ cells from 10 uveitis patients that paralleled disease 
activity and was reduced by MMF therapy. Their results were not replicated in this 
study. Resting CD3+ cells were found to express CD69 at very low levels median 0 
(range 0-15%). These differences may be due to differences in protocols or perhaps to 
low grade antigenic contamination o f unstimulated wells.
Repeated testing in individual patients to assess the effect o f different doses of 
immunosuppression and different levels o f activity showed that elevated IL-2 and IFNy 
expression is associated with uveitis although parallels between the percentage 
expression and the clinical course o f disease were not demonstrated.
Despite its limitations, as discussed above, this study does not support the use of flow 
cytom etric assessm ent o f  in tracellu lar cytokines to quantify the level o f 
immunosuppression and thus aid clinical management in patients receiving systemic 
immunotherapy for ocular indications.
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CHAPTER 4
A s s e s s m e n t  O f  C y t o k in e  P r o d u c t io n
In
HIV P o s it iv e  Pa t ie n t s
138
4.1 INTRODUCTION
4.1.1 Pathology of HIV Infection
4.1.1.1 Classification o f  Viruses
HIV-1 and -2 are enveloped RNA viruses belonging to the lentivirus subgroup of the 
retrovirus family(393). Lentiviruses are characterized by cytopathicity in vitro, lack of 
oncogenicity, establishment o f chronic infections and slow rates of development of 
disease. HIV-1 has a worldwide distribution and is thought to have developed from 
cross-species transmission from chimpanzees. HIV-2 in contrast is more prevalent in 
Africa and is thought to have developed from cross-species transmission from another 
primate, the sooty mangabey. HIV-1 has been further divided into subgroups and 
subtypes. Transmission o f virus is by direct contact with infected bodily fluids such as 
blood and semen. HIV targets the CD4+ T-cell population leading to immune 
activation followed by eventual depletion of CD4 cells and development of AIDS.
4.1.1.2 Viral Replication
Viral replication is initiated by attachment o f the virus to a target cell through the 
interaction o f the viral envelope glycoprotein, gpl20, with the CD4 receptor. The 
primary cellular targets for HIV-1 infection in vivo are CD4+ T cells and macrophages. 
CD4+ binding induces conformational changes in gpl20 that enables binding to the 
cellular co-receptor molecules CXCR4 and CCR5. Binding to these co-receptors allows 
fusion o f the virus with the host cell and the natural ligands can block the infectivity of 
HIV-1. The natural ligand for CXCR4 is stromal cell-derived factor 1 and CCR5 
naturally binds to the p-chemokines. Following fusion, synthesis o f viral cDNA by 
reverse transcription can be completed in the target cell cytoplasm. The cDNA is then 
translocated to the nucleus where it is integrated into the host cell chromosome by the 
virally encoded integrase in concert with host cell DNA repair enzymes to form a 
provirus. HIV-1 can infect both resting and activated CD4+ T cells but integration of 
HIV-1 DNA into the nucleus probably does not occur unless the T cell is antigen 
activated. In resting T cells reverse transcribed HIV-1 genomes can stay in the 
cytoplasm for days to weeks awaiting activation before they become non-functional. 
Once the DNA is integrated, activation o f HIV transcription and gene expression is 
dependent on the activity o f both cellular and viral factors. Structural and enzymatic 
proteins are produced and the virion assembles at the plasma membrane. Completed 
virions incorporate a number o f cellular proteins including major histocompatability
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antigens and adhesion molecules as well as the virally encoded proteins. Infectious 
virions then bud through the plasma membrane. Productively infected cells generally 
die within a few days from cytopathic effects but some survive long enough to revert to 
a resting memory state and thus establish a stable latent reservoir. Upon subsequent 
exposure to antigen these cells will become activated and release infectious virions. 
Approximately 1010 virions are generated daily.
4.1.1.3 Time Course o f  Infection
There are 3 phases in the natural history of HIV-1 infection: primary infection, 
progressive immune depletion and AIDS.
4.1.1.3.1 Primary Infection
During the primary or acute phase virus present in the infecting inoculum replicates in 
the host and produces a viremia. 50-70% of individuals infected with HIV-1 are 
symptomatic during this acute phase with an infectious mononucleosis type syndrome 
appearing 1 to 12 weeks after exposure. A vigorous antiviral immune response is 
generated which eventually leads to a dramatic reduction in viremia. Virus specific 
CD8+ T cells appear early and probably represent a critical host factor in the control of 
acute HIV-1 infection. Antibodies to HIV-1 are initially absent and seroconversion 
usually occurs within a few weeks of the onset o f the acute illness. Nearly all infected 
individuals develop antibody responses to several o f the protein products o f the HIV-1 
genome. Unfortunately most o f these are non-neutralizing. The CD4+ T cell count 
diminishes during symptomatic primary HIV-1 infection due to virus-induced CD4+ T 
cell depletion and sequestration o f circulating CD4+ T cells in lymphoid organs. After 
the acute illness resolves CD4+ T cells counts tend to rise again but usually not to pre­
infection levels.
4.1.1.3.2 Progressive Immune Depletion
Primary infection is followed by a long period o f often asymptomatic infection. 
Clinically this is a time of latency but the virus continues to replicate reaching a steady 
state, the level o f which determines the rate o f disease progression. There is a gradual 
loss o f CD4+ T cells. Both viral load (HIV-1 RNA level) and CD4 count are used when 
making decisions about when to initiate therapy. There is huge individual variation in 
the length o f the asymptomatic period with some progressing to AIDS within 2 years 
and other long-term non-progressors maintaining their CD4+ count for over 20 years. 
Vigorous virus specific CD8+ T cell responses are seen in many long-term non-
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progressors and the frequency o f HIV-1 specific CD8+ T cells has been shown in some 
studies to decline as the clinical and immunological status of the patient deteriorates. 
Rates o f disease progression are affected by viral factors (sequence variation e.g. 
mutations in env leading to a change in the pattern of chemokine receptor use), host 
factors (e.g. polymorphisms in chemokine receptor or chemokine genes) and 
environmental factors (e.g. concurrent infections). Increased rates of apoptosis lead to 
loss o f CD4+ cells. In addition to the depletion of CD4+ T cells that occurs during the 
course o f infection there are qualitative defects in the function of the surviving CD4+ T 
cells.
4.1.1.3.3 AIDS
Acquired immunodeficiency syndrome is characterized by low or very low CD4 counts. 
The median time from acquisition of HIV-1 infection to AIDS is approximately 8-10 
years. Wasting, thrombocytopenia dementia and neuropathy can occur as a direct 
consequence o f  HIV infection. Immunodeficiency leaves affected individuals 
vulnerable to opportunistic infections and malignancies although these are rare in 
patients with CD4 counts above 500 cell/mm3. As the CD4 count drops below 500 
cells/mm3 patients may begin to suffer from oral candidiasis, pneumococcal infection 
and various skin disorders. The risk o f more serious potentially life-threatening 
opportunistic infections such as P. jerov ic i pneumonia, Candida oesophagitis, 
Toxoplasma encephalitis and cryptococcal meningitis increases significantly as the CD4 
count falls below 200 cells/mm3. A CD4 count of less than 200/mm3 is considered 
diagnostic o f AIDS according to the Centres for Disease Control and Prevention case 
definition. At CD4 counts under 50/mm3 patients are at increased risk for the 
occurrence o f infections such as cytomegalovirus retinitis. The HIV pandemic 
continues worldwide with the World Health Organization estimating that in 2003 37.8 
million people were living with the virus worldwide and in that year 2.9 million people 
died o f AIDS.
4.1.2 Effect of Infection on Cytokine Profile
T cell-mediated immune responses are known to be important in the pathogenesis of 
HIV infection. It has been proposed that a shift from type 1 to type 2 cytokine 
responses is important in disease progression to AIDS(394, 395). Others have found no 
evidence for such a shift(396-398). Studies undertaken to investigate the nature of the 
cytokine responses in HIV have been confusing in their results. The variation in data
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may be explained by differences in technique, cell stimulation protocols, cell population 
or patient population under study(271, 395). In addition T cells are influenced by their 
environment and in vivo cytokines may be produced by other cells such as monocytes, 
NK cells or B cells making studies on T cell clones potentially misleading.
Studies using ELISA techniques(263, 397, 399-402) may not accurately reflect the 
contribution o f each cell type as bulk cytokine levels are measured in cell culture 
supernatants or in serum or plasma samples. Intracellular cytokine staining with flow 
cytometry is recognized as a method o f reliably quantifying lymphocyte cytokine 
responses at a single cell level (274, 282, 403, 404). Because responses are seen at the 
single cell level this technique is invaluable in situations such as HIV infection where 
there may be very low absolute numbers o f some cell types. Whole blood techniques 
ensure that the cellular environment is preserved as far as possible. Studies assessing 
cytokine genes by reverse transcriptase polymerase chain reaction under non-stimulated 
conditions attempt to avoid this problem but are limited by the fact that translation into 
functional proteins may not take place(394, 405-407).
In untreated, HIV infected, individuals reduced IL-2 production with reduced CD4 
count appears to be a consistent finding in HIV-disease progression(397). Previous 
studies have, however, demonstrated both impaired(399, 408-410) (394, 399) and 
enhanced (397, 400, 405) (403, 405, 411, 412)IFNy responses. Ullum and colleagues 
performed ELISA on whole blood supernatants and demonstrated an increase in total 
IFNy in patients with HIV and a decrease in patients with AIDS(400). They state that 
IFNy production correlated with CD8 count. FACS analysis following intracellular 
cytokine staining o f stimulated T cells supports the conclusion that untreated HIV 
infected individuals have increased percentages o f lymphocytes, particularly o f the 
CD8+ subset, able to produce IFNy(403, 411,412).
4.1.3 Treatment of HIV Infection
Since 1996 a number o f agents have been used in combination for the treatment o f HIV 
infection. At the time o f this study patients were treated with combination anti­
retroviral therapy (ART) including nucleoside reverse transcriptase inhibitors, non­
nucleoside reverse transcriptase inhibitors and protease inhibitors. Inhibitors o f HIV 
fusion have more recently become available. Treatment o f HIV infection aims to 
achieve prolonged suppression o f viral replication. When potent combination therapy is 
successfully administered levels o f HIV RNA in plasma and infected cells in lymphoid
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tissue rapidly decrease. The rapid first-phase clearance is due to the death of infected 
activated CD4+ T cells and the prevention o f new infections. The second phase 
clearance rate is slower and more variable. This is attributed to clearance of infected 
macrophages or chronically infected CD4+ T cells with lower rates of cell death. 
Clearance o f virions bound to dendritic cells in the germinal centres o f lymph nodes 
may also contribute to this second phase. Failure to reduce plasma HIV RNA levels to 
below the limit o f detection o f the currently available assays (50 copies/ml) indicates 
inadequate suppression and a risk for the development o f resistant virus. However, 
even successfully treated individuals do not have complete suppression o f virus 
replication. Latently infected CD4+ T cells may survive for years, archiving virus, 
often drug resistant, that can re-emerge and replicate after the withdrawal of 
chemotherapy. High rates o f viral turnover allow for the emergence o f drug resistant 
viral mutants. In addition treatment is often limited by cost, drug related toxicities and 
compliance issues. Despite these considerations treatment with combination 
antiretroviral therapy (ART) has led to dramatic improvements in HIV-related 
morbidity and mortality(413, 414).
Suppression o f viral replication with therapy allows CD4+ cell numbers to increase and 
the magnitude o f this increase is proportional to the steady-state HIV RNA levels. 
Therapy results in the rapid redistribution o f CD45RO+ memory T cells from the 
lymphoid tissue(415, 416) back into the circulation and in the slower production of new 
CD45RA naive cells. Accompanying this increase in cell numbers is some restoration 
o f immune function. Both CD4+ and CD8+ T cell responses to recall antigens are 
regenerated leading to a restored ability to deal with opportunistic agents. Primary and 
secondary prophylaxis for agents such as Pneumocystis, Toxoplasma, cytomegalovirus, 
M. avium complex, Cryptococcus and Candida can often be withdrawn(417).
4.1.4 Postulated Effects of Treatment on Cytokine Profile
Clerici and colleagues report that ELISA and mRNA cytokine analysis o f resting 
PBMCs from 2 combination ART treated patients demonstrated reduced IFNy 
expression and raised IL-10 expression compared to ART naive patients(418). In this 
study they found that IL-2, IL-12 and IFNy production was robust in ART naive 
patients. All patients had less than 500 copies HIV RNA/ml. Martinon and colleagues 
found a similar result for total resting PBMCs in their 16 patients although the reduction 
in IFNy production was not statistically significant(419). Imami and colleagues, in
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contrast, found little expression o f IFNy, IL-2, IL-4 or IL-10 mRNA in resting PBMCs 
of 9 ART naive individuals using RT-PCR(407). After initiation of combination ART 
they describe a continuous increase in IFNy and IL-2 mRNA with successful reduction 
in viral load and increase in CD4+ T cell counts. Type-2 cytokine specific mRNA 
expression fell to undetectable levels. This finding is supported by that o f Sondergaard 
and colleagues who report an increase in IFNy in supernatants tested by ELISA in 12 
patients following the initiation o f ART(402). FACS analysis of intracellular cytokines 
in 15 HIV patients in whom protease inhibitors were added to nucleoside analogue 
regimes demonstrated a statistically significant increase in the proportion o f CD4+ cells 
producing IL-2 to levels similar to those of HIV seronegative controls after 12 months 
of treatment(420). A similar increase in IL-2 producing CD8+ cells was seen but this 
did not reach statistical significance in this study. No differences in the proportion of 
CD4+ or CD8+ cells producing IFNy could be detected during this time of follow up 
and the proportion o f IL-4 producing CD4+ cells remained <5% in all patients prior to 
and during treatment with additional protease inhibitors.
Immunological recovery following combination ART is variable with some patients 
experiencing sustained rises in CD4 cell numbers whilst in other patients CD4 cell 
counts remain static or fall despite suppression o f HIV. Furthermore, persistent 
functional T cell defects have been shown to occur even in the context of undetectable 
peripheral blood HIV viral loads and where there has been a rise in total CD4 
count(421-423). Lederman et al found many defects in immune function after ART in a 
large cohort o f patients followed for 3 years(424). Interestingly, despite these 
functional defects very few opportunistic infections occurred during follow up. Song 
and colleagues report on CMV retinitis patients who had immune restoration on 
combination ART allowing them to stop CMV prophylaxis but who later lost this 
protective mechanism when the CD4 count dropped below 50 cells/mm3(425). They 
noted that the HIV viral load did not appear to predict CMV reactivation. Other 
surrogate markers may better predict functional recovery after treatment. Cytokines are 
directly affected by virus cytotoxicity and are used in the treatment o f HIV. An 
understanding o f the effects o f  antiviral therapy on cytokine expression is 
important(421) and may lead to more accurate monitoring of clinical disease. Published 
studies aiming to provide information on the changes in cytokine production with 
treatment are very variable and limited by small numbers and heterogeneous patient 
groups.
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4.2 AIMS
This study aimed to document changes in cytokine profile of T cells in patients on 
combination ART. Screening for CMV retinitis in AIDS patients with low CD4 counts 
is widespread. The risk o f CMV retinitis has, however, been observed to drop 
dramatically with the advent o f combination ART, even in patients with only modest 
increases in their CD4 count. This study aimed to elucidate changes in immune 
function brought about by treatment with combination ART.
4.3 METHODS
4.3.1 Patient Selection
This was a cross sectional study in an urban general hospital and patients with 
HIV/AIDS were prospectively and sequentially recruited from the HIV outpatient clinic 
at Ealing Hospital from April 1999 to June 2000. The study was open to all patients 
attending the unit but patients who had received IL-2 therapy or cytotoxic 
chemotherapy were excluded. The Local Research Ethics Committee approved the 
study and written informed consent was obtained from all study participants. Blood 
samples were taken for analysis by flow cytometry at standard outpatient clinic visits.
4.3.2 Data Collected
The inform ation collected on each patient included: gender, ethnicity, CDC 
classification(426), estimated duration o f HIV infection, history o f opportunistic 
infections, medication history and length o f time on HAART, current CD4+ count and 
CD4+ nadir (defined as the lowest recorded CD4+ count), CD8+ count and current HIV 
viral load. For the purposes o f this study, HAART was defined as consisting of at least 
three different antiretroviral drugs. Patients stable on no therapy had had no 
antiretroviral therapy for at least 6 months or were not yet considered to require 
HAART (in line with the British HIV Association guidelines (427)). Patients on 
HAART for less than three months were also considered as they are unlikely to have 
undergone full immune reconstitution and are generally considered to remain at risk of 
opportunistic infections during this period (428).
Absolute numbers o f CD4+ and CD8+ T cells were determined by flow cytometry 
using a FACScan cytometer (Beckton Dickinson). HIV viral load was quantified using 
an ultrasensitive polymerase chain reaction (PCR) kit (Roche Diagnostic Systems; limit
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of detection 50 HIV copies/ml). Peripheral blood was collected into sodium heparin 
containing vacutainer tubes and analysed within 2 hours without refrigeration.
Patients were divided into various sub-groups for analysis (see Figure 4.1). 
Comparisons were made between cytokine expression in the patient groups and that in 
samples from healthy laboratory workers (“Normals”). A number of patients provided 
samples on multiple occasions.
Cell stimulation, phenotypic and cytokine staining and flow cytometry were performed 
as described in Section 2.2.7.
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Figure 4.1: Groups for Analysis
ANALYSIS GROUPS
A
1. Normals
2. HIV Patients
B
1. Normals
2. Stable on no HAART
3. HAART
C
1. Normals
2. Stable on no HAART
3. HAART > 3 months
4. HAART < 3months
D
1. Normals
2. Stable on no HAART
3. CD4>200 on HAART
4. CD4<200 on HAART
E
1. Normals
2. Stable on no HAART
3. CD4 increased > 100 from nadir on HAART
4. CD4 increased <100 from nadir on HAART
F
1. Normals
2. Stable on no HAART
3. HIV viral load < 50 on HAART
4. HIV viral load > 50 on HAART
G
1. Normals
2. Stable on no HAART
3. HIV viral load ^500 on HAART
4. HIV viral load >500 on HAART
H
1. Female Patients
2. Male Patients
I
1. British bom
2. Sub-Saharan African
3. Other origin
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4.3.3 Statistical Analysis
Statistical calculations were performed using SPSS for Windows (version 9.0-12.0 
SPSS Inc, IL, USA). Non-parametric Kruskal-Wallis testing was used with Mann- 
Whitney testing to locate differences. In order to limit the number of comparisons 
Mann-Whitney testing was only used if a difference was seen with the Kruskal-Wallis 
test. Results are presented in Tables 3A-I. “N/A” denotes not applied and “Sig.” 
denotes significance. P<0.05 was taken to be significant. A Bonferroni correction was 
used for multiple pairwise comparisons. Boxplots show the median, interquartile range, 
outliers and extreme cases.
In those patients providing repeat samples cytokine production at the first and second 
visit was compared using the Wilcoxon test for 2 related samples.
4.4 RESULTS
73 patients (49 male, 24 female) were analysed. 34 were men having sex with men; 37 
were heterosexual; 1 was an intravenous drug user and 1 was a haemophiliac. Patients 
were at different stages o f  HIV infection and AIDS as shown in the Patient 
Characteristics tables. Antiretroviral therapy was prescribed in line with the British 
HIV Association (BHIVA) guidelines(427). All those on treatment were taking 
antiretroviral therapy involving 3 or more drugs and most patients were on treatment 
regimes involving at least one protease inhibitor or non-nucleoside reverse transcriptase 
inhibitor. This was designated as highly active anti-retroviral therapy (HAART). 
Regimens involving only nucleoside reverse transcriptase inhibitors all included 
abacavir.
Results are expressed as percentage production of cytokine by cell type eg: %CD4IL2= 
CD4+IL2+/[(CD4+IL2+) + (CD4+IL2-)] x 100. They were compared to those obtained 
from 15 healthy laboratory workers (“Normals” Group 1; ages 22-47, 7 males, 8 
females) and between patient sub-groups. Results are limited to the type 1 cytokines 
IL-2 and IFNy as neither IL-4 or IL -10 expression were detected in patients and 
Normals.
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4.4.1 ANALYSIS A: Effect of HIV Infection
HIV patients had significantly different IL-2 and IFNy production from Normals. IL-2 
production was markedly reduced in both CD4+ and CD8+ subsets (p=0.000 and 
p=0.001 respectively) in HIV patients. IFNy production was increased in the CD4+ and 
CD8+ subsets (p=0.04 and p=0.02 respectively) in HIV patients. See Figure 4.2-4.7. 
Figure 4.2: Patient Characteristics
Group n
Median 
CDC Age
Classification (range) 
years
Median
CD4
(range)
Median
CD8
(range)
Cells/mm Cells/mm
Median HIV 
Viral Load 
(range)
RNA
copies/ml
2. HIV 
Patients 73
A 1x7; A2x6 
A 3x7; B 1 
B3xl 1; C2x3 
C3x24; 14x?
39 250 860 2270
(23-71) (4-900) (150-2570) (0-1960000)
Figure 4.3: Statistical Analysis; Normals vs HIV Patients
CD4IL2 CD8IL2 CD4IFN CD8IFN
Mann-Whitney Testing
Normals vs 
HIV patients Sig. 0.000 0.001 0.04
0.02
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Figure 4.4: CD4 Cells Producing IL-2; Patients vs Normals
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Figure 4.5: CD8 Cells Producing IL-2; Patients vs Normals
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Figure 4.6: CD4 Cells Producing IFNy; Pts vs Normals
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Figure 4.7: CD8 Cells Producing IFNy; Pts vs Normals
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4.4.2 ANALYSIS B: Effect of HA ART
4.4.2.1 IL-2 Production by CD4+ and CD8+ Cells
The significant reduction in IL-2 production compared to Normals seen in both CD4+ 
and CD8+ subsets persisted when patients were sub-grouped according to whether they 
were on HAART or stable on no HAART. However, when IL-2 production by patients 
on HAART was compared to IL-2 production by patients stable on no HAART a 
significant difference was seen in the CD8+ (p-0.012) but not the CD4+ (p=0.459) 
subset. See Figure 4.8-4.10.
4.4.2.2 IFNy Production by CD4+ and CD8+ Cells
No difference was seen in IFNy production by CD4+ and CD8+ cells of HIV patients 
stable on no HAART compared to Normals. In contrast, patients on HAART had 
significantly elevated IFNy production by CD4+ and CD8+ T cells compared to 
Normals (p=0.045 and p=0.036 respectively). A significant difference in IFNy 
production by patients on HAART compared to those off HAART was not seen. See 
Figure 4.9.
Figure 4.8: Patient Characteristics; HAART vs No HAART
Group n CDC Median Median Median CD8 Median
Classification Age CD4 (range) HIV Viral
(range) (range) Cells/mm3 Load
years Cells/mm3 (range)
copies/ml
2. Stable 13 A 1x5, A2, C2, 35 530 1000 43600
on no A3x3, B3, 7x2 (23-44) (80-900) (450-2570) (1 260-1 000
HAART 000)
3. HAART 60 A lx 2 , A 2x5, 39 240 800 973
A3x4, B 3x l0 , (23-71) (4-650) (150-2280) (50-1 960 000)
C 2, C 3 x 2 5 ,
7x13
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Figure 4.9: Statistical Analysis; Effect of HAART
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-W allis Testing
Comparing all
groups
(1-3)
2
X
df
Sig.
25.842
2
0.000
16.593
2
0.000
6.528
2
0.038
5.987
2
0.050
M ann-W hitney Testing
1 vs 2 Sig.(Corrected)
0.000
(0.000)
0.001
(0.003)
0.828
(1)
0.321
(0.963)
1 vs 3 Sig.(Corrected)
0.000
(0.000)
0.005
(0.015)
0.015
(0.045)
0.012
(0.036)
2 vs 3 Sig.(Corrected)
0.153
(0.459)
0.004
(0.012)
0.163
(0.489)
0.485
(1)
Figure 4.10: CD8 Cells P roducing IL-2; Effect of HAART
HAART -
64
a
3Oi-__ Stable on no 
HAART
Normals -
10.00 20.00 30.00 40.00 50.000.00
% CD8+ lym phocytes producing IL2
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4.4.3 ANALYSIS C: Time on HAART
4.4.3.1 IL-2 Production by CD4+ Cells
HIV patients produced very significantly reduced IL-2 levels compared to Normals. 
Further analysis revealed no significant differences between patient sub-groups 
irrespective o f time on HAART. See Figure 4.11—4.13.
4.4.3.1 IL-2 Production by CD8+ Cells
Patients stable on no HAART were found to have significantly reduced IL-2 production 
by CD8+ cells compared to Normals (p=0.006). Patients on HAART for less than 3 
months were also seen to have significantly reduced IL-2 production by CD8+ cells 
compared to Normals (p=0.012). This difference was not seen when comparing patients 
on HAART for at least 3 months and Normals.
Patients stable on no HAART were seen to have significantly less IL-2 production by 
CD8+ cells from patients who had been on HAART for at least 3 months (p=0.024). 
See Figures 4.11, 4.12 and Figure 4.14.
4.4.3.3 IFNy Production by CD4+ and CD8+ Cells
No significant differences were seen between HIV patients and Normals or between 
patient sub-groups for IFNy production by CD4+ or CD8+ cells when patients where 
grouped according to their time on HAART. See Figure 4.12.
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Figure 4.11: Patient Characteristics; Tim e on HAART
Group n
CDC
Classification
Median
Age
(range)
years
Median
CD4
(range)
cells/mm3
Median 
CD8 
(range) 
cells/m m3
Median
HIV Viral
Load
(range)
RNA
copies/ml
2.
Stable 
on no 
HAART
13 A 1x5, A2, C2, A3x3, B3, 7x2
35
(23-44)
530
(80-900)
1000
(450-2570)
43 600
(1 260-1 000 
000)
3.
HAART
> 3
months
54
A 1x2, A2x5, 
A3x4, B3x9,
C2, C3x20, 7x13
39
(23-71)
250
(4-650)
860
(150-2280)
659
(0-692 460)
4.
HAART
< 3
months
6 C3x5, B3 42(31-57)
35
(9-120)
305
(260-630)
22 400 
(1 390-1 960 
000)
Figure 4.12: Statistical Analysis; Time on HAART
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing 
all groups 
(1-4)
->
X
df
Sig.
27.760
3
0.000
18.649
3
0.000
7.533
3
0.057
6.023
3
0.111
Comparing
patient
groups
(2-4)
X
df
Sig.
4.541
2
0.103
9.944
2
0.007
N/A N/A
Mann-Whitney Testing
1 vs 2 Sig.(Corrected)
0.000
(0.000)
0.001
(0.006)
N/A N/A
1 vs 3 Sig.(Corrected)
0.000
(0.000)
0.012
(0.072)
N/A N/A
1 vs 4 Sig.(Corrected)
0.001
(0.003)
0.002
(0.012)
N/A N/A
2 vs 3 Sig.(Corrected)
N/A 0.004
(0.024)
N/A N/A
2 vs 4 Sig.(Corrected)
N/A 0.157
(0.942)
N/A N/A
3 vs 4 Sig.(Corrected)
N/A 0.117
(0.702)
N/A N/A
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Figure 4.13: CD4 Cells Producing IL2; Effect of Time on HAART
HAART < 3 
months
HAART >/=  
3months
tHStable on no HAART
Normals o  o
0.00 20.00 40.00 60.00 80.00
% CD4+ lym phocytes producing IL2
Figure 4.14: CD8 Cells P roducing 1L2; Effect of Time on HAART
HAART < 3 
months
HAART >/=  
3months
Stable on no 
HAART 27
Normals
0.00 10.00 20 .00  30 .00 40 .00  50.00
%CD8+ lymphocytes producing IL2
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4.4.4 ANALYSIS D: Effect of CD4 Count
4.4.4.1 IL-2 Production by CD4+ Cells
All HIV patient groups produced very significantly reduced IL-2 levels compared to 
Normals. Further analysis revealed no differences between patients sub-grouped 
according to CD4 count. See Figures 4.16 and Figure 4.17.
4.4.4.2 IL-2 Production by CD8+ Cells
Patients stable on no HAART were found to have significantly reduced IL-2 production 
by CD8+ cells compared to Normals (p=0.006). Patients with CD4<200 cells/mm3 on 
HAART were also seen to have significantly reduced IL-2 production by CD8+ cells 
compared to Normals (p=0.048). This difference was not seen when comparing patients 
with CD4>200 cells/mm3 on HAART and Normals.
Patients stable on no HAART were seen to have significantly reduced IL-2 production 
by CD8+ cells from patients with CD4>200 cells/mm3 on HAART (p=0.030). See 
Figure 4.16 and Figure 4.18.
4.4.4.3 IFNy Production by CD4+ and CD8+ Cells
No significant differences were seen between HIV patients and Normals or between 
patient groups for IFNy production by CD4+ and CD8+ cells when patients were 
grouped according to CD4 count. See Figure 4.16.
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Figure 4.15: Patient Characteristics; CD4 Count
Group n CDC Classi­fication
Median
Age
(range)
years
Median
CD4
(range)
cells/mm3
Median
CD8
(range)
cells/m
m3
Median HIV 
Viral Load 
(range)
copies/ml
2. Stable on 
no HAART 13
A lx5 , A2, C2, 
A3x3, B3, 7x2
35
(23-44)
530
(80-900)
1000
(450-
2570)
43 600 
(1 260-1 000 
000)
3. CD4 > 200 
on HAART 35
A 1x2, A2x5, 
A3x3, B3x4, 
C2, C3xl 1,7x9
38.5
(23-71)
360
(210-650)
910
(350-
2280)
616
(0-133 879)
4. CD4 < 200 
on HAART 25
A3, B3x7, 
C3xl3, 7x4
39.5
(26-68)
90
(4-200)
550
(150-
2120)
2750
(0-1 960 000)
Figure 4.16: Statistical Analysis; CD4 Count
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing all
groups
d-4)
df
Sig.
28.298
3
0.000
17.187
3
0.001
6.993
3
0.072
6.444
3
0.092
Comparing 
patient groups 
(2-4)
X2
df
Sig.
5.393
2
0.067
8.810
2
0.012
N/A N/A
Mann-Whitney Testing
1 vs 2
Sig.
(corrected)
0.000
(0.000)
0.001
(0.006)
N/A N/A
1 vs 3 Sig.(corrected)
0.000
(0.000)
0.013
(0.078)
N/A N/A
1 vs 4 Sig.(corrected)
0.000
(0.000)
0.008
(0.048)
N/A N/A
2 vs 3
Sig.
(corrected)
N/A 0.005
(0.030)
N/A N/A
2 vs 4
Sig.
(corrected)
N/A 0.020
(0.120)
N/A N/A
3 vs 4
Sig.
(corrected)
N/A 0.349
(1)
N/A N/A
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Figure 4.17: CD4 Cells Producing 1L2; Effect of CD4 Count
CD4</= 200 
on HAART
CD4>200 on 
HAART
H U HStable on no HAART
Normals o  o
0.00 20.00 40.00 60.00 80.00
% CD4+ lym phocytes producing IL2
Figure 4.18: CD8 Cells Producing IL2; Effect of CD4 Count
CD4</= 200 on 
HAART 64
CD4>200 on 
HAART
Stable on no 
HAART
Normals
0.00 10.00 20.00 30.00 40.00 50.00
%CD8+ lymphocytes producing IL2
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4.4.5 ANALYSIS E: CD4 Change from Nadir
4.4.5.1 IL-2 Production by CD4+ Cells
All HIV patient groups were found to produce very significantly reduced IL-2 levels 
compared to Normals. Further analysis revealed no differences between patient groups 
irrespective of HAART or response to HAART. See Figure 4.20 and Figure 4.21.
4.4.5.2 IL-2 Production by CD8+ Cells
Patients stable on no HAART were found to have significantly reduced IL-2 production 
by CD8+ cells compared to Normals (p=0.006). Significant differences were not seen 
between IL-2 production by CD8+ cells for patients on HAART irrespective of the CD4 
response to treatment and Normals.
Those stable on no HAART had a significant reduction in IL-2 production by CD8+ 
cells compared to those with a good response to HAART therapy (CD4 increased by at 
least 100 from nadir) (p=0.042). See Figure 4.20 and Figure 4.22.
4.4.5.3 IFNy Production by CD4+ and CD8+ Cells
No significant differences were seen between HIV patients and Normals or between 
patient sub-groups for IFNy production by CD4+ and CD8+ cells when patients were 
grouped according to the CD4 change from nadir on HAART. See Figure 4.20.
Figure 4.19: Patient Characteristics; CD4 Change From Nadir
Group n
CDC
Classi­
fication
Median
Age
(range)
years
Median
CD4
(range)
cells/mm3
Median
CD8
(range)
cells/mm3
Median HIV 
Viral Load 
(range)
RNA copies/ml
2. Stable on no 
HAART 13
A 1x5, A2, 
C2, A3x3, 
B3, 7x2
35
(23-44)
530
(80-900)
1000
(450-2570)
43 600
(1 260-1 000 000)
3. CD4 > 100 
from nadir on 
HAART
27
A2x3,
A3x2, B3x5, 
C2x2,
C3xl 1, 7x5
41
(23-53)
360
(180-650)
990
(320-2280)
400
(0-95 200)
4. CD4 < 100 
from nadir on 
HAART
30
A 1x2,
A2x2,
A3x2, B3x6, 
C3xl2, 7x6
39
(26-71)
120
(4-650)
620
(150-2120)
3190
(0-1 960 000)
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Figure 4.20: Statistical Analysis; CD4 Change from Nadir
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing all groups 
(1-4)
1
X“
df
Sig.
25.805
3
0.000
15.812
3
0.001
5.99
3
0.112
6.378
3
0.095
Comparing patient groups 
(2-4)
1
X
df
Sig.
2.032
2
0.362
7.750
2
0.021
N/A N/A
Mann-Whitney Testing
1 vs 2 Sig.
(corrected)
0.000
(0.000)
0.001
(0.006)
N/A N/A
1 vs 3 Sig.
(corrected)
0.000
(0.000)
0.016
(0.096)
N/A N/A
1 vs 4 Sig.
(corrected)
0.000
(0.000)
0.015
(0.090)
N/A N/A
2 vs 3 Sig.
(corrected)
N/A 0.007
(0.042)
N/A N/A
2 vs 4 Sig.
(corrected)
N/A 0.017
(0.102)
N/A N/A
3 vs 4 Sig.
(corrected)
N/A 0.838
(1)
N/A N/A
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Figure 4.21: CD4 Cells Producing IL2; Effect of CD4 Change from Nadir
Change from 
nadir</=100 on HAART
Change from nadir>100 _ 
on HAARTa
3
2o
t HStable on no HAART -
Normals - o o
0.00 20.00 40.00 60.00 80.00
% CD4+ lym phocytes producing IL2
Figure 4.22: CD8 Cells Producing IL2; Effect of CD4 Change from N adir
Change from 
nadir</=100 on HAART
Change from nadir>100 _ 
on HAARTQ.3
2(D
Stable on no HAART -
27
Normals -
0.00 10.00 20.00 30.00 40.00 50.00
%CD8+ lymphocytes producing IL2
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4.4.6 ANALYSIS F: HIV Viral Load 50 copies/ml
4.4.6.1 IL-2 Production by CD4+ Cells
All HIV patient groups were found to have very significantly reduced IL-2 production 
compared to Normals. Further analysis revealed no differences between patient sub­
groups irrespective o f HAART or the ability to suppress viral replication below the 
limit of detection. See Figure 4.24 and 4.25.
4.4.6.2 IL-2 Production by CD8+ Cells
Patients stable on no HAART were found to have significantly reduced IL-2 production 
by CD8+ cells compared to Normals (p=0.006). Patients with HIV viral load >50 
copies/ml on HAART were also seen to have significantly different IL-2 production by 
CD8+ cells compared to Normals (p=0.018). This difference was not seen when 
comparing patients with HIV viral load <50 copies/ml on HAART and Normals (p-1).
Patients stable on no HAART were seen to have significantly different IL-2 production 
by CD8+ cells from patients with HIV viral load>50 copies/ml despite HAART 
(p=0.030). See Figure 4.24 and Figure 4.26.
4.4.6.3 IFNy Production by CD4+ and CD8+ Cells
No significant differences were seen between patients and Normals or between patient 
groups for IFNy production by CD4+ and CD8+ cells when patients were grouped 
according to suppression o f viral replication. See Figure 4.24.
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Figure 4.23: Patient Characteristics; HIV Viral load (50)
Group n
CDC
Classi­
fication
Median
Age
(range)
years
Median
CD4
(range)
cells/mm3
Median
CD8
(range)
cells/mm3
Median
HIV Viral
Load
(range)
RNA
copies/ml
2. Stable on 
no HAART 13
A lx 5 , A2, 
C2, A3x3, 
B3, 7x2
35
(23-44)
530
(80-900)
1000
(450-2570)
43 600 
(1 260-1 
000 000)
3. HIV viral 
load 
£ 50 on 
HAART
12
A l, A2, A3, 
B3x2,
C3x5, 7x2
26
(23-53)
290
(30-650)
49
(320-1910)
3
(0-50)
4. HIV viral 
load
>50
on HAART
48
A l, A2x4, 
A3x4, 
B3x8, C2, 
C3xl8, 
7x12
39
(29-71)
230
(4-650)
825
(150-
2280)
2500 
(92-1 960 
000)
Figure 4.24: Statistical Analysis; HIV Viral Load (50)
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing all X 25.379 16.875 6.835 6.073
groups d f 3 3 3 3
(1-4) Sig. 0.000 0.001 0.077 0.108
Comparing patient X 2.638 8.441 N/A N/A
groups d f 2 2 - -
(2-4) Sig. 0.267 0.015 - -
Mann-Whitney Testing
1 vs 2 Sig.
(corrected)
0.000
(0.000)
0.001
(0.006)
N/A N/A
1 vs 3
Sig.
(corrected)
0.001
(0.003)
0.205
(1)
N/A N/A
1 vs 4 Sig.
(corrected)
0.000
(0.000)
0.003
(0.018)
N/A N/A
2 vs 3 Sig.
(corrected)
N/A
0.025
(0.150)
N/A N/A
2 vs 4 Sig.
(corrected)
N/A
0.005
(0.030)
N/A N/A
3 vs 4 Sig.
(corrected)
N/A
0.572
(1)
N/A N/A
164
Figure 4.25: CD4 Cells Producing IL2; Effect of HIV Viral Load (50)
HIV Viral Load >50 
on HAART
HIV Viral Load</=50 
on HAART
Q.3O
Stable on no HAART
Normals
0.00 20.00 40.00 60.00 80.00
% CD4+ lym phocytes producing IL2 
Figure 4.26: CD8 Cells Producing IL2; Effect of HIV V iral Load (50)
HIV Viral Load >50 
on HAART
HIV Viral Load</=50 
on HAART
Q .
3P
Stable on no HAART
Normals
0.00 10.00 20.00 30.00 40.00 50.00
% CD8+ lym phocytes producing IL2
oo
o o
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4.4.7 ANALYSIS G: HIV Viral Load 500 copies/ml
4.4.7.1 IL-2 Production by CD4+ Cells
All HIV patient groups were found to produce very significantly reduced IL-2 levels 
compared to Normals. Further analysis revealed no differences between patient sub­
groups either on or off HAART when patients were grouped according to HIV viral 
load greater or less than 500 copies/ml. See Figure 4.28 and Figure 4.29.
4.4.7.2 IL-2 Production by CD8+ Cells
Patients stable on no HAART were found to have significantly reduced IL-2 production 
by CD8+ cells compared to Normals (p=0.006). Patients with HIV viral load >500 
copies/ml on HAART were also seen to have significantly reduced IL-2 production by 
CD8+ cells compared to Normals (p=0.042). This difference was not seen when 
comparing patients with HIV viral load<500 copies/ml on HAART and Normals 
(p=0.156).
Patients stable on no HAART were seen to have significantly different IL-2 production 
by CD8+ cells from patients with HIV viral load>500 copies/ml on HAART (p=0.018). 
See Figure 4.28 and Figure 4.30.
4.4.7.3 IFNy Production by CD4+ Cells
A significant difference was found between Normals and patients with HIV viral load 
>500 copies/ml despite HAART for IFNy production by CD4 cells (p=0.012). See 
Figure 4.28 and Figure 4.31.
4.4.7.4 IFNy Production by CD8+ Cells
No significant differences were seen between patients and Normals or between patient 
sub-groups for IFNy production by CD8+ cells when patients were grouped according 
to HIV viral load greater or less than 500 copies/ml. See Figure 4.28.
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Figure 4.27: Patient Characteristics; HIV Viral load (500)
Group n CDCClassification
Median
Age
(range)
years
Median
CD4
(range)
cells/mm3
Median
CD8
(range)
cells/mm3
Median HIV 
Viral Load 
(range)
RNA
copies/ml
2. Stable on 
no HAART
13
A 1x5, A2, 
C2, A3x3, 
B3, ?x2
35
(23-44)
530
(80-900)
1000
(450-2570)
43 600 
(1 260-1 000 
000)
3. HIV viral 
load < 500 
on HAART
24
A 1x2, A2x3, 
A3x3, B3x3, 
C3x9, 7x4
39
(23-71)
310
(20-650)
860
(320-2120)
71
(0-434)
4. HIV viral 
load >500 on 
HAART
36
A2x2, A3x2, 
B3x7, C2xl, 
C 3 x l4 ,7x10
39
(29-68)
210
(4-640)
760
(150-2280)
4051
(560-1 960 
000)
F igure  4.28: S tatistical A nalysis; H IV  V iral Load (500)
C D 4IL2 CD 8IL2 CD 4IFN CD8IFN
K ruskal-W allis T esting
Comparing all groups 
(1-4)
x2
d f
sig.
24.973
3
0.000
16.524
3
0.001
10.200
3
0.017
7.358
3
0.061
Comparing patient groups 
(2-4)
x2
d f
sig.
2.147
2
0.342
8.254
2
0.016
5.382
2
0.068
N/A
M ann-W hitney  T esting
1 vs 2
Sig.
(corrected)
0.000
(0.000)
0.001
(0.006)
0.828
(1)
N/A
1 vs 3
Sig.
(corrected)
0.000
(0.000)
0.026
(0.156)
0.212
(0.636)
N/A
1 vs 4
Sig.
(corrected)
0.000
(0.000)
0.007
(0.042)
0.002
(0.012)
N/A
2 vs 3
Sig.
(corrected)
N/A
0.035
(0.210)
N/A N/A
2 vs 4 Sig.
(corrected)
N/A
0.003
(0.018)
N/A N/A
3 vs 4 Sig.
(corrected)
N/A
0.957
(1)
N/A N/A
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Figure 4.29: C'D4 C ells Producing IL2; Effect of HIV Viral Load (500)
H IV  viral load>500  
on HAART
H IV  viral load<500  
on HAART
Stable on no HAART
27
Normals
000 20 00 4 0  00 6 0  00 80 00
% CD4+ lym p h ocy tes producing IL2
4.30: CD8 Cells Producing IL2; Effect of HIV Viral Load (500)
H IV  viral load>500 .  
on HAART
oo
85
H IV  viral load<500 _ 
on HAART
Stable on no HAART -
Normals -
0 .00  10 00  20  00  30 00  40  00  50 00
% CD8+ lym p h ocy tes producing IL2
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Figure 4.31: CD4 Cells Producing IFNy; Effect of HIV Viral Load (500)
HIV viral load>500 
on HAART
HIV viral load<500 
on HAART
Stable on no HAART
Normals
0.00 20.00 40.00 60.00 80.00
% CD4+ lym phocytes producing IFNy
4.4.8 ANALYSIS H: Gender
Male and female patients were not seen to have significant differences in type 1 
cytokine production by CD4+ and CD8+ cells. See Figure 4.32.
Figure 4.32: Patient Characteristics; Gender
Group n
CDC
Classification
Median Age 
(range)
years
Median CD4 
(range)
cells/mm3
Median HIV 
Viral Load 
(range)
RNA
copies/ml
Females 25
A 1x5, A2, 
A3x2, B3x5, 
C2, C3x6, 7x5
36
(24-71)
230
(9-670)
904
(0-220 036)
Males 48
A 1x2, A2x5, 
A3x5, B l, 
B3x7, C2, 
C3xl8, 7x9
39
(23-68)
250
(4-900)
2565
(0-1 960 000)
Figure 4.33: Statistical Analysis; Gender
CD4IL2 CD8IL2 CD4IFN CD8IFN
Mann-Whitney Testing
Comparing Female to Male Pts Sig. 0.373 0.236 0.641 0.905
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4.4.9 ANALYSIS I: Origin
Analysis o f patients’ origin (British born, Sub-Saharan African or Other) revealed no 
significant differences in type 1 cytokine production by CD4+ or CD8+ cells in the 
different groups. See Figure 4.35.
Figure 4.34: Patient Characteristics; Origin
Group n CDC Classi­fication
Median Age
(range)
years
Median CD4
(range)
cells/mm3
Median HIV Viral 
Load (range)
RNA copies/ml
1.British 
Born 34
A 1x4, A2x3, 
A3x4, B3x4, 
C 2x l, C3xl 1, 
7x7
42
(23-71)
325
(10-900)
2230
(0-692 460)
2. Sub-
Saharan
African
24
A l, A2, A3x2, 
B3x7, C 2x l, 
C3x8, 7x4
38
(24-54)
165
(20-670)
3190
(0-1 960 000)
3. Other 
Origin 15
A 1x2, A2x2, 
A3, B 1,B 3, 
C3x5, 7x3
33
(23-57)
250
(4-880)
1260
(0-192 000)
Figure 4.35: Statistical Analysis; Origin
CD4IL2 CD8IL2 CD4IFN CD8IFN
Kruskal-Wallis Testing
Comparing 2.493 1.313 0.251 1.550
all groups df 2 2 2 2
(1-3) Sig. 0.288 0.519 0.882 0.461
Mann-Whitney Testing
1 vs 2 N/A N/A N/A N/A
1 vs 3 N/A N/A N/A N/A
2 vs 3 N/A N/A N/A N/A
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4.4.10 ANALYSIS J: Repeat Samples
14 patients were investigated for cytokine production on 2 occasions, 2 on 3 occasions, 
3 on 4 occasions, 1 on 5 occasions and 1 on 6 occasions (See Figure 4.36).
Figure 4.36: Frequency of A ttendance
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4.4.10.1 2 Visits
14 patients were investigated for cytokine production on 2 occasions. One patient was 
excluded because the results of his first analysis were lost. Patient characteristics at 
each visit are documented in Figure 4.36. No patient changed CDC classification 
between visits. Patient 3 and patient 40 were on no antiretroviral therapy at the first 
visit, the other patients were on HAART regimes. All patients were on HAART at the 
second visit. The second visit was 119 days after the first for patient 3 and 315 days 
after the first for patient 40. The median interval between visits was 126 days (range 
28-336 days).
No significant differences were seen in IL-2 or IFNy production by CD4 or CD8 cells 
when comparing the first and second visit (Figures 4.38-4.42). Cytokine production 
was noted to be stable despite observed improvements in CD4 count, CD8 count and 
HIV viral load between visits (Figure 4.37)
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Figure 4.37: 2 Visits; Patient Characteristics
Pt CDC CD4 CD4 CD8 CD8 HIV HIV HAART HAART
no.
Classification
count count count count Load Load
(V'isit 1) (V'isit 2)
(Visit 1) (Visit 2) (V'isit 1) (Visit 2) (V'isit 1) (Visit2)
3 A3 150 200 2570 2990 220036 635 No Yes
4 C3 50 370 260 1030 361327 30 Yes Yes
6 C3 170 250 1240 1600 4649 6600 Yes No
7 B3 60 170 400 620 185 202 Yes Yes
22 C3 180 250 1740 1390 668 25 Yes Yes
23 C2 640 400 860 620 904 0 Yes Yes
26 C3 10 120 270 1650 1390 0 Yes Yes
27 B3 180 461 1050 1140 0 90 Yes Yes
33 C3 300 270 1720 1390 0 0 Yes Yes
38 ?2 250 860 720 109 136 Yes Yes
40 C2 440 1560 1040 57000 4250 No Yes
46 C3 420 1050 970 153 9410 Yes Yes
47 C3 330 740 n/a 0 2230 Yes Yes
M edian 180 270 1050 1090 668 136
M inim um 10 120 260 620 0 0
M axim um 640 510 2570 2990 361327 9410
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Figure 4.38: CD4 Cells Producing IL2: First Visit compared to Second Visit
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Figure 4.39: CD8 Cells P roducing IL2: F irst Visit com pared to Second Visit
CM
CDCo
3■D
2
CL
CO0)
o
o.c
CL
E
+
COQO
io<r
80 “
6 0 -
4 0 -
20"
First Visit Second Visit
V is it
174
Figure 4.40: CD4 Cells Producing IFNy: First Visit compared to Second Visit
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Figure 4.41: CD8 Cells Producing IFNy: First Visit com pared to Second Visit
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Figure 4.42: Statistical Analysis; First vs Second Visit
CD4IL2 CD8IL2 CD4IFN CD8IFN
Wilcoxon Signed Ranks Test
Z -.524(a) -1.223(a) -.622(a) -.178(b)
Sig. .600 .221 .534 .859
a Based on negative ranks, 
b Based on positive ranks.
4.4.10.2 3 Visits
Patients 3 and 20 both provided samples on 3 occasions. Patient 3 started HAART 
between the first and second visits and was CMV PCR positive at the first visit. Patient 
20 was on HAART throughout the test period. Figures 4.43-4.47.
Figure 4.43: Viral Load Changes; Patient 3
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Figure 4.44: T Cell Changes; Patient 3
3500
3000
2500  
|  2000 - 
=  1500 -
CD4 count cells/mm3 
CD8 count cells/mm3
CO
1000
500 -
406119
Time in days between samples
176
Figure 4.45: IL2 and IFNy Changes; Patient 3
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Figure 4.46: Viral Load and T Cell Changes; Patient 20
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Figure 4.47: IL2 and IFNy Changes; Patient 20
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4.4.10.3 4 Visits
Patients 5, 8 and 21 provided samples on 4 occasions. Figures 4.48-4.55. All 3 patients 
were on HAART throughout the test period. Patient 8 had active CMV retinitis at the 
first visit and developed a retinal detachment.
Figure 4.48: Viral Load and T Cell Changes; Pt 5
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Figure 4.49: Cytokine Production by CD4 & CD8 Cells; Pt 5
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Figure 4.50: T Cell Changes; Patient 8
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Figure 4.51: Viral Load Changes; Patient 8
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Figure 4.52: Cytokine Production by CD4 & CD8 Cells; Pt 8
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Figure 4.53: T Cell Changes; Patient 21
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Figure 4.54: Viral Load Changes; Patient 21
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Figure 4.55: Cytokine Production by CD4 and CD8 Cells; P t 21
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4.4.10.4 5 Visits
Patient 30 provided samples on 5 occasions. This patient was being treated for active 
CMV retinitis throughout the test period. He started treatment with antiretrovirals 2 
days before the first sample and remained on HAART throughout the test period. 
Figure 4.56-4.58.
Figure 4.56: T Cells Changes; Patient 30
1000
800
CD4
count600 -
400 -
CD8
count200
162 190 246
Time in days between samples
Figure 4.57: V iral Load Changes; Patient 30
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Figure 4.58: Cytokine Production by CD4 and CD8 Cells; Pt 30
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4.4.10.5 6 Visits
Patient 19 provided samples on 6 occasions. This patient was being treated for active 
progressive outer retinal necrosis (PORN) over the period of the first 3 visits. The 
ocular disease then became inactive. He started HAART 3 months before the first 
sample and was on HAART throughout the test period. Figures 4.59-4.62.
Figure 4.59: CD4 Changes; Patient 19
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Figure 4.60: CD8 Changes; Patient 19
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Figure 4.61: V iral Load Changes; Patient 19
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Figure 4.62: Cytokine Changes; Patient 19
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4.5 SUMMARY
In summary, HIV infection reduces IL-2 production by both CD4+ and CD8+ cells 
compared to normal controls. IL-2 production in the CD8+ subset was significantly 
reduced in patients on no HAART compared to patients on HAART (p=0.012). This 
reduction appeared to normalize in the CD8+ subset in patients on HAART who had 
received at least 3 months of HAART therapy, who had CD4 counts >200 cells/mm3 
and who had HIV viral load less than or equal to 50 copies/ml. Those with effective 
suppression of viral replication were seen to have IL-2 production in the CD8+ subset 
comparable with normal controls (p=l). IFNy production by CD4+ and CD8+ T cells 
was significantly increased in HIV patients compared to Normals (p=0.04 and p=0.02 
respectively). No difference was seen in IFNy production by CD4+ and CD8+ cells of 
HIV patients stable on no HAART compared to Normals. In contrast, patients on 
HAART had significantly elevated IFNy production by CD4+ and CD8+ T cells 
compared to Normals (p=0.045 and p=0.036 respectively). Those with poorly 
controlled viraemia (HIV viral load >500 copies/ml) despite HAART had significantly 
increased IFNy production by CD4+ cells compared to Normals (p=0.012). Patient 
gender or origin appeared to have no effect on type 1 cytokine production by CD4+ and 
CD8+ cells. Cytokine measurements appeared to remain relatively stable over time. I 
was not able to correlate clinical events with changes in IL-2 or IFNy production 
measured over a period o f time.
4.6 DISCUSSION
IL-2 is known to be central to the pathogenesis o f HIV infection and treatment with 
supplementary IL-2 has been shown to enhance the immune response, increasing 
absolute CD4+ counts (429, 430). Similarly, defective proliferation by HIV-specific 
CD4+ cells can be corrected by the in vitro addition of exogenous IL-2 (431, 432). This 
study demonstrates a reduction in the IL-2 response o f CD4+ and CD8+ positive 
lymphocytes in 73 HIV infected individuals consistent with other reports (403, 433- 
435). In this study further sub-group analysis revealed no further information about IL-2 
expression by CD4+ cells. In particular no significant overall increase in IL-2 
expression by CD4+ T cells with successful HAART was detected as reported by both 
Weiss et al. (433) and Imami et al.(436). The observed failure of treatment to reverse 
CD4+ T cell anergy was independent of viral load or CD4+ count. This lack of reversal
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on HAART even in patients with significant immunological recovery as judged by an 
increased CD4 count of greater than 100 cell/mm3 from nadir is in accord with the 
findings o f Lederman et al(424) who reported that lymphocyte proliferation did not 
change significantly with time on antiretroviral therapy.
Sub-group analysis did reveal differences in IL-2 production in the CD8+ subset. This 
was significantly reduced in patients on no HAART compared to patients on HAART 
(p=0.012). Further sub-group analysis suggested that IL-2 production by CD8+ cells 
tended to normalize in patients on HAART who had received at least 3 months of 
HAART therapy, who had CD4 counts >200 cells/mm3, who had a CD4+ change from 
nadir of more thanlOOcells/mm3, and who had HIV viral load less than or equal to 50 
copies/ml. Those with effective suppression of viral replication were seen to have IL-2 
production in the CD8+ subset comparable with normal controls (p= 1). This improved 
CD8+ responsiveness occurred in patients with even very advanced immunodeficiency 
and low CD4+ counts.
These results add to the body o f evidence suggesting the importance of CD8+ cells in 
the clinical functional immune recovery seen early in patients on HAART. IL-2 is 
known to reduce apoptosis and increase survival (437) o f T-cells in HIV infection and 
this is happening at a time when CD4+T-cells are not showing improved function. O f 
interest is that changes in CD8+ IL-2 were seen in patients who had been on HAART 
for 3 months or more. It is known that HAART results in a rapid first phase (8-12week) 
increase in CD4+ and CD8+ T-cell numbers that likely represents redistribution from 
tissue sites(415, 416). Kempen et al report increased survival in patients with 
cytomegalovirus (CMV) retinitis who continued to have profound immunodeficiency 
despite receiving HAART(438). They defined immune recovery on HAART as a rise 
in CD4+ count rise by at least 50 cells/mm3 from the time of CMV retinitis diagnosis to 
a level o f > 100 cells/mm3. They suggest that this reduction in mortality may have 
been due to immune recovery to a degree less than that included by their definition but 
sufficient to improve survival and/or control of HIV replication despite lack of immune 
recovery and/or benefits of HAART beyond those measured by its effects on CD4+ cell 
counts and HIV viral load measurements. The findings in the CD8+ subset in this study 
support benefits of HAART beyond those measured by the effects on CD4+ cell counts 
and HIV viral load measurements. Improvements in CD8+ function may occur sooner 
than those in CD4+ function and may be important at low CD4+ T cell counts.
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In contrast the IFNy data showed that IFNy production by CD4+ and CD8+ T cells was 
significantly increased in HIV patients compared to Normals (p=0.04 and p=0.02 
respectively). Patients on HAART also had significantly elevated IFNy production by 
CD4+ and CD8+ T cells compared to Normals (p=0.045 and p=0.036 respectively). 
Sub-group analysis showed that those with poorly controlled viraemia (HIV viral load 
>500 copies/ml) despite HAART had significantly increased IFNy production by CD4+ 
cells compared to Normals (p=0.012). Memory CD4+ T cells have been subdivided into 
central and effector memory cells based on their expression of surface antigens, their 
cytokine profiles and their ability to proliferate(439). Younes et al compared results 
from 10 viremic and 8 aviremic HIV-1 infected patients and found that persistent HIV 
generates a high frequency of IFNy HIV-specific CD4+ T cells, lowers the frequency of 
IL-2 producing cells and interferes with the establishment and/or maintenance of long- 
lived memory(431). The findings presented here are consistent with this. Previous 
reports (397, 440) have shown increased IFNy levels by ELISA in patients with high 
CD4+ counts with serum IFNy levels falling as disease progressed. The observed fall in 
IFNy levels with progressive disease may simply have been due to reduced cell 
numbers. The use o f single cell analysis removes the problem of low cell numbers and 
demonstrates that the ability to produce IFNy per se does not fall in advanced HIV 
disease. Klein et al. (403) reported a reduction in IFNy expression in the CD4+ subset 
with progression to AIDS but in the CD8+ subset they saw an increase in IFNy with 
progression which is consistent with our findings.
Our patient population was notably heterogenous with a large number o f women, 
immigrants and patients presenting late in the course o f their disease. There are 
published reports of CD4+ lymphocyte counts in HIV infection being different in men 
and women(441) but we were unable to demonstrate a gender difference in CD4+ 
lymphocyte function. Likewise no effect o f ethnicity was seen in line with the 
previously reported UK study where similar rates o f CD4+ lymphocyte decline were 
seen in HIV-1 infected Africans and non-Africans in London(442). These results 
suggest that the high proportion o f women and African patients in our patient 
populations does not bias our results.
Analysis o f repeat samples from individual patients suggest that although the test 
appears to be repeatable, results did not correlate well with other measures of clinical 
activity such as CD4 count, CD8 count or HIV viral load. The results suggest that IL-2
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and IFNy measurements are not good surrogate markers for monitoring the level of 
immunosuppression or the effect of HAART within individuals.
These studies measured the magnitude of bulk T lymphocyte responses to mitogen 
rather than the response of viral-specific sub-population of T cells. PMA+ionomycin 
was used in order to obtain the maximal level of T cell activation for each sample. This 
was considered important for reducing variability when comparing repeated 
measurements over time. It is, however, likely that the magnitude of CD4 and CD8 
responses alone will not be as predictive o f protection from disease as a combination of 
magnitude and other factors such as epitope breadth and affinity, phenotype, and 
function of antigen-specific cells(443). This can now be taken into account. Antigen 
specific responses can be obtained by using intact protein, viral lysates or peptides. 
MHC-peptide oligomers that require known peptide sequences matched to specific class 
1 or class II MHC can be used and MHC class I restricted tetramer complexes provide 
information on peptide specific CD8 responses. In general peptides containing 15 
amino acid residues each, and overlapping by 11 amino acid residues elicit equivalent 
CD4 responses to the intact proteins from which the peptide sequences were 
derived(444). These 15 amino acid peptides theoretically contain every single T cell 
epitope and can be used independently o f the patient’s MHC haplotype. When protein 
antigens are used an additional incubation period in the absence o f brefeldin A is 
performed to allow for optimal antigen processing and presentation.
This study has the advantage o f quantifying lymphocyte cytokine responses at the single 
cell level and relating this to clinical parameters. It confirms functional defects in T cell 
function in HIV infected patients on HAART compared to Normals that are clearly 
quantifiable even in the setting o f higher T cell numbers or a good response to therapy. 
Despite single cell intracellular cytokine analysis and good patient numbers the data 
does not support the theory that a simple Thl to Th2 switch, reversing on HAART 
therapy, is responsible for the cytokine changes occurring in HIV infection.
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C H A P T E R  5 
O v e r a l l  C o n c l u s io n s  
A n d
Su g g e s t e d  F u r t h e r  R e s e a r c h
The potential for cytokine production on a single cell basis in HIV positive patients with 
different clinical profiles and patients receiving treatment for autoimmune disease was 
assessed. PMA and ionomycin were chosen as a potent stimulus for T-cell activation 
that would maximize cytokine expression. Maximal stimulation was chosen to avoid the 
possibility for variable results that may be seen with submaximal stimuli.
Despite exquisite sensitivity measurement of IL-2 or IFNy by intracellular staining and 
flow cytometry does not appear to correlate well with clinical profiles or drug regimes 
in autoimmune uveitis. Whilst perhaps not surprising in those who have purely ocular 
disease analysis also showed no relationship in patients who had autoimmune uveitis on 
a background o f systemic disease such as Behcet’s. This is in contrast to other 
published reports. Difficulties in categorizing patients according to activity may have 
been responsible for masking an effect. Visual acuity and vitreous haze are considered 
the best indicators of activity but are markedly affected by media opacities. These 
indices also become much less helpful in chronic uveitis when chronic macular oedema, 
epiretinal membranes or ischaemia are more common. In these situations the patients 
symptoms are often the best indicator o f activity and perhaps patient scoring of activity 
would have been helpful. The ocular survey o f ocular disease in immunosuppressed 
patients highlights the importance o f patient symptoms for guiding further investigation. 
Systemic treatment with drugs known to modulate Thl cytokine production would have 
been expected to show demonstrable changes in cytokine production. Such changes 
were seen for IL-2 production in patients on CsA regimes. The changes seen in these 
patients were of the on-off type and were not titratable against dose of CsA.
Difficulties in seeing an effect may be due to problems with the power o f the study 
although the numbers o f patients tested was high compared to other studies o f a similar 
type. Also the statistics used are deliberately conservative to limit the risks of finding 
spurious significance with the large number o f comparisons. The complexity of the 
immune response itself, however, with cytokine networks upregulating and down 
regulating in response to minute changes in the intercellular environment makes 
interpretation difficult. Better interpretation of the data would be possible with a clearer 
understanding o f what the normal variations are. This could be obtained by taking 
repeated samples from a larger number o f healthy subjects over a year to document the 
effect o f repeat testing and intercurrent infections.
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Repeat samples were taken to give an impression of changes in cytokine profile over 
time in HIV and uveitis patients on treatment. Due to the large amount of patient 
variables this data was not analyzed statistically but each patient is presented here as a 
case study. This provides interesting information about the individuals with elevated 
IFNy being associated with immune activation but trends could not be seen that can be 
extrapolated to the general patient populations.
Analysis of the data that I do have is also limited by the fact that the patient groups were 
complex and patients were on a wide range of disease modifying therapies. Analysis of 
more homogenous patient groups would provide a clearer idea of the effect of disease 
on IL-2 and IFNy. Virologically HIV has three distinct phases: conversion, immune 
depletion and AIDS. In AIDS frequent intercurrent infections will result in immune 
activation and thus complicate the picture. Chronic immune activation is probably 
responsible for the high levels of IFNy seen in our patients. Testing of patients before 
the initiation o f systemic medications would have given a clearer idea of the effect of 
disease on IL-2 and IFNy so that the added effect o f disease modifying therapies could 
be more clearly seen. Analysis o f uveitis patients who are managed with periocular or 
intraocular steroids would provide a useful negative control group.
The holy grail remains a surrogate marker that could be used to quantify the level of 
immunosuppression. Although cytokines can be accurately measured and can be 
quantified, because the immune system is highly complex and highly responsive 
effectors o f the immune response may not be stable enough to be good candidates for 
assessing clinical progress. Further investigation o f cytokine profiles would be 
interesting for the information it provides about disease processes and treatment. This 
study does not, however, support the use of IL-2, IFNy to guide clinical practice in the 
highly complex system that is the patient. Instead, it emphasizes the need for careful 
history and examination. Likewise, the ocular survey in transplant patients highlighted 
the value o f symptoms in reducing unnecessary screening.
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